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ABSTRACT 
Objective:  
To use a novel nanocomposite polymer based on polyhedral oligomeric silsesquioxane-
poly(carbonate-urea)urethane with superior bio-mimetic properties in the development 
of endovascular stent-grafts. 
 
Methods: 
A self-expanding and sutureless aortic stent-graft was developed using nanocomposite 
polymer bonded to Nitinol. A new aortic model was designed for physiological 
assessment of stent-grafts and compliance and viscoelasticity were measured and 
compared with porcine aortas as control.  The stent-grafts (n=4) were fatigue tested 
using in vitro accelerated model for 400-million cycles equivalent to 10-years in human 
body and compared with zero-cycled control. A curved and conformable stent-graft was 
developed for thoracic aorta and aortic arch. Compliance and stiffness index of the 
thoracic stent-graft were measured in vitro and compared to FDA-approved Gore Tag
TM
 
stent-graft based on ePTFE (expanded polytetrafluoroethylene). MRI compatibility of 
the thoracic stent-graft was assessed by analysing signal attenuation and velocity 
measurements (flux) and compared to FDA-approved Medtronic Valiant
TM
. 
 
Results: 
The stent-graft had expanded diameter of 31.1 mm and was successfully collapsed to 
6.5 mm to achieve delivery profile similar to current devices. The thoracic stent-graft 
had uniform graft thickness of 150.7±6.6 µg and conformed to the curvature of aortic 
arch. The new aortic model was significantly more compliant than porcine aortas with 
no significant difference in elastic stiffness. All the stent-grafts successfully completed 
accelerated pulsatile fatigue testing. Scanning electron microscopy images confirmed  
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uniform surface topography. There was no loss of tensile strength, or compliance and no 
evidence of thermo-mechanical degradation in the nanocomposite polymer. Compliance 
of the thoracic stent-graft was significantly better compared with ePTFE stent-graft 
(3.3±0.61 vs. 2.3±0.95 %/mm Hg x 10
-2
; P=0.0003). On MRI, there was no significant 
signal attenuation and no significant difference in flux between Valiant and 
nanocomposite polymer stent-grafts (102±2.27 vs. 99.8±2.4 ml/sec; P=0.33). 
 
Conclusions: 
A new endovascular stent-graft based on novel design and nanocomposite polymer with 
properties of compliance, viscoelasticity, anti-thrombogenicity and MRI compatibility 
has been developed. Sutureless technology with new biocompatible material bonded to 
Nitinol stents proved to be robust with no separation over accelerated 10-year cycle. 
These stent-grafts have the potential to address poor long-term durability, 
thrombogenicity, and compliance mismatch associated with present generation devices 
and reduce reintervention rate. 
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Figure 6.2: Distension-time curve generated by wall-tracking system. The Y-axis is 
represented by Distention in µm on the graph above and Pressure in mm of Hg in the 
graph below. The time in seconds is on X-axis for both the graphs  
Figure 6.3: A fully expanded curved stent-graft from POSS-PCU NP bonded to nitinol 
and having curvature similar to aortic arch 
Figure 6.4: The smooth inner surface of the stent-graft with uniform thickness and 
curved design.  
Figure 6.5: Compliance results. Data presented as mean values. Pressures in mm Hg on 
X-axis and Compliance in %/mm Hg x 10
-2 
on Y-axis. 
Figure 6.6: Elastic Stiffness Index Results. Data presented as mean values. Pressures in 
mm Hg on X-axis and Elastic stiffness index β on Y-axis 
Figure 7.1: Phantom setup for NP stent-graft. Stent-grafts were scanned separately in a 
glass cylindrical container filled with water dosed with 10mL gadopentetate 
dimeglumine.  
Figure 7.2: Schematic diagram illustrating the MRI flow phantom setup. Large elevated 
fluid reservoir connected to fluid tank on the floor using Tygon tubing. Stent-grafts 
positioned as shown with corresponding uncovered tubing for baseline comparison. 
Figure 7.3: MR static images for Medtronic Valiant
TM
 stent-graft. Minimal 
susceptibility artefacts were seen, however the image quality was good. 
Figure 7.4: MR static images for NP stent-graft. No significant susceptibility artefacts 
affecting imaging quality were seen. 
Figure 7.5: Axial slice from Medtronic Valiant
TM
 stent-graft showing signal magnitude 
inside and outside used to calculate % signal attenuation. 
Figure 7.6: Axial slice from NP stent-graft showing signal magnitude inside and 
outside used to calculate % signal attenuation. 
Figure 7.7: Velocity flux comparison for Medtronic and NP stent-grafts. Columns 
represent mean values and error bars represent standard deviation 
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Chapter 1 
Polyhedral oligomeric silsesquioxane nanomaterials for cardiovascular 
applications 
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Nanocomposites are materials whose components are mixed at a nanometer scale. Due 
to their quantum-scale sizes, they can serve as bridges between molecules in the 
polymer. This nature allows them to exhibit different properties from conventional 
microcomposites. Their behavior is governed by the method of nano-reinforcement, the 
nano-interface, the synthetic process utilised, its microstructural effects, and the 
interaction between the polymeric and reinforcing component.  
 
Nanostructured composite materials are combinations of at least two constituent 
materials, a matrix (host) and a reinforcement component (guest, nanofiller)
1
. It is 
known that the properties of the materials change considerably when the size is 
significantly small, i.e, within 1–100 nm size range. Since these materials have 
improved physical, chemical, and mechanical properties, they are significantly versatile 
for a wide range of applications. The method by which nanomaterials are synthesised is 
a crucial factor behind the behavior of nanocomposite materials.  
 
1.1 Polyhedral Oligomeric Silsesquioxane (POSS) 
 
The chemical structure of the silsesquioxane family is defined as RnSinO1.5n, which 
makes a structure consisting of an inner inorganic framework of silicon and oxygen 
atoms, externally covered by organic groups (R). Conventionally, cage-like 
silsesquioxanes appear as polyhedral oligosilsesquioxanes or polyhedral oligomeric 
silsesquioxanes (POSS). POSS is one of the molecules in the silsesquioxane family 
which has a regular three-dimensional (3D) shape (polyhedral = many-side, 3D) formed 
by a few units (oligomeric), each containing silsesquioxane. Incorporation of POSS can 
change the surface properties including hydrophobicity, surface energy, and surface 
topography. Physical and thermal properties improved by incorporation of POSS 
include, low dielectric constants, increased glass transition temperature, low coefficient 
of thermal expansion, thermal stability, and heat evolution
2
. Improvement in the 
mechanical properties comprise tensile strength, viscosity, and enhanced viscoelastic  
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properties
3
. Further improvements have also been reported such as improved oxidation 
resistance, reduction of inflammability, oxygen permeability, and reduced inflammatory 
reactions, revealing the advantage of using these materials in various applications
4
. The 
unique characteristics of POSS nanoparticles offers diverse application potential in a 
wide range of areas, including the biomedical field, which is intensely under 
investigation. 
 
1.2 Cardiovascular applications of POSS 
 
Application of biomaterials in cardiovascular system and blood contacting devices 
necessitates specific characteristics such as blood compatibility and 
antithrombogenicity. To meet the essential requirements for these applications, we have 
developed a nanocomposite material by introducing POSS moieties into poly(carbonate-
urea)urethane (POSS-PCU) as a pendant chain. Studies on its cytocompatibility, 
antithrombogenicity, and biostability have shown that this new nanocomposite polymer 
has unique characteristics for these applications.
5
 The enhanced characteristics of 
POSS-PCU make it an ideal material of choice for the development of advanced 
cardiovascular implants. This polymer is currently being used in the fabrication of many 
biomedical devices, including synthetic leaflet heart valves, percutaneous valve 
prostheses, small and large diameter bypass graft, and coated stents. 
 
Development of new generation implants based on advanced novel materials can 
potentially overcome the main problems in current clinical practice. The candidate 
material for this particular application should offer enhanced hemocompatibility and 
biostability to ensure improved long-term performance of the implant. POSS-PCU, as a 
paradigm POSS material, is a pioneering prototype of advanced novel materials which 
possesses superior hemocompatibility, biostability, antithrombogenicity, and 
calcification resistance, owing to its enhanced physicochemical properties and nano-
reinforced structure and surface nanotopography. Its superior properties compared with  
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conventional polymers are among the main advantages of using this material in the 
cardiovascular system. Early results of the development of small diameter bypass grafts 
and heart valve prototypes using this novel nanocomposite have been very promising. 
 
1.3 Prospects 
 
With a nanocomposite suitable for cardiovascular application, attempts are now focused 
on development of new generation cardiovascular devices with improved 
hemocompatibility and long-term performance. If successful in the long run, the clinical 
implications would be tremendous, as the superior properties of the new generation 
cardiovascular implants could overcome the complications and limitations of currently 
available devices. Projects on the development of percutaneous heart valves, and coated 
stents based on these POSS containing novel nanocomposites are currently active. In 
addition, small diameter POSS-PCU graft has recently shown exceptional results in an 
in vivo study and will undergo clinical trial in coronary artery bypass grafting and renal 
access soon. Besides the mentioned properties, resistance to calcification, enhanced 
mechanical and surface properties, capability of grafting bioactive peptides to enhance 
attachment, proliferation, and differentiation of circulatory stem cells into endothelial 
cells are among other advantages of using these materials in the development of 
cardiovascular devices. By the emergence of new generation cardiovascular devices 
based on POSS nanomaterials, it is likely to overcome some of the major problems of 
current implants, saving lives and improving the quality of life of a significant number 
of patients. 
 
In this work, we present the use of POSS-PCU for development of endovascular stent-
grafts for abdominal aortic aneurysms and thoracic aortic pathologies, based on 
engineering approaches to achieve optimum folding efficiency and superior durability. 
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Chapter 2 
Introductory review of scientific literature pertaining to Abdominal Aortic 
Aneurysm (AAA) stent-grafts with emphasis on past and present problems and 
future prospects 
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  Endovascular aneurysm repair (EVAR) has quickly gained popularity for 
infrarenal abdominal aortic aneurysm (AAA) repair during the last 2 decades. The 
improvement of available EVAR devices is critical for the advancement of patient care 
in vascular surgery. Problems are still associated with the grafts, many of which can 
necessitate the conversion of the patient to open repair, or even result in late rupture of 
the aneurysm. This review attempts to address these problems, by highlighting why they 
occur and what the failings of the currently available stent-grafts are, respectively. In 
addition, the review gives critical appraisal as to the novel methods required for dealing 
with these problems and identifies the new generation of stent-grafts that are being or 
need to be designed and constructed in order to overcome the issues that are associated 
with the existing first and second-generation devices. 
 
2.1 INTRODUCTION 
 
2.1.1 Epidemiology and natural history of AAA 
  AAA occurs when weakened areas of abdominal aortic wall result in ballooning 
of the blood vessel. An AAA is defined as an enlargement of the aorta of at least 1.5 
times its normal diameter or greater than 3 cm diameter in total. AAAs are more 
commonly located in an infra-renal position. Attributed risk factors include increased 
age, smoking, atherosclerosis and hypertension
6
. AAAs are about 3 times more 
common in men than in women. They account for 1.81% of deaths in people over the 
age of 65 years in England and Wales, with an incidence of 3.5 new aneurysms 
occurring for every 1000 person years
7
. 
Most AAAs are detected incidentally during clinical investigation (for example, 
ultrasound or X-ray) for other conditions. Because most AAAs are asymptomatic, it is 
difficult to estimate their prevalence, but screening studies in the UK have estimated a     
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prevalence of 1.3–12.7% depending on the age group studied8. The incidence of 
symptomatic AAA in men is approximately 25 per 100,000 at age 50, increasing to 78 
per 100,000 in those older than 70 years
8
. The implementation of a national screening 
programme for AAA is under way and the first centres started screening in March 2009. 
The remaining centres will be managed in a phased roll-out over the next 5 years. 
Symptoms that can occur as an aneurysm enlarges include a pulsating sensation 
in the abdomen, back pain and abdominal pain that may spread to the back. Patients 
with a symptomatic AAA need rapid medical attention. Among patients with a ruptured 
AAA the mortality rate is about 80% which increases up to 90% when in- hospital 
deaths are included
9
. Even when they undergo emergency surgery, only about half 
survive beyond 30 days. It has long been established that, for large aneurysms at least, 
prophylactic measures are required to prevent aneurysm rupture
7
 and one in three 
aneurysms will rupture if left untreated
10
. The risk of rupture increases with the size of 
the aneurysm, and those aneurysms larger than 6 cm in diameter have an annual risk of 
rupture of 25%.  
Several studies indicate that without surgery the 5-year survival rate for patients 
with aneurysms larger than 5 cm is about 20%
8
. In current UK clinical practice, elective 
surgery is generally recommended for patients with aneurysms larger than 5.5 cm in 
diameter and with aneurysms larger than 4.5 cm in diameter that have increased by 
more than 0.5 cm in the past 6 months. Current guidelines from the Vascular Society 
and the National Screening Committee recommend that patients with asymptomatic 
aneurysms of less than 4.5 cm in diameter should be followed up with ultrasonography 
every 6 months, and aneurysms of 4.5–5.5 cm in diameter should be followed up every 
3 or 6 months. 
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2.1.2 Surgical Management of Abdominal Aortic Aneurysms 
Patients can be treated by conventional open surgical repair (OSR) which 
involves laparotomy and insertion of a prosthetic graft to replace the aneurysmal aorta. 
OSR can also be performed laparoscopically, either by hand-assisted laparoscopic 
surgery or totally laparoscopic surgery. However, AAAs can also be treated by a 
minimally invasive approach which involves placement of an endoluminal stent-graft 
through the transfemoral approach. This procedure called as Endovascular Aneurysm 
Repair (EVAR) has revolutionised the treatment of AAAs in the last 2 decades.  
For over half a century, OSR has been used as the standard treatment modality 
for AAA with a high degree of success, mortality rates having been reduced from 20% 
to ~5% in the past 30 years
11
. However, there are still several complications associated 
with OSR: it is a highly invasive procedure (an incision is made from the sternum to the 
pubic bone or across the waist) that is most often performed on the elderly. In addition, 
although mortality rates are reasonably low in uncomplicated cases (5%), higher rates 
are often associated in those with co-morbid diseases such as coronary artery disease 
and renal failure
12
. OSR may also result in significant harm to the patient, with 
myocardial infarction, respiratory and renal failure and changes in functional status 
possibly occurring
13;14
. Finally, recovery rates are in the region of several months, 
resulting in a reduction in quality of life for the patients for up to 3 months post-
operatively
15
. 
2.1.3 Introduction to Endovascular aneurysm repair  
  Because of these problems, and due to the high number of patients for whom 
OSR was contraindicated, in 1991, Volodos et al
16
 reported his clinical experience of 
using self-fixing synthetic remote endoprosthetics for aorta reconstruction. In the same 
year, Parodi et al. reported repair of AAA in five subjects using an endovascular 
approach with a modified stent and graft material
17
. The concept of inserting the graft 
with the metallic stents at either end has been considered before, and at least four  
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Figure 2.1 Schematic diagrams showing (A) abdominal aortic aneurysm before 
endovascular intervention and (B) aneurysm post-intervention with a stent-graft in situ
18
 
 
 
 
 
 
patents exist for this process
19-22
. The stent-graft system reported by Parodi was initially 
developed and patented by Lazarus in 1987
22
. Lazarus
22;23
 subsequently developed a 
device specific for endovascular treatment of AAA at the same time as Parodi, In 
Parodi’s report, the device used had just one short stent allowing adequate proximal 
anchorage only; in most cases reflux at the distal end of the graft was found, and 
reintervention was required. Nonetheless, a comparative improvement in aneurysm size 
was found in all patients post-operatively, suggesting that EVAR of AAA was at least 
technically feasible.  
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2.1.4 Early devices   
Following this initial clinical study, further trials ensued
23-25
, coupled with rapid 
commercialisation and the development of the first tube graft, created by Endovascular 
Technologies (later to be taken over by Guidant, Menlo Park, CA) which was first 
implanted in 1993. This graft was then further developed into the Ancure device, which 
has now been withdrawn from the market following a $92.4 million lawsuit
9 
for failing 
to report device malfunction and adverse events to the FDA. Since 1993, around 15 
other types of stent-grafts have been developed, come to the market and into clinical 
usage
26
, with each claiming an advantage over the others. Some, however, have 
followed the Ancure endograft and have been withdrawn from the market. These 
include the Vanguard (Boston Scientific, Natick, MA), the Parodi and the Chuter all of 
which had design flaws, and caused an increased risk to the patient as compared with 
OSR. In addition, high development costs have seen the withdrawal of the Lifepath by 
Edwards Lifescience (part of Baxter Healthcare Corp. Irvine, CA), even though the 
Lifepath recently had positive results from its clinical trial
27
.  
 
2.1.5 Basic Design   
The basic design of all endografts is somewhat similar; the aortic aneurysm is ‘crossed’  
by a tubular graft that has a wide diameter (~20-36 mm) and is supported by stents 
along its length (see Figure 2.1). The tube either bifurcates into two smaller diameter 
stent-grafts that sit into the iliac arteries, or it simply decreases in size so that it sits in 
one iliac artery and a femoro-femoral bypass is carried out (this is called an 
aortouniiliac device). Aortouniiliac and bifurcated stent-grafts are usually modular in 
design i.e. the main body and a short length of the iliac stent-grafts are initially 
implanted, and extenders are added to make the device itself longer. In this manner, the 
stent-graft can be altered to fit the anatomy of the patient easily.  
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2.1.6 Current devices   
  Tables 2.1 and 2.2 show some of the main stent-grafts available on the 
worldwide market, their different characteristics, and some primary and secondary 
outcomes from their pivotal clinical trials. It should be noted, however, that these trials 
have been sponsored by the device company and may, therefore, be subject to some 
conflicts of interest.  
  Only five, the Aneurx and Talent (Medtronic Inc. Minneapolis, MN), the 
Excluder (WL Gore and Associates, Flagstaff, AZ), the Zenith (Cook Inc., 
Bloomington, IN) and the Powerlink (Endologix, Irvine, CA), currently have FDA 
approval and are available commercially, and therefore clinically in the US. All the 
other devices shown have investigational device exemption and are undergoing trials in 
the US and many of them have been approved in the EU.  
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Table 2.1 General characteristics of the various grafts available on the US and EU markets.  
Keys: SE, self-expanding; BE, balloon-expanding, F, French; P, proximal (i.e. the stent-graft body); D, distal 
extenders; PTFE, polytetrafluoroethylene *a Co-based alloy with high Cr content 
 
Device 
and 
approval 
Profile; 
SE/BE 
Design type Metal Graft Neck Proximal 
fixation 
method 
Diameter 
of the 
artery 
Graft 
attachment 
Aorfix 
(CE) 
22 F 
(P); SE 
 
Bifurcated 
with 
contralateral 
limb and 
extenders 
 
Nitinol Polyester >20 
mm 
Oversizing 
and hooks 
24-31 Embroidered 
Aneurx 
(FDA) 
21 F 
(P); 16 
F (D) 
SE 
Bifurcated 
with 
contralateral 
limb and 
extenders 
 
Nitinol Woven 
polyester 
>10 
mm 
Oversizing 18-26 Sutures; graft 
inside stent 
Excluder 
(FDA) 
18 F 
(P);  
12 F 
(D) SE 
Bifurcated 
with 
contralateral 
limb 
extenders 
 
Nitinol PTFE 15 
mm 
Anchors 2 
mm long  
19-26 
aorta  
8-13.5 
iliac 
Chemically 
bonded; graft 
inside stent 
Zenith 
(FDA/CE) 
18/20 F 
(P); 14 
F (D)  
SE 
Bifurcated 
main body 
and two 
iliac legs 
 
Stainles
s steel 
Polyester >15 
mm 
Suprarenal 
barbs 
22-32 
aorta;  
8-24 iliac 
Sutures; graft 
outside stent 
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Powerlink 
(CE) 
21 F 
(P) 
SE 
Unibody 
with 
extenders if 
required 
 
Co-Cr 
alloy 
Woven 
polyester 
15 
mm 
Oversizing 26 Sutures; graft 
outside stent 
Anaconda 
(CE) 
18/20 F 
(P); 16 
F (D) 
SE 
Fully 
modular, 
main body 
and two 
legs 
Nitinol PTFE 15 
mm 
‘Saddle’ 
of 
oversized 
nitinol  
ring 
16-31.5 Sutured at 
proximal and 
distal ends; graft 
outside stent 
Lifepath 
(CE) 
25 F 
(P); 19 
F (D) 
BE for 
main 
body, 
SE for 
legs 
Bifurcated 
main body 
and two 
iliac legs 
Elgiloy
*  
 
Woven 
polyester 
15 
mm 
Oversizing 27 Sutures; graft 
outside stent 
Talent 
(FDA) 
22–24 
F (P); 
18 F 
(D) 
Bifurcated 
with 
contralateral 
limb and 
extenders 
Nitinol Polyester 15 
mm  
Oversizing 16-36 
aorta 
8-22 iliac 
Sutures; graft 
outside stent 
 
 
 
 
 
 
 
 
39 
 
 
Table 2.2 Patient numbers and endpoints from pivotal clinical trials for the various stent-grafts.  
Keys: Mortality, mortality to AAA related; No, number; OR, open repair 
Author No  Mortality  Endoleak Aneurysm size post-
op 
Conversion to 
OR 
 
Aorfix 24 0% at 30 day 8% at 30 days No data available yet 4% in 60 days 
 
Aneurx
28
 1193 2.5% at 4 y 14% at 30 days 
14% at 12 mths 
14% at 4 years 
 
Increase >5mm, 
11.5% at 4 years 
4.4% in 4 years 
Excluder
29
 235 0% at 2 y 22% at 30 days 
17% at 12 months 
20% at 24 months 
 
No data available 1.3% in 2 years 
Zenith
30
 200 0.5% at 12 m 17% at 30 days 
7.4% at 12 months 
5.4% at 24 months 
 
Decrease > 5mm, 
>75% at 24 months 
1.5% in 12 
months 
Powerlink
31
 192 0.5% at 24 m 6.76 at 24 months Decrease >5 mm 64% 
at 24 months 
 
1.5% in 12 
months 
Anaconda
32;33
 54 3.9% at >30 days 
 
9.8% at >30 days 
12.3% at 21 months 
Decrease >7 mm at 6 
months 
 
2% at 21 
months 
 
Lifepath
27
 224 0.4% at >30 d 
 
6.8% at 12 months Decrease >5 mm 58% 
at 12 months 
 
2.2% in 12 
months 
Talent
34
 240 0% at >30 d 10% at 12 months Decrease >5 mm, 
59% at 12 months 
2.5% in 23 
months 
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2.1.7 EVAR ineligibility due to complex aortic anatomy 
  The feasibility of EVAR depends mainly on anatomic factors that represent the 
important predictors of success. Anatomic selection criteria for EVAR are based 
principally on characteristics of the proximal infrarenal neck, aneurysm sac, and iliac 
arteries. An unfavourable neck anatomy, based on its diameter, length, angulation, 
morphology, and presence of calcification and mural thrombus, is the most frequent  
cause of exclusion from EVAR
35;36
. In a study by Arko et al
35
 , 55% patients were 
considered suitable for EVAR and 45% patients deemed ineligible. The primary 
anatomical reason for ineligibility was a short infrarenal neck (44%), a large proximal 
neck diameter (25%), iliac aneurysms (10%), extremely tortuous or calcified neck (7%), 
iliac occlusion (6%) and small distal aortic bifurcation and accessory renal arteries 
(5%). In addition 4% were rejected due to poor quality imaging. 
 
  Similarly, Carpenter et al
37
 reported short aneurysm neck (54%), inadequate 
access from small iliac arteries (47%), wide aneurysm neck (40%), bilateral common 
iliac artery aneurysms (21%), excessive neck angulation (14%), excessive mural 
thrombus in aneurysm neck (10%), and accessory renal arteries (6%) with many 
patients having a combination of factors. 
 
  The guidelines of EVAR are constantly being redefined, mostly as a result of 
increasing operator experience and improvement in stent-graft technology that is 
constantly providing new and versatile devices. Although, with new technology the 
number of patients eligible for EVAR will increase, complex aortic anatomy will be a 
significant limitation, at least in the foreseeable future. 
2.2. EVAR FAILURE MECHANISMS 
2.2.1 Profile of Delivery Systems 
  In terms of profiles, the problems that exist with the currently available stent-
grafts are that the femoral and iliac arteries are often too small or tortuous for easy  
 Chapter 2 – Introduction – Aortic Stent-grafts  
 
41 
 
 
 
passage of the delivery system. In order for the stent-graft to be placed across the 
aneurysm, it must first be inserted into the femoral artery using a cut-down process. 
Therefore, both of the femoral and iliac arteries must be patent, must have as little 
tortuousity as possible, and one of them must allow a catheter, up to 24 French (Fr) (8 
mm) in diameter, to be introduced to the aorta. In most bifurcated devices, the other 
femoral artery must allow a ~16 Fr catheter access so that the contralateral iliac artery is 
stented. In many patients, especially women, the arteries are too small to allow 
access
37;38
. In addition, subjects with AAA often have concomitant vascular disease, so 
the femoral and iliac arteries can be atherosclerotic or tortuous and access is therefore 
not possible
39
. Calcification also compromises passage of the delivery sheath for the 
stent. 
This has been overcome by one commercially available device to date. The 
Powerlink (Endologix, Irvine, CA) is the only commercially available bifurcated, 
unibody device. This device requires one artery to be patent to allow a 21 Fr catheter to 
pass, and the contralateral to allow a 9 Fr catheter to pass
31
. Another stent-graft, 
currently in Phase I clinical trials, is the Trivascular Enovus graft (Santa Rosa, CA) 
which was initially acquired by Boston Scientific, Natick, MA
40
. They performed a 
phase II clinical trial in United States in 2006, but the study was terminated as they 
found it too expensive to pursue. The Enovus is now being tested by TriVascular2, a 
company in which the original inventors are involved.  In order to deploy this stent-
graft, the graft alone is inserted into the aorta and is placed in its correct position. The 
graft material has many channels where the struts of a normal stent-graft would be. 
Once the graft is in place, a biopolymer (currently patent protected) is injected into 
these channels, expanding the graft material to its correct diameter. This biopolymer 
hardens in the body and becomes the ‘metal struts’ of a normal stent, thus providing the 
strength a stent-graft needs. Using this method, the diameters of the catheters required 
to deliver this unibody device are as low as 14 Fr for both arteries.  
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2.2.2 Endoleaks and Graft Migration 
Endoleak is recognized as the main problem associated with stent-grafts, and is used as 
an endpoint in clinical trials
27;34;41
. Post-procedural leakage can cause aneurysm rupture 
and is therefore the chief cause of aneurysm-related mortality and the need to convert to 
OSR
9
. Four different types of endoleak exist; the definitions of each are given in Table 
2.3.  
 
 
Table 2.3 Categorisation of Endoleaks 
 
Categorisation of endoleaks Definition 
 
Type I 
 
Inadequate seal at graft ends, 
resulting in leaks at the 
proximal or distal anchorage 
sites 
 
Type II Residual blood flow into 
aneurysm sac from patent 
arteries, e.g. lumbar and 
mesenteric 
 
Type III 
 
Integrity of graft compromised; 
leak from modular components 
 
 
Type IV 
 
Porous graft material  
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2.2.2.1 Type I and Migration.  This type of endoleak was the primary cause for stent-
graft failure in the initial trial performed by Parodi. Even today, the existing tubular 
stent-grafts are often difficult to use as the distal neck of the aorta is often too short and 
calcified to allow secure tubular stent attachment
30. Since Parodi’s work, most 
aneurysms are treated using a bifurcated device, and oversizing at the distal end usually 
provides satisfactory anchorage
42
.  
  With respect to proximal endoleaks, the main cause is that of stent-graft 
migration. A variety of methods are used to prevent stent-graft migration, such as 
oversizing the stent by ~15%, the use of suprarenal uncovered stents to provide extra 
frictional attachment, and the use of hooks, barbs, radial force, and longitudinal 
columnar support. The use of barbs is somewhat controversial, as these require full 
penetration of the wall of the aorta, and may lead to rupture of adjacent structures
43
. 
They may also lead to damage of the endothelial cell layer, possibly causing 
uncontrolled proliferation of smooth muscle cells, thus potentially leading to intimal 
hyperplasia and possible stent-graft failure.  
  Regardless of fixation, migration has been noted with all current endovascular 
devices. The migration rate is ~2% at 1 year using each of the FDA-approved 
devices
29;44;45
. Graft migration has been shown to occur with infrarenal fixation and is 
thought to relate to aneurysm neck length, aneurysm neck and device apposition zone 
length, and distal device support within the iliac system
45-49
. Fogarty et al
50
 reported an 
incidence of 8% at 5 years, suggesting low deployment of the device below renal 
arteries as the most important predictor of subsequent migration.  For each millimetre 
increase in the distance between renal arteries and the top of the stent-graft on post 
deployment CT scans, the risk of migration increased by 6%
51
.  
  A total of 1119 patients, who received treatment in the Aneurx clinical trial and 
had a minimum of two years follow up, were examined by Zarins et al
45
 for stent 
migration. The authors found that migration was more likely to occur in patients whose  
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fixation length (i.e. the length of neck covered by the stent-graft) was less than 10 mm 
of the aneurysm neck (19% versus 9% in patients with a fixation length greater than 15 
mm). The authors suggested that the predictors of migration were fixation length and 
renal artery to stent-graft distance. Factors that were not predictive include: age, pre-
implantation aneurysm size, neck length, neck diameter, degree of device oversizing 
and use of extender cuffs at implantation. They concluded that type I endoleak is 
primarily caused by poor imaging of the renal arteries during deployment (inferior 
image quality, lack of magnification, movement or parallax) and substandard patient 
selection.  
  Stent-graft migration is now considered to be preventable by positioning the 
device just below the renal arteries and extending the device to the level of hypogastric 
arteries bilaterally. 
  Type I endoleak can also be caused by suture fracture, as occurred with the 
Vanguard device
52;53
. This device comprised rows of stents each attached to the other 
via sutures. Fracture of these sutures leads to row separation at the anchorage sites 
leading to Type I endoleak.  
  Type I endoleaks can be often identified on completion angiogram on table 
following EVAR. They require proximal adjunctive procedures to obtain a primary seal. 
This can be in the form of balloon dilatation; further intervention will also depend on 
whether there is associated graft malposition. For type I proximal endoleaks without 
graft malposition during stent deployment, a giant Palmaz stent is used to encourage 
stent apposition to the proximal neck. However, if an endoleak appears to be due to 
graft migration during deployment, they may then require proximal aortic cuff, 
generally oversized to prevent further endoleaks
54
. Type I endoleak is associated with a 
significant risk of rupture if untreated, so if endovascular procedures are unsuccessful, 
conversion to open repair may be required
55
. 
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2.2.2.2 Type II. During OSR, occlusion of patent vessels can be carried out to prevent 
blood from entering the aneurysm sac. Such a procedure cannot be performed during 
EVAR, and blood flow into the aneurysm sac from the lumbar and mesenteric arteries  
can lead to Type II endoleak. It has been suggested
56;57
, that the best method for dealing 
with those who have this type of endoleak is to increase their surveillance compared 
with those who do not have it. There is some controversy regarding the best method for 
dealing with Type II endoleak. Initially, it was suggested by the EUROSTAR registry 
that there is no increased risk of aneurysm rupture
58
, although this has now been revised 
and the authors have suggested that this type of endoleak may increase the size of the 
aneurysm and the incidence of reintervention but they still do not suggest that it is a 
direct cause for rupture
57
. Others, however, have found a direct link to aneurysm rupture 
caused by Type II leak
56
.  Many of these endoleaks were treated by radiological or 
surgical intervention because of the fear of rupture. Several techniques exist for the 
treatment of Type 2 endoleaks, including embolisation via a transarterial or translumbar 
route, laparoscopic ligation of aortic sac side branches and vessels and thrombin 
injection
59
.  Reintervention usually repairs the problem without difficulty
60
, however it 
has been reported that there is a high risk of treatment failure and overall outcome may 
not be altered
59
.  
The management of Type 2 endoleaks has evolved with time. Recently, a more 
conservative approach has been adopted because many of them seem to be relatively 
benign. 
 
2.2.2.3 Type III.  The graft material is sutured to the stent in all devices, with the 
exception of the Excluder graft which is heat bonded. With suture fracture, graft erosion 
may occur, particularly in areas of severe angulation. Stent fracture can also cause Type 
III endoleak, with the stent strut pushing through the graft material, causing a large hole, 
although it is claimed that this is not a frequent occurrence
61
. 
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An additional issue with Type III leak is that most stent-grafts available are modular. 
Although this modular design is, in concept, a valuable addition that allows changes in 
the shape of the stent-graft according to the patient’s needs, it does increase the 
possibility of leakages occurring around the connecting areas and allows bowing and 
kinking to occur. In most devices, the connections are simply held together by friction, 
i.e. no active gating mechanisms are used and leaks can therefore occur between each of 
these connections.  
Type III endoleaks require treatment due to their association with enlargement 
and considerable risk of aneurysm rupture
55;62;63
. If a modular separation is the cause of 
the endoleak, the aim is to restore continuity of the graft elements by inserting an 
appropriately sized cuff. Fabric defects may be treated by relining the device with 
another stent-graft, either bifurcated or uniiliac.  
 
  In order to overcome these problems, ongoing research into using polymeric 
materials, other than expanded polytetrafluoroethylene (ePTFE) and polyethylene 
terephthalate (Dacron/polyester), as suitable grafts is being carried out
64
. A possible 
solution to overcoming some of the problems with Type III endoleaks would be to 
develop both a new polymeric material that can be chemically bonded to the stent and a 
new stent design in which the graft and stent are merged into one deployable structure, 
rather than the graft simply lying outside the stent as a separate entity only attached via 
stitching or chemical bonds. By integrating the stent with the graft, this will reduce the 
chance of graft failure and so endoleak itself. To a certain degree, this has been 
achieved by the Endofit prosthesis (Endomed Inc., Phoenix, AZ), where the graft 
material encapsulates the stent, resulting in a stent-free lumen and a smooth channel 
through which the blood can flow, but the polymer is still based on ePTFE and the 
design does not integrate the graft with the stent. Additionally, superior methods of 
connecting the extender cuffs to the main body should be investigated. For instance, a 
gating mechanism that locks the cuffs to the main body would potentially aid in  
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mitigating against Type III leaks.  
 
2.2.2.4 Type IV. Currently, the ePTFEs and woven polyesters used are very thin so that 
the profile of the device can be kept to a minimum. The Anaconda uses a particularly 
thin Dacron (0.15 mm vs. ~0.35 mm), and the porosity of all existing grafts are 
approximately the same, at ~65%
65
, with the incidence of Type IV endoleak being fairly 
high peri-operatively (this is known as ‘contrast blushing’). 
  Post-operatively, as general thrombosis of the graft usually occurs quickly, 
treatment is rarely required for Type IV endoleak after endograft deployment. However, 
the Endofit, mentioned above, uses laminated ePTFE which provides an impermeable 
barrier, preventing any Type IV endoleak from occurring. In this manner, Type IV 
endoleak can be reduced or prevented. 
 
2.2.3 Endotension 
  Endotension is the continued pressurisation of the sac with subsequent sac 
enlargement in the absence of apparent endoleak; it is often caused by pressure 
transmission through a sealed or thrombosed endoleak
66
. Although the pathophysiology 
of endoleak is beginning to be elucidated and its management is being established, 
controversy exists about the etiology and clinical consequences of endotension. Gilling-
Smith
67
 classified endotension into subcategories according to the pressure 
characteristics: grade I (high pressure and high flow); grade II (high pressure and low 
flow); and grade III (high pressure and no flow), which is true endotension or sealed 
endoleak. Table 2.4 includes the possible etiologies of endotension. 
An increase in aneurysm size can occur with endotension, but if there is no 
demonstrable endoleak or the aneurysm is shrinking in size, additional intervention is 
usually not required
67
. Several procedures are possible: open replacement of the graft, 
wrapping the endograft by a new graft through laparotomy, and endovascular relining of 
the stent-graft. Conversion to OSR usually treats endotension satisfactorily
68
. 
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Table 2.4 Possible aetiologies of endotension 
 
Pressure transmission to the AAA sac around the ends of graft 
Layer of thrombus between the graft and aortic wall 
Graft displacement exposing thrombus layer at aortic neck 
Endoleak channel sealed by thrombus 
Undetected endoleak 
Intermittent endoleak channel 
Very low-flow endoleak channel 
 
Pressure transmission through graft wall 
High graft porosity 
Microleak through graft interstices 
Transudation/exudation of fluid through graft fabric 
Graft pulsatility/wall movements 
 
Pressure transmission from branch vessels 
Thrombus over orifice of internal mesenteric or lumbar arteries 
 
 
Pressure build-up from fluid accumulation in situ 
Graft infection 
Thrombus fibrinolysis/hygroma 
Genetic modulation 
Enzymatic activity 
Hyper-osmolarity 
Others 
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2.2.4 Stent fatigue and fracture 
  A study carried out by Jacobs and co-workers
52
, which examined fracture of 
stent-grafts over a 10-year period in their centre, found that of 404 devices examined 43 
had metallic stent fracture, i.e. over 10% of all stent-grafts used had fractured within 4 
years (the follow-up period for each patient). In addition, a further 17 had other 
problems with the graft (e.g. suture fracture, graft holes). Although this study included 
stent-grafts that are no longer commercially available and stent-grafts used for the 
treatment of thoracic aortic aneurysm, the results are, nonetheless, still of value in 
understanding the role of metal fatigue.  
  Unfortunately, Jacobs et al. did not describe the follow-up treatment given to the 
43 subjects (observation, reintervention endovascular treatment, or conversion to OSR). 
However, as mentioned above, fracture of a stent strut may lead to a Type III endoleak, 
or if the attachment barbs and hooks fracture, the stent-graft may migrate leading to 
Type I endoleak. 
  Nevertheless, strut fracture can be obviated by superior in vitro life testing at 
higher pressures and better design. Although endografts are subjected to accelerated 
life-testing, for an equivalence of 10 years, before approval can be obtained from the 
FDA, it is thought that the mock silicone arteries that are used to perform these tests 
undergo a “frequency dependent change [potentially leading to] a lower than expected 
loading and an attendant reduction in [the actual] severity of testing”69. Thus, it may be 
the case that the in vitro conditions in these bench tests do not mimic exactly in vivo 
conditions, and therefore evaluation of the fatigue properties of the stent-graft is not 
properly performed. It should also be noted that the aorta is subject to the highest 
pressures in the body, and, as mentioned previously, many of these patients will have 
concomitant high blood pressure. Therefore, testing of the stent-grafts should be carried 
out at blood pressures higher than normal (e.g. systolic, 160 mmHg; diastolic, 100 
mmHg).  
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2.2.5 Deployment problems and repositioning 
  Except for the Lifepath stent-graft, all stent-grafts are self-expanding (although 
the Talent stent-graft is made from Nitinol, it also possesses a balloon for inflation to 
ensure total expansion of the stent, and to allow easy positioning
70
).  Many stents, such 
as the Zenith, have initial partial deployment which allows partial repositioning; no 
repositioning can be performed when the graft is fully deployed. Most stents cannot be 
repositioned after deployment, and in some, such as the Excluder stent-graft, the 
deployment system is designed to allow rapid expansion of the stent. Inaccurate 
deployment will also lead to the increased use of extenders, thus increasing the 
probability of Type III endoleak
45
.  
  Although many of the stent-grafts do allow some manoeuvrability post-
implantation, this is mostly in the form of moving the stent down the aorta, and if 
barbs/anchors have been deployed, too much movement may itself cause dissection of 
the artery. The Anaconda (Sulzer Vascutek, Austin, TX), however, appears to be unique 
in overcoming the problem of manoeuvrability by anchoring the stent-graft using an 
unusual ‘saddle’-like ring-stent that provides a compliant seal against the vessel wall. It 
is possible to move this stent-graft around post-deployment without causing tears to the 
aortic wall. 
 
2.2.6 Limb Occlusion 
Kinking, caused by fracture of the stent or insufficient support given to the graft, can 
result in obstruction of a bifurcated limb
34
. This often leads to endovascular 
reintervention being required, although this is usually successful. Limb occlusion was a 
serious problem with the Stentor/Vanguard, and with the Ancure devices, but is found 
less frequently now with more modern designs which are generally stiffer, thus 
preventing kinking. The Aorfix (Lombard Medical, Oxford, UK), for example, has been 
specifically designed to be a flexible stent-graft, making it resistant to kinking and 
twisting
71
. Additionally, this device can be used in aneurysm necks with angles up to  
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65  . Krämer et al
72 
studied the geometric changes in bifurcated aortic endografts and 
identified changes in the iliac limbs in response to physical forces, yet not fully 
understood, which may result in kinking of the prosthesis thereby compromising its 
haemodynamic properties and causing thrombosis and limb occlusion. It is therefore 
conceivable that these changes may have profound effects on durability of currently 
available devices and limit the long-term success of EVAR
72
. 
 
2.2.7 Biocompatibility 
  Due to the large size of the aorta, problems such as intimal hyperplasia and 
restenosis are not usually an issue with EVAR. Consequently, the research currently 
being carried out on drug-eluting stents, aimed at preventing restenosis in small vessels, 
is not very relevant to AAA, and no incidence of AAA being treated with such a stent 
could be found in the literature. Additionally, most endografts are made from Nitinol, 
which has been shown to be selectively biocompatible
73
, though there are reports that 
the nickel, which is toxic, does leach out slowly. This leaching may result in nickel 
corrosion, and might therefore be one of the causative factors for strut degradation (a 
failure mechanism of the device)
74
. However, although this corrosion was identified in 
some first-generation nitinol stent-grafts
74;75
, improved nitinol processing (i.e. reduced 
nickel content) has meant that so far there have been no reports of fracture due to 
corrosion in second generation devices
53
. This could, of course, simply be due to the 
short follow up period carried out to date in these studies. 
  The issue of stent-graft incorporation into the aortic wall, however, remains a 
problem. In animal models, endothelialisation of the stent-graft seems to occur quickly 
(within 3 months) and along the whole length of the graft
65;76
. Although there are 
occasional reports of this occurring in humans
77
, it is thought that endothelialisation 
does not commonly take place
78
. Therefore, further work on developing methods to 
encourage endothelialisation should be performed, so that the stent-graft becomes  
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integrated with the body. Work in our group is currently underway on the development 
of a polymer where ‘stem-cell switching’ occurs, thus encouraging endothelialisation in 
situ, from the circulating blood, onto the graft itself. 
 
2.2.8 Compliance Mismatch 
  The movement of a stent within the aneurysm depends on the 
compliance of the stent, the compliance of the graft (which varies widely, depending on 
the state of expansion) and cyclical changes in the pressure. The natural history of AAA 
involves diameter enlargement, which may lead to rupture. Stent-graft design alters 
aortic wall dispensability (which is a surrogate marker for aortic compliance) at the 
aneurysm neck, the site of endograft sealing, which may have serious consequences for 
endograft efficacy and durability
79
. Compliance mismatch is more relevant in the 
proximal aorta, which is the major contributor to total arterial compliance and is an 
important determinant of cardiac afterload. Reduction in compliance leads to an 
increase in systolic and pulse pressure while peripheral resistance remains unaltered.  
After reconstruction of the proximal aorta with noncompliant grafts, there is a 
significant increase in systolic and pulse pressure as well as left ventricular hypertrophy 
(LVH)
80
.  It has been shown that stiff vascular prosthesis increase pulsatile load 
(characteristic impedance), which results in LVH. The development of more compliant 
prostheses, which match the host artery compliance, is expected to reduce the 
haemodynamic changes induced after their implantation. 
 
2.2.9 Aortoduodenal Fistulas 
  Aortoduodenal fistula (ADF) is an abnormal communication between the aorta 
and usually the fourth part of the duodenum. ADF constitutes a rare but life-threatening 
complication of aneurysm repair. Until recently, they were primarily associated with 
OSR, occurring at a rate of 0.4% to 2.4%
81-86
. However EVAR patients are not immune 
to the development of ADF and a small number of cases have been reported in the 
literature
47;81-83;85-92
. The exact cause for the development of ADF following EVAR  
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remains unclear. A strong hypothesis is that local infection, which could be secondary 
to the grafting procedure or pre-existent (EVAR done for mycotic aneurysms) could 
result in intestinal necrosis and the formation of a fistula between the aneurysm and the 
intestinal wall. EVAR of inflammatory AAAs has been directly associated with ADF in 
previous reports; cultures taken at laparotomy grew micro-organisms of colonic 
origin
90
.  
  Endotension may also lead to the formation of ADF resulting from pressure 
necrosis of the aneurysm against the intestinal wall
81
. Bertges et al
83
 also suggested that 
extensive sac embolisation after EVAR may eventually lead to an ADF; therefore it 
may be wise to limit the embolisation sessions and the number of coils inserted into the 
sac to treat an endoleak. 
  The surgical treatment of ADF following EVAR is similar to infections after 
OSR, consisting of graft removal and revascularisation coupled with repair of adjacent 
area of bowel and placement of omentum between the intestinal and aortic repairs
93
. 
Endograft explantation may vary with different device designs. In the case of stent-
grafts without suprarenal fixation, the excision of the graft is not a complex procedure; 
stent-grafts with suprarenal barbs frequently necessitate supraceliac control
94
. These  
procedures carry significant perioperative morbidity and mortality. A high index of 
suspicion and emergency treatment is essential for aortic graft infections. 
 
 2.2.10 AAA Rupture 
  Sac regression, a reassuring sign of aneurysm exclusion and depressurisation of 
aneurysm sac, are the primary goals of EVAR
95
. Sac enlargement after EVAR, 
however, is associated with continued or intermittent pressurisation of the sac, 
secondary to endoleak or endotension, and has been associated with late aneurysm 
rupture
96;97
. Determination of AAA rupture following EVAR may be difficult to verify; 
however Brewster et al
18
 reported an incidence of 1.5% occurring at a mean interval of 
30 months following stent-graft placement. Abbruzzese et al
98
 reported a similar 
incidence of 1.1%. The causes of rupture included late-onset type I proximal attachment 
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leak, persistent type II endoleaks with sac expansion, device structural failure with late-
onset type III endoleak, modular endograft component separation and fabric defect 
resulting from friction and erosion of the graft wall from an adjacent stent strut. Female 
gender, adverse anatomy with short, wide and angulated infrarenal necks responsible for 
causing stent migration and late endoleaks are predictors of late rupture post-EVAR
18
. 
Mortality following treatment for late-rupture is variable in different reported series 
from 43%
98
 to 83%
99
. 
  Regular life-long follow up is essential following EVAR to detect endoleaks and 
sac expansion and with appropriate treatment, the incidence of late rupture and 
subsequent mortality can be hopefully reduced. 
 
 
2.2.11 Secondary interventions and Mortality 
As discussed above, the common indications for reintervention following EVAR are 
persistent primary endoleaks, significant graft migration, late-onset endoleaks, and graft  
limb stenosis or thrombosis, and endotension causing sac enlargement
18;98
. In some 
instances, changes in AAA sac and iliac artery morphology can cause graft-related 
problems although sac shrinkage has occurred as a result of effective aneurysm 
exclusion, a phenomenon termed as “paradox of success”99. The procedures required 
commonly include placement of proximal and distal extension limbs, coil embolisation 
of branch vessels, angioplasty and stenting of graft limb kinks and open procedures like 
conversion to OSR, graft limb thrombectomy, repair of common femoral artery 
pseudoaneurysms and extra-anatomic bypass for limb occlusion. Hobo et al
100
 studied 
the influence of endograft extensions during the primary EVAR procedure on the 
postoperative complications, mortality and secondary interventions. Based on the data 
of the EUROSTAR (The European Collaborators on Stent-Graft Techniques for AAA 
and Thoracic Aortic Aneurysm and Dissection Repair) registry, they reported a 
substantial increase in late device kinking and secondary transfemoral interventions in 
patients with an iliac device limb extension. This indicates that single devices are 
potentially less vulnerable to late failure. In a separate study
101
, they also reported that  
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though the overall incidence of secondary interventions after EVAR had decreased 
significantly as compared to earlier experience, trans-abdominal and extra-anatomic 
reinterventions had decreased less and are associated with an increased mortality risk. 
This finding suggests continuing need for surveillance for device-related complications. 
  
  Several studies have demonstrated that EVAR reduces the rate of complications 
and mortality compared with open repair even though EVAR patients as a group are 
older with multiple co-morbidities
102-104
. In randomised controlled studies, perioperative 
mortality was 4.6% after open repair and 1.2% to 1.6% after EVAR
102;104
. Compiled  
data from published series on surgical conversion report an average mortality rate of 
22%
105
. 
 
  A recent series has shown that after the introduction of EVAR, elective repairs 
have increased, ruptured AAAs have decreased, and procedure-related mortality has 
decreased for both intact and ruptured AAA
106
. This has led to decrease in overall 
AAA-related deaths despite an unchanged mortality rate of elective open AAA repair. 
The need for any reintervention, large preoperative AAA size, family history of 
aneurysmal disease, and renal insufficiency have been identified as the most important 
predictors of aneurysm-related mortality (ARM)
18 
. Overall mortality from late 
conversion is markedly higher than elective primary OSR and is influenced by rupture 
and infection. 
 
 
Incidence rates of EVAR failures at different time points are outlined in table 2.5. 
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Table 2.5 Incidence rates of EVAR failure modes at different time-points
58;107
 
No. Mode of failure Incidence (%) 
  30 days 12 months and 
beyond 
1. Endoleak 
Type I 
Type II 
Type III 
Type IV 
 
3.5 
14.0 
 
6.8 
10.3 
4.2 
10 (earlier reports: 
now significantly 
reduced) 
2. Endotension 1.5-5 (overall) 
3. Stent fatigue and fracture 3.1 (overall) 
4. Iatrogenic injury to access artery 4.8 (immediate) 
5. Graft limb thrombosis  2.5 (12 months), 3.9 
(beyond 12 months) 
6. Graft stenosis 0.3 1.5 
7. Aortoduodenal fistula 0.4-2.4% (overall) 
8. Stent migration  1.4 (12 months) 
4.0 (beyond 12 
months) 
9. AAA rupture 0.3 0.6 
10. Conversion to open repair 1.7   2.0 
11. Secondary interventions 16.2 (overall) 
12. Mortality 2 2.6 
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2.3. OUTCOMES BASED ON ANATOMIC AND DEVICE-SPECIFIC 
ANALYSIS 
 
2.3.1 Cook Zenith. Unlike most other commercially available stent-grafts, the Zenith 
device has undergone remarkably few changes since its introduction in 1997
108
. The 
initial report of the Zenith Multicenter Trial provided evidence that endovascular repair 
of AAA with the Zenith stent-graft was superior to open surgery for both associated 
morbidities and aneurysm-related death
30
. The conclusions were tempered by the 
expectation that endovascular repair would require more detailed follow-up than open 
repair and might not provide as durable a result. However middle and long term data 
suggest positive results with a very low incidence of previously reported adverse 
endovascular outcomes like limb thrombosis, stent fracture, and component 
separation
108
. The occurrence of late endoleaks and persistent sac enlargement was 
noted in a subset of patients which will require further investigation and long-term 
follow up. Overall, the application of Zenith endovascular graft to infrarenal aneurysms 
with appropriate anatomy is associated with a very low risk of failure and provides a 
promising platform for future developments
108
. 
 
2.3.2 Gore Excluder. EVAR with the original-permeability Excluder (W.L. Gore & 
Associates, Flagstaff, Ariz) has been associated with postoperative sac expansion in the 
absence of endoleak. The graft material was modified to reduce its permeability and 
released for commercial use in mid-2004. In early follow-up, the low-permeability 
Excluder device is associated with a significantly greater aneurysm shrinkage rate than 
the original version
109
. Clinically important enlargement also appears significantly 
different within 1 year of implantation. Despite these promising results, longer follow-
up is needed to determine whether these differences will persist. When evaluated in a 
retrospective review, the Excluder had similar clinical outcomes at 5 years compared to 
other commercially available devices
98
. There were no differences in postoperative 
mortality, aneurysm rupture, ARM, conversion to open repair, or reintervention rates. 
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2.3.3 Medtronic AneuRx. In a retrospective review by Abbruzzese et al
98
, AneuRx was 
the most commonly used stent-graft at their institute (49%) over a period of 6 years 
(1999 to 2005). The clinically relevant outcomes were similar when compared with 
Zenith and Excluder stent-grafts. The ARM was low (3.6%) with 95% freedom from 
reintervention at 5 years. The graft related adverse events were low as well. Smith et 
al
110
 reported similar results suggesting that endovascular treatment with modular 
AneuRx is safe and effective, producing acceptable results of disease-free survival and 
mid-term clinical outcome. A word of caution for the AneuRx device is an earlier report 
of significant risk of endograft migration
111
, the incidence of which increased with time.  
This is associated with adverse neck anatomy but since its first use, at least two major 
graft and delivery system upgrades have been made which have reduced this risk
112
. 
 
2.3.4 Medtronic Talent. The Talent device is a modular endograft system that uses a 
self-expanding skeleton of serpentine Nitinol stent springs inlaid in a woven polyester 
fabric. While the Talent device allows for treating more adverse neck anatomy, it does 
require a slightly larger delivery sheath
112
. In a report by Brown et al comparing the  
Cook Zenith and the Medtronic Talent endograft within the EVAR trials within the 
United Kingdom, no statistically significant differences were found in regard to 
secondary interventions, aneurysm-related death, or all-cause mortality
113
. However, the 
Talent device is associated with worse clinical outcome in patients with aneurysms > 6 
cm in combination with proximal neck > 2.6 cm, so this group of patients should have 
more intensified surveillance during follow-up for endoleak and migration
114
. 
 
2.3.5 Endologix Powerlink. The Powerlink device is a unibody bifurcated endovascular 
graft utilised for the repair of AAAs. It is thus different from other commercially 
available devices. Its delivery is achieved through one surgically exposed femoral artery 
as opposed to two. The Powerlink device appeared to be durable and effective in 
excluding aneurysm flow and prevention of sac enlargement over a period of long-term 
follow up
115
. The graft and the stent materials have been free from failure and fatigue.  
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The requirement for only one surgically exposed femoral artery facilitates graft 
placement in patients with limited access routes and reduces the morbidity of an 
additional groin wound. However the overall survival at 72 months was no different as 
compared to open repair, indicating that the Powerlink system is just as durable in 
protecting patients from aneurysm-related death as open repair
115
.  
 
2.4. FURTHER DISCUSSION 
Although EVAR has evolved considerably since 1991, it is clear from the literature and 
clinical trials carried out to date that there is a long way to go before it will overtake 
OSR and become the modality of choice for treatment of AAA.  
 
Results from Clinical Trials and Current state of EVAR 
 
2.4.1 The EVAR Trial 1: EVAR trial-1 showed that although aneurysm-related death 
from EVAR is 3% less likely to occur when compared with OSR, overall survival in the  
two groups were similar. The results suggest that EVAR offers no advantage with all-
cause mortality and Quality of Life, is more expensive and leads to a greater number of 
complications and re-interventions.  
Apart from being not representative of current practice, important limitations of the 
EVAR trial-1 include the entry criteria with possible over-representation of more expert 
centres and relatively shorter follow up (4 years). 
 
2.4.2 The EVAR Trial 2: The EVAR Trial 2 compared patients unfit for OSR and who 
received EVAR, with patients unfit for OSR who received no treatment
116
. All were 
followed-up for a minimum of 12 months. The investigators noted that 30-day mortality 
was “considerable” at 9% in the EVAR group. Additionally, after 4 years 30% of all 
patients had died from aneurysm-related causes and a total of 64% had died from all 
causes with no difference found in the two groups (62% in no-treatment group and 66% 
in EVAR group). Costs for the EVAR group were, however, considerably higher when  
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compared with the no intervention group (mean difference, £8649) with no difference 
found in health-related quality of life scores. This analysis is very interesting as the 
original aim in using EVAR was to treat patients such as those in this trial. 
 
  There are several limitations of the EVAR Trial 2. The reported 30-day 
mortality rate of 9% for EVAR and the 4-year mortality of 64% are both much higher 
than previously reported in high-risk patient cohorts. Patients assigned to EVAR who 
died while awaiting treatment (8% of the total, 14 deaths) were counted as receiving 
EVAR. In marked contrast to the treated group’s mortality of 9%, the mortality rate in 
the 47 patients (27% of the no treatment group) who crossed over to receive an AAA 
repair was only 2%. Although level 1 evidence, the effect of treatment delays before 
receiving EVAR and the high rate of crossover to receive EVAR has undermined 
confidence in the conclusions drawn from its intent-to-treat results. 
 
2.4.3 DREAM Trial: Four-year results of the DREAM Trial from the date of discharge 
suggest a higher mortality after EVAR as compared to open repair however the 3% 
perioperative benefit of the EVAR group was excluded in this analysis. Potentially there 
is a 10% to 15% benefit for open repair at four years from discharge likely to swamp the 
3% benefit from perioperative period known to occur in the EVAR group. The Trialists 
believe that open repair could win in the long term in DREAM; however no such trends 
have been found in other trials comparing EVAR with OSR. 
 
  Although the DREAM trial patients were considered to be suitable for both open 
and endovascular repair, this decision was not based on standardized risk-stratification 
systems. Consequently, it is conceivable that patients were included in the DREAM trial 
who actually had an elevated risk of dying in the first 2 years after surgery. This would 
make the indication for AAA repair questionable in these patients. Furthermore, the trial 
has also been criticised for being underpowered. The sample size calculation was based 
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on primary endpoint of short-term mortality and complications and the trial’s power to 
detect differences in follow up outcomes is unclear. 
 
2.4.4 EUROSTAR Registry: The EUROSTAR registry evaluated the quality-adjusted 
life expectancy post-operatively for both EVAR and OSR and found that EVAR was 
likely to prolong a healthy 70-year old male’s life by only 3 weeks. This was increased 
to 2 months in 70-year old men in poor health. They showed that in younger patients 
OSR is superior, but older patients still do better with EVAR. The age where both 
treatments are equivalent is 64 years. EVAR of infrarenal AAAs with the first- and 
second-generation devices that predominated in this study was associated with a risk of 
late failure, according to an analysis of observed hard end points of 3% per year. It is 
unclear from the report whether patients died from aneurysm-related or other causes. 
Early action against significant risk factors like proximal type I endoleak, mid-graft type 
III endoleak, graft migration and postoperative kinking of the graft has been 
recommended to improve long-term results. 
  
  Because participation in the EUROSTAR project is entirely voluntary, data 
collection is neither comprehensive nor complete. The best we can hope for is that the 
data submitted are reasonably representative of practice in European Hospitals as a 
whole. For effective benchmarking this is not good enough. To maintain a standard of 
data submission in terms of both quality and timing, all those patients from centres that 
consistently fail to deliver the data were excluded from the database. This resulted in 
near complete submission of follow-up information. When evaluating Eurostar results it 
is important to take account of the fact that, inevitably, the outcome of treatment with 
the earlier generations of endovascular devices will influence the overall results. Some 
of the devices are no longer commercially available and the newer generation stent–
grafts may perform differently. 
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  Results from other earlier studies comparing outcomes in patients treated with 
EVAR versus those treated with OSR are inconclusive. Both the EVAR trial-1
102
 and 
the EUROSTAR registry
117
 showed that there was little difference in outcomes in 
patients treated with EVAR compared with those treated with OSR. In contrast, Hua et 
al.
118
 found that there was a significant increase in both 30-day mortality (P<0.05) and 
30-day morbidity (P<0.0001) in patients treated with OSR when compared with the 
EVAR group. It is often the case that 30-day mortality is found to be reduced for EVAR 
compared with OSR
102;103
. Ultimately, all investigators conclude that longer-term 
follow-up is required before any firm conclusions can be made regarding the superiority 
of one treatment over the other. 
   
  One of the major problems with EVAR, compared with OSR, is the risk of 
endoleak. For instance, patients lost to follow-up after EVAR can be at risk of aneurysm 
rupture and possible death as a consequence of endoleak. In addition, reintervention is 
often required at a rate that is higher than that of OSR
117
. In fact, Becquemin et al.
119
  
found that 27% of patients who underwent EVAR required a secondary procedure 
(mean follow-up was 28 months). Another issue is that hospital and physician time is 
required post-operatively to ensure the integrity of the stent-graft. Becquemin’s group, 
for example, performed clinical examination, abdominal plain radiography, duplex 
scanning, and computed tomography at 1, 6, 12, and 18 months, and yearly thereafter on 
each of their EVAR patients. In contrast, Biancari et al.
120
, who performed OSR on 284 
patients, performed a mean of 2.2 ultrasound scanning examinations on 77 patients, a 
mean of 1.3 arteriography scans on 28 patients and a mean of 1.5 computed tomography 
scans on 11 patients. Clearly, physician and hospital times are less, post-operatively, for 
OSR patients compared with EVAR patients. 
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  There is a subject of cost differences between OSR and EVAR. Given the 
clinical equipoise of the two treatment options, clearly cost will be the deciding factor in 
which option is used. If the cost of the grafts and stent-grafts used in OSR and EVAR, 
respectively, were equal, EVAR would be much the cheaper option. Hospital costs, 
such as length of stay in hospital
121
 and length of operation
102
 have been shown to be 
significantly less for EVAR compared with OSR. In a study by Dryjski et al
122
,  the cost 
of graft in OSR was on an average $750 which was much lower than the average cost of 
EVAR stent-graft ($12,974) making the overall cost of EVAR higher than OSR in spite 
of lower ICU use and overall hospital stay. Moore and colleagues
121
 also found that the 
length of stay in the Intensive Care Unit (ICU) of the hospital was significantly shorter 
for the EVAR group compared with the OSR group (p<0.05); however now most 
patients do not need any ICU stay following EVAR, especially in high volume 
institutions. In a review by Drury et al
107
, it was suggested that when undertaking 
surgical repair in a high-risk patient, it can be difficult to organize the required critical 
care services, and consequently EVAR with its reduced requirements may have some 
advantages.  
 
  Thus, even given the follow-up costs (tests mentioned above in Becquemin’s 
study) that are associated with EVAR, the endovascular approach would be the more 
cost-effective treatment, if the device cost was low. However, endografts can cost 
upwards of $11,000, a cost that significantly adds to the overall costs. In Moore and co-
workers’ analysis, they found that the device accounts for 58% of total costs for EVAR 
patients. The authors suggest that this cost is prohibitively high to allow EVAR to 
become the treatment of choice, and that it is unlikely that the devices will become 
cheaper with time, as vast sums of money are required to develop them
121
. They go on 
to suggest that EVAR will only be used where the patient is unable to undergo OSR or 
by patient and physician preference, rather than financial considerations.  
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In the question of EVAR vs. OSR, as we have seen, the randomized controlled trial 
(RCT) evidence is limited. The enrolment period of the DREAM
123
 trial was November 
2000 to December 2003 and EVAR 1
102
 was September 1999 to December 2003. This 
RCT evidence may be dated. Further evidence may come from the ongoing large multi-
centre trial, The Open vs. Endovascular Repair (OVER) trial for AAAs, which had an 
enrolment period beginning in 2001 and ending in 2010. The recruitment period will be 
more up-to-date and thus, based on the results from this analysis, we should expect 
lower perioperative mortality rates in both EVAR and OSR groups, but similar 
mortality differences, as well as lower rates of endoleaks and ischaemia
124
. 
 
  EVAR has been increasingly used for the treatment of ruptured abdominal aortic 
aneurysms and it has a clear benefit as laparotomy, aortic cross-clamping and 
retroperitoneal dissection is avoided thereby reducing haemodynamic shifts as well as 
the likelihood of inflammatory response
125
. Significantly decreased mortality of 
endovascularly repaired ruptured AAA at 30 days vs. OSR has been demonstrated in  
three prospective trials
125-127
. However, institutional and surgeon experience is essential 
to fully benefit from the use of this procedure for the treatment of ruptured AAAs. In a 
recent survey, a significant survival benefit was independently associated with increased 
institutional volume
78
.  
 
 
 
2.5 Conclusions & Prospects for the Future 
  This past decade has witnessed a remarkable evolution and transformation in our 
approach to the treatment of aortic aneurysms. Even with the learning curve and early 
clinical trial results included, recent studies have suggested that the long-term outcomes 
of endovascular infrarenal AAA repair are excellent.  
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  The endograft market is one in constant flux. Lessons learnt from the past 14 
years of EVAR have meant that stent-grafts themselves are constantly evolving (e.g. 
Cordis have produced the Quantum, followed by the Fortran and are now developing a 
third-generation stent-graft). With this in mind it is difficult to evaluate where EVAR 
will be in the next decade. It is likely that, with further developments and new 
generation devices arriving on the market, the problems mentioned above will be 
overcome, and that EVAR could become the treatment of choice for AAA. In the next 
decade, we can expect continuing improvements in endovascular device design to 
include the treatment of suprarenal and thoracoabdominal aneurysms. The role of OSR 
will diminish but not disappear. As more experience and skill in EVAR is gained, 
surgeons will be challenged to maintain their skills in open repair.  
 
  EVAR is associated with a life time risk of rupture because most patients will 
live for several years after the procedure
117
. Purpose of future research should be 
improving the efficiency of the follow-up schedule after EVAR and evaluation of new  
stent-graft designs to prevent graft failure. Graft materials and construction are 
constantly undergoing testing to provide better configurations. Hopefully, new 
generations of devices with improved material and stent design will minimise EVAR 
complications while providing increased indications for its use and durability. 
 
  Our group have developed the POSS-PCU polymer with several superior 
properties as discussed earlier. In this work, we have used this polymer to develop novel 
aortic stent-grafts with unique sutureless design. We have used a new aortic model for 
their physiological assessment in vitro and analysed its long-term durability and 
compliance. We have also evaluated compatibility with magnetic resonance imaging, 
which is a crucial factor for their development. The hypothesis, aim and objectives are 
outlined below. 
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2.6 Hypothesis, Aim & Objectives 
2.6.1 Hypothesis 
As discussed here, there is an unmet clinical need to develop new devices to improve 
long-term durability of endovascular stent-grafts and reduce the risk of complications 
and reinterventions. The use of a novel nanocomposite polymer which has superior 
properties of compliance, biocompatibility, and increased mechanical strength, 
sutureless technology with polymer bonding to nitinol and engineered approach can 
lead to the development of state-of-the-art stent-grafts which will have long-term 
durability. These devices can help in reducing the risk of complications, and improve 
the patient outcomes following endovascular aneurysm repair. 
 
2.6.2 Aim 
To develop aortic stent-grafts using a novel nanocomposite polymer based on 
polyhedral oligomeric silsesquioxane – poly (carbonate-urea) urethane (POSS-PCU) 
 
2.6.2 Objectives 
The main objectives of this work are: 
1. To utilise POSS-PCU bonded to surface-modified Nitinol to develop a 
sutureless aortic stent-graft for abdominal aortic aneurysms 
2. To develop a prototype using engineered approach and modified origami 
technology and assess folding efficiency in comparison to current device 
(Medtronic Talent
TM
)  
3. To use the same principles and develop an innovative curved device conforming 
to the anatomy of thoracic aorta and aortic arch, which will potentially allow 
manoeuvring and tracking for varying patient anatomies 
4. To test a new physiologic aortic model based on POSS-PCU and analyse its 
compliance and elastic stiffness in comparison to presently used latex model 
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5. To confirm durability of the sutureless design by extensive in vitro analysis in a 
simulated pulsatile flow model (for 400 million cycles equivalent to 10 years in 
human body) based on recommendations by Food and Drug Administration 
(FDA) 
6. To test structural, mechanical, elastic and thermal properties of the fatigue-tested 
POSS-PCU and compare them to zero-cycled control 
7. To analyse compliance, viscoelasticity and elastic stiffness of the curved device 
in comparison to presently used thoracic stent-graft (Gore Tag
TM
)  
8. To compare magnetic resonance properties (image artefacts, signal attenuation 
and flow velocity) of the curved POSS-PCU nitinol stent-graft with a device in 
current clinical use (Medtronic Valiant
TM
) 
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Chapter 3 
 
Design and analysis of aortic stent-grafts based on an engineered approach using 
surface modified Nitinol and a Nanocomposite polymer 
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3.1 INTRODUCTION 
Improvement of device durability is a major challenge facing stent-grafts for 
aortic aneurysms. The stent-graft device is essentially a combination of a traditional 
textile vascular graft and an intravascular stent. This design is potentially linked to 
many of the device’s difficulties, including incompatibility failures between the device 
scaffold and cover material, protein absorption and thrombogenic effects, cover material 
degradation, large device insertion profile and poor device trackability. 
 
  We present an innovative design for a self-expanding stent-graft that 
incorporates a Nitinol (NiTi) alloy scaffold with a polyhedral oligomeric silsequioxane- 
poly (carbonate-urea) urethane nanocomposite polymer, chosen for its excellent 
biocompatibility and superior vascular properties. The polymer is a new type of 
biomaterial that is hydrophobic and non-thrombogenic, and has been shown to favour 
endothelialisation
5;128
. The proposed device combines deployable structure technology 
to improve the folding efficiency and performance of the device in vivo. The scaffold 
geometry is designed similar to the aortic vessel. This design is further analysed using 
numerical methods to simulate the nonlinear response of a NiTi alloy scaffold. The 
fatigue resistance is confirmed by comparing predicted strain amplitude values to 
published data. These principles are used to develop a stent-graft for infrarenal 
abdominal aortic aneurysms (AAA).  
 
  In addition, we also aim to address the problems associated with the present 
generation of thoracic aortic endovascular devices by developing a novel stent-graft 
using the above principles. The new technology allows pre-forming of the angulation of 
the host aortic arch into the device and due to the bonding of the graft around the metal 
skeleton, reduces the risk of mechanical stress-related disruption, kinking, migration, 
and endoleak. Because of the folding technology a more flexible and potentially 
narrower gauge delivery system can be employed but most importantly the device can  
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be constructed so that once deployed it will be inherently stronger, more stable and have 
the degree of angulation tailored to the individual patient. There is also scope to include 
branch grafts in the folded metal structure to incorporate the major vessels. Such a 
device has the potential to treat many more patients with this increasingly common 
condition in our ageing population. It will reduce the need to occlude or reconstruct the 
great vessels thus significantly reducing complications and risk of operative death 
associated with hybrid procedures. 
 
3.2 DEVELOPMENT OF AN ENDOVASCULAR STENT-GRAFT FOR AAA 
USING ORIGAMI FOLDING TECHNOLOGY 
This paper proposes to improve the performance of the device using a new 
approach to stent-graft design that utilises deployable technologies. Specialised folding 
patterns derived from the art of origami
3
, were adapted for folding of a stent-graft 
system to produce a device that packs efficiently and which is small enough to be 
inserted percutaneously. In addition, it is proposed to improve the in vivo performance 
of the device by using a nanocomposite polymer for the device graft material. The 
polymer is a type of polyurethane that has been developed specifically for vascular 
applications. Polyurethanes are composed of hard and soft segments, incompatibility 
between which, results in microphase separation. This behaviour infers tough, 
viscoelastic response, that is ideal for vascular applications
5;128
. Biostability is achieved 
by incorporation of a biologically stable soft segment group made up of polycarbonate 
molecules to form a poly (carbonate urea-urethane) (PCU). The material’s surface 
properties are defined by Polyhedral Oligomeric Silsesquioxane (POSS) groups that are 
covalently bonded to the polymer backbone. These nanoparticle pendant groups modify 
the material’s surface morphology making it resistant to thrombus formation and they 
are also suitable for chemically modification to promote endothelialisation or for drug 
delivery. 
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This paper describes the prototyping and analysis of a stent-graft design which 
incorporates deployable structures technology with a nanocomposite PCU graft and a 
Nitinol self-expanding scaffold. It aims to document a new stent-graft design concept 
and provide a methodology for device scaffold optimisation.  
An efficient folding pattern for a thin tube has been developed that is based on 
origami paper folding theory
3
. It is proposed to incorporate this pattern in the device to 
optimise folding and to thereby minimise the device insertion profile. The main 
objectives of this study are: 
1. To define the origami pattern in the nanocomposite polymer (NP) and develop a 
methodology for folding the tubular structure 
2. To optimise bonding between Nitinol and NP 
3. To design a device scaffold that facilitates deployment, is compatible with the 
origami folding pattern, is flexible and provides the necessary radial strength 
when implanted 
4. Embed the wire scaffold in PCU material 
 
3.2.1 Origami Pattern in Polymer 
It has been demonstrated that origami derived folding patterns can by used to minimise 
the diameter of a folded tubular structure and it is proposed to use this technology to 
achieve a minimal insertion profile for the stent-graft device. However, there are a 
number of challenges in adoption of this pattern in the NP. These include: 
 Developing a methodology for defining the pattern hinge lines in the NP 
material. (The high flexibility of the polymer material increases the difficulty of 
this task.) 
 Incorporating a scaffold that infers suitable radial strength, is compatible with 
the origami folding pattern and which folds efficiently to minimise the device 
insertion profile. 
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 Ensuring that the stent has a smooth inner surface to minimise turbulence in the 
blood flow. 
 
3.2.2 Moulding 
3.2.2.1 Model 
Plaster of Paris was used to cast models of the origami pattern. The casting mould was 
made using plastic sheet, which was folded into the desired origami pattern and formed 
into a cylindrical shape. The mould was then positioned vertically in a container of sand 
as shown in figure 3.1. A tube was fitted over the outside of the plastic mould to 
maintain its cylindrical shape and a wooden dowel was aligned with the central axis 
mould to add reinforcement to the casting. Plaster was cast into the mould in 10 mm 
thick layers, the first of which sealed the base of the plastic model. This approach 
reduced the risk of leakage at joins in the plastic mould. This method was used to 
produce a 55 mm diameter model (shown in figure 3.1) of the partially deployed 
origami pattern and if dip coated, would allow a NP moulding of the pattern to be 
produced. 
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A B 
Figure 3.1: Plaster of Paris used to cast models of Origami pattern. Plaster casting 
arrangement (A) and Plaster of Paris origami model (B) 
 
 
3.2.2.2 Dip Coating Procedure 
A low viscosity or thin polymer formulation was chosen for dip coating to promote a 
homogenous coating. This formulation was developed by adding additional N, N-
dimethylacetamide (DMAC) to a 20 wt% polymer solution and resting it overnight to 
ensure that the DMAC was fully dissolved. The plaster of Paris model was manually 
dipped in the polymer solution and allowed to dry at room temperature for 30 minutes. 
While drying, the mould was rotated to minimise dripping and to promote an even 
coating along the pattern hinges and valleys lines. After this period the model was 
placed in an oven for 4 hours at 60 
o
C to evaporate residual solvent, before the 
procedure was repeated three times. When the target thickness of approximately 100 μm 
was achieved, the coated model was maintained at 60 
o
C overnight to ensure all solvent  
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was removed and the polymer was suitable for removal from the model. 
 
3.2.2.3 Results and Discussion 
NP cylinder was moulded with an origami pattern using the dip coating procedure. The 
moulding was approximately 55 mm in diameter and 115 mm in length. Although this 
approach was successful in defining the origami pattern, a number of limitations were 
identified. Firstly, unless the moulding was tensioned both in the hoop and longitudinal 
directions the material exhibited a non-uniform surface topography that corresponded to 
that of the plaster of Paris model. This effect is undesirable as it could interfere with the 
blood flow through the device and result in negative biological effects. In addition, 
close examination shows that mould was thicker at the valley hinge lines, showing 
evidence of voids and other defects at these areas. This may be related to shrinkage 
effects as the N, N-dimethylacetamide (DMAC) solvent was evaporated from the 
polymer, or possibly due to absorption of the polymer material into the plaster model. 
Although qualitative testing showed that the moulding tended to fold at the designated 
hinge lines, close examination showed that this was related to a localised thickness 
gradient, where the thickest section lay at along the hinge line. Hence, folding was 
actually occurring to either side of this line and not exactly along the line itself. 
Accurate location of hinge lines is essential for efficient operation of the pattern and 
therefore, this effect was seen as a significant limitation. Embedding the scaffold 
during, or after the dip coating process represented a further challenge. It was concluded 
therefore, an alternative approach should be investigated and this is described below. 
 
3.2.3 Casting Approach 
The origami pattern functions by means of preferential fold lines, or hinge lines. Hinge 
lines can be created by introducing area of locally thin section. This approach was 
investigated using flat cast sheets of the NP material, with the aim of developing a 
methodology that addressed the limitations of moulding approach.  
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3.2.3.1 Method 
1. A 100 μm thick, flat sheet of polymer was cast into a stainless steel tray 
2. The origami pattern was printed on paper and taped to the PU sheet so it could 
be viewed through the sheet 
3. A second polymer sheet was cast (200 μm) and cut into panels that corresponded 
to the origami pattern used in (2), however, which had been reduced in size by 
10% 
4. The cut panels were glued to the surface of the cast polymer sheet, using the 
printed pattern as a location guide. The polymer was used as glue. 
 
3.2.3.2 Results and Discussion 
A NP sheet was manufactured using the procedure described and the result is 
shown in figure 3.2. The pattern hinge lines are located between the panels, i.e. where 
the material is locally thinner. The structure could easily be manually folded (see 
figure.3.2(B)) indicating that this approach showed promise for fabrication patterns with 
significantly smaller elements. Although the outer surface of the sheet had a non-
uniform surface topography, the inner surface was smooth, making it ideal for inner 
surface for the graft. No significant defects were identified in the fabrication and 
qualitative testing indicated that it demonstrated good mechanical strength and 
toughness. It is proposed to wrap this sheet into a cylindrical form and glue it in place.  
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(A)                             (B) 
    
 
Figure 3.2 NP defined with origami pattern using casting method with number of rows 
of rectangular elements (A), Folded version of A showing collapse efficiently to a 
minimum volume (B) 
 
 
Compact packaging of a tubular structure, such as a stent-graft, can be achieved 
by introducing carefully designed creases that behave as line hinges. The cylinder 
shown schematically in figure 3.3(a) shows a folding pattern composed of a number of 
rows of rectangular elements. Each repeated element is compromised of fold lines that 
allow it to collapse efficiently to a minimal volume. This folding system can be 
incorporated into a stent-graft design by orientating the scaffold in an opposing fashion 
as indicated by the dashed lines shown on figure 3.3(b).  
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Figure 3.3: Thin walled cylinder folding pattern. Scaffold orientation in opposing 
fashion as indicated by dashed lines. 
 
 
3.2.4 Scaffold 
The polymer cover material is highly flexible. To overcome this and to facilitate the 
deployment of the device, a metallic scaffold was embedded in the NP cover. The 
scaffold has a number of requirements 
 
 drive deployment 
 radial strength when fully deployed 
 flexibility when folded for delivery 
 minimal insertion profile 
 compatible with origami folding pattern 
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A NiTi alloy commonly known as Nitinol was used to construct the device scaffold. 
Nitinol is classed as a superelastic material as it can elastically recover strains in excess 
of 8% via a stress induced (reversible) transformation. The stress-strain curve follows a 
non-linear path with significant thermal variations occurring as the material undergoes 
the phase change. The phase change can also be thermally activated at certain critical 
temperatures. This provides the facility to freeze large deformations into the material 
that can be elastically recovered upon heating above a critical temperature; hence the 
term shape memory alloy. These unusual properties can be used to facilitate the elastic 
deployment of the device from the catheter tip. 
This section describes the procedure used to fashion NiTi wire into support scaffolds for 
the stent-graft device. NiTi wire of 0.6 mm diameter was shape set into a zigzag pattern 
using the rig shown in figure 3.4 (A). The following procedure was used: 
1. Wire was constrained between pins in rig. 
2. The constrained wire was heated in an oven at 550 oC for 15 minutes. 
3. The constrained wire was removed from oven and air cooled until it could be  
safely handled and removed from the rig. 
 
(A) (B) 
  
Figure 3.4: Shape setting of zigzag pattern with wire constrained in pins in a rig (A) 
and helical pattern with zigzag wire hoops placed around a collapsible mandrel (B) 
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The shape setting procedure was then repeated, however this time to form the wire into 
a hoop: 
4. The zigzag wire was wrapped around a cylindrical tube and bound in place using 
stainless steel wire figure 3.4 (B). 
5. The arrangement was again heated in an oven at 550 oC for 15 minutes and air 
cooled. 
6. The wire was cut to a suitable length and joined using copper sleeves to form a 
hoop (figure 3.5). 
 
Preliminary testing was conducted to investigate the capabilities of the shape setting 
procedure and its application for design of the stent-graft. Figure 3.5 shows examples of 
NiTi alloy hoops (approximately 50 mm in diameter) shape set for use in mould stent-
graft cover described earlier. The hoops were joined by overlapping a short section of 
the wire ends and clamping them with a brass sleeve.  
 
3.2.5 Adhesion Testing 
Surface modification of nitinol to promote its bonding with POSS-PCU nanocomposite 
polymer has been performed by Dr Raheleh Bakhshi, under supervision of Professor 
Alexander M. Seifalian and these results have been recently published. However, this  
  
Figure 3.5: Zigzag superelastic wire hoop (A) and wire hoop series (B) 
 
 
 
 Chapter 3 – Design of Aortic Stent-grafts from a Nanocomposite Polymer 
80 
 
 
 
work has been referenced here as this concept is critically important and has been 
integrated in the development of endovascular stent-grafts, as described in this chapter.  
 
Prolonged implantation of NiTi in the human body can result in corrosion of the 
material and the release of deleterious ions, leading to harmful biological consequences. 
Coating the NiTi surface with a nonbiodegradable polymer, such as the PCU, can 
enhance surface resistance to the biological environment, improving its 
biocompatibility
4
. Furthermore, a surface coating can be used to infer desirable 
characteristics; for example drug elution and cell attachment. However, polymer 
coatings can be difficult to apply and it can be difficult to maintain an effective bond for 
extended periods in vivo
129-132
. In the case of coated vascular stents, it must be 
demonstrated that any coating can withstand the high strains associated with device 
deployment without delamination and also maintain its integrity for an extended period 
post-implantation.  
 
The risk of delamination can be reduced by modifying the substrate surface to promote 
adhesion. The integrity of the thin film and the adhesion properties between a coating 
and a metallic substrate surface depend on the surface chemical composition and its 
physical properties, including, morphology and roughness of the metallic substrate prior 
to the film deposition
133
.  
 
We have previously developed and optimised an electrohydrodynamic atomisation 
(EHDA) deposition process for stent coating
134
. To complete the process of coating, the 
NiTi strip has to be sprayed for 3 hours.  
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An Instron 5565 tensometer equipped with a 500 N load cell was used to 
measure the peel strength of the POSS-PCU coated NiTi strips. The coated specimens 
were loaded in the test machine as shown in figure 3.6. The peeling process was 
initiated manually. The lower machine grip was used to clamp the NiTi strip and the 
upper grip held the polymer film, with an initial distance of 10 mm between the grips. 
The test was conducted with a crosshead displacement rate of 5 mm/min to a final 
extension of 40 mm. The thickness of the POSS-PCU coating on the samples tested was 
determined using SEM. 
 
 
Figure 3.6: Peel test arrangement. Polymer coating held at the top grip and nitinol wire 
at the bottom grip. Arrow shows the moving directions of the grips 
 
The susceptibility of POSS-PCU coated-NiTi to disintegration has been assessed in 
vitro by incubating the coated strips in biological/chemical solutions. For each type of 
coating as well as control, five nitinol strips were used for peel strength assessment. For 
each sample, the test was repeated three times. Peel strength data (figure 3.7) confirms 
that a significant improvement in adhesion can be achieved by using the modification 
procedures. Analysis of the data shows that above an extension of 25 mm the load 
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required to remove the polymer from the modified strip for all the samples is on average 
3 times greater than that for the control. 
 
 
 
0 10 20 30 40 50
0
1
2
3
4
5
Peel Extension (mm)
P
e
e
l 
L
o
a
d
 (
N
)
 
Figure 3.7: Peel strength test for untreated and treated NiTi strip. Graph shows peel 
extension in mm in comparison to the load applied in N (◊) 100 μm electrosprayed 
coating on treated NiTi; (♦) 50 μm electrosprayed coating on treated NiTi; (■) Cast 
coating on treated NiTi; (●) Untreated NiTi 
 
Comparative in vitro degradation of the coating on modified and non modified NiTi 
demonstrates the ability of the coating to remain integral with the stent upon long time 
exposure to biological environments. The coating has potential to protect the materials 
surface, mitigate corrosion and increase the longevity of the device in vivo. 
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Figure 3.8:  Combined peel strength test for untreated and treated NiTi strip with peel 
extension in mm on X-axis and load (N) applied on Y-axis 
 
3.2.5.1 Results and Discussion 
The results of the peel strength tests are shown in figure 3.8. The data confirms 
that a significant improvement in adhesion can be achieved using the surface treatment 
procedure. Analysis of figure 3.8 shows that above an extension of 25 mm the load 
required to remove the polymer from the treated strip is on average 3 times greater than 
that for the control. It should be noted that the below an extension of 10 mm both curves 
show a positive slope. In this range the applied load is not great enough to break the 
bond between the polymer and the strip; however, the applied extension causes the 
exposed polymer (i.e. the polymer that was manually peeled from the strip) to strain.  
 
This initial region of the curve should be ignored and is not significant to the 
overall peel strength measured.  
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The peel strength test results are important and necessary to be included here as 
these set the scene for subsequent studies. Comparative in vitro degradation testing on 
modified and non-modified nitinol demonstrates the ability of the coating to remain 
integral with the stent upon long time (70 days) exposure to biological environments 
under static condition. The results of peel strength have shown that an increase in the 
bond strength of the POSS–PCU to the metal alloy can be readily achieved upon surface 
modification. In addition, nickel release profiles showed the dramatic effect that POSS–
PCU had on the corrosion resistance of nitinol samples. 
 
Work is currently on going to confirm the repeatability of the values shown in 
figure 3.9 and to investigate if the treatment process can be optimised further. However, 
the results of preliminary testing have shown that significant improvement to the bond 
strength can be readily achieved.  
 
3.2.6 Scaffold Manufacture 
A prototype was made to investigate if the folding system could be implemented in 
physical device. A device scaffold was constructed from Nitinol wire. The wire was 
constrained in the desired shape and annealed at 550 
o
C for five minutes followed by air 
cooling
5
. This shape-setting process was applied twice: firstly to define the zigzag  
 
shape, and secondly to apply the cylindrical curvature. The wire ends were joined using 
a stainless steel microtube sleeve that was crimped to secure it in place. Flared versions 
of the hoops, designed for device fixation system, were constructed using a similar 
process. Straight wire segments, which would act as spacers between the hoops, were 
cut from virgin material. The scaffold sub-components were subjected to a surface  
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modification process to enhance the bond between the NiTi wire and the PCU polymer. 
This process is described elsewhere.  
3.2.7 Graft Manufacture 
The device was moulded from a PCU polymer blend made from methylene 
diisocyanate, polycarbonate diol and ethylene diamine in DMAC. The DMAC acted as 
a solvent, which was removed by raising the temperature to 60 
o
C. A low viscosity (20 
wt %), polymer formulation was selected to assist with achieving a uniform coating. 
The PCU polymer graft was manufactured by coating a stainless steel tubular mould 
that could be collapsed to permit removal of the graft. A single coat was applied to the 
mould and dried before the scaffold segments were positioned over the mould. A 
second coating was applied to embed the scaffold in the polymer. In parallel with this 
step, a 250 μm thick polymer sheet was cast in a glass dish. The straight wire segments 
were embedded in the sheet during the casting process and were subsequently cut from 
the sheet allowing a 0.5 mm border (approx.) to help prevent the sharp wire ends from 
piercing through device cover. The straight segments were then glued in place using the 
polymer and a further two more thin coats were applied to develop a graft wall 
thickness of approximately 200 μm.  
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3.2.8 Assembled Prototype 
 
Figure 3.9: (a) Stent-graft first prototype alongside paper model of desired folding 
pattern and (b) perspective view of stent-graft in expanded and folding configurations 
 
Figure 3.9 (a) shows the completed prototype together with a paper model of the folding 
pattern described earlier. The scaffold configuration corresponds to the folding pattern 
used in the paper model. Wire spacers were located between the scaffold hoops to 
improve the torsional stiffness, whilst also ensuring good definition of the folding 
pattern and therefore, efficient packing of the graft material between the hoops. Figure 
3.9(b) shows a perspective view of the expanding device alongside a folded device. The 
device was folded by feeding it through a reducing funnel and into sheath that was heat 
shrunk to constrain the device in its folded condition. A collapsed diameter of 6.5 mm 
was achieved from an expanded diameter of 31.1 mm. The prototype’s folding ratio 
compares favourably with commercially available systems. For example, the Medtronic 
Talent stent-graft system, which was initiated in the United States in 1998
135
, has 
delivery profiles between 7.3 and 8.3 mm for expanded diameters between 22 and 46 
mm. Moreover, improvements to the packing and sheathing systems used should make 
it possible to reduce the packaged diameter to less than 4mm, thereby making it suitable 
for percutaneous insertion.  
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Straight-wire segments were used in the first version, but later removed due to 
the fear that they may pierce and damage the polymer. In the second version, the 
distance between the hoops was reduced as well (figure 3.10). 
 
 
Figure 3.10: Stent-graft modified prototype with removal of nitinol straight-wire 
segments (from first prototype) due to concern about graft material perforation 
 
 
3.3 MECHANICAL TESTING OF NITINOL ALLOY 
The mechanical properties of superelastic NiTi alloys are highly dependent of material 
composition, heat treatment history and mechanical processing. Tensile tests were 
therefore conducted to characterise the mechanical behaviour of the grade of material in 
use. The first phase of testing was conducted on NiTi strip used during the adhesion 
testing described earlier. Further test will also be conducted on the wire used in the 
scaffold prototyping; however, this will be included in future work.  
3.3.1 Materials and Methods 
Mechanical tests were conducted on a strip of NiTi alloy that was 5.715 mm in width 
and had a thickness 0.254 mm. The material was bought from a supplier in strip form, 
but had been rolled and subsequently annealed to restore its superelastic properties. The  
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specimen was held in custom designed grips, shown schematically in figure 3.11, with a 
gauge length of 143 mm. An Instron static test machine, equipped with a ±20 kN load 
cell, was used to apply a tensile load to the specimen with a constant strain rate of 20 x 
10
-3
 /s. A preload of 100 N was applied to remove any slack from the system. The test 
was conducted in two steps: 1) the specimen was loaded and unloaded to characterise 
the superelastic behaviour. 2) The same specimen was then loaded to failure to 
determine the tensile strength and the failure characteristics of the material.  
 
 
 
 
 
Figure 3.11: Custom-designed grips used for tensile testing of NiTi strip. Front view on 
the left and sectional view on the right 
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3.3.2 Results and Discussion 
Figure 3.12 shows the stress versus strain curve obtained. In the first loading cycle, the 
specimen is tensioned to a stress of approximately 650 MPa before being unloaded. 
This stress was high enough to induce a full transformation to martensite, with the 
stress-strain curve following a non-linear loop that is characteristic of the superelastic 
response of Nitinol. This behaviour confirms that the material is operating above its Af 
temperature and fully superelastic at room temperature.  
 
 
 
 
Figure 3.12: Mechanical response of NiTi strip. The stress-strain curve showed in this 
graph following a non-linear loop characteristic of nitinol 
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Qualitative analysis of the stress-strain curve profile shows that the Young’s 
modulus of the material varies greatly across its superelastic strain range. In the 
austenite phase the material has a Young’s modulus of 29.4 GPa, which was 3 times 
greater than that for the martensite phase (9.7 GPa). Moreover, the Young’s modulus 
increases by 61.5% to 25.2 GPa, when the material is unloaded from the martensite 
phase.  
 
The same specimen was then loaded to failure and the stress-strain curve 
obtained is also plotted in figure 3.12. Transformation to martensite occurs at a stress of 
approximately 470 MPa, which is 18.7% lower than that for the first loading cycle. This 
is likely to be related to residual martensite content from the first loading, which is 
known to reduce the stress required for initiation of the phase transformation. After the 
transformation plateau, the material becomes fully martensite and regains its strength.  
 
 
The specimen failed in a brittle manner with an ultimate tensile stress of 962.2 MPa. 
This value as slightly lower than typical values quoted in the literature and the material  
did not exhibit a plastic region, as expected. The brittle properties may be related to the 
significant amount of cold work seen by the material to flatten it from a circular cross-
section to from a strip; however, further testing should be conducted on more specimens 
to confirm this effect.  
 
3.4 DEVELOPMENT A CURVED THORACIC ENDOVASCULAR STENT-
GRAFT 
 
Currently, EVAR stent-grafts, as an alternative to more dangerous open surgery repair, 
are used to treat AAA/TAA diseases. These stent-grafts consist of a combination of the 
traditional expandable stent made of metallic mesh wires and a flexible cover. The 
packaging is achieved by folding the metallic mesh structure.   
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The cover, which is stitched or bonded to the structure, is considered to be flexible 
enough to fold neatly between the metallic mesh wires as the mesh is compressed. 
However, there can be physical and mechanical incompatibilities between the metallic 
structure and the cover that lead to incomplete deployment of the device, uneven 
distribution of stresses, or even rupture / tearing of the cover during the expansion of the 
stent-graft. Furthermore, there is no such device existing on the market which has a 
natural curved shape to fit the shape of thoracic aorta. This report describes a novel 
curved stent-graft which is designed specifically for the treatment of TAA and aortic 
arch pathologies. 
 
This stent-graft consists of zigzag nitinol rings and a graft made of polymer. The nitinol 
rings can be formed from nitinol wires or from laser cutting on nitinol tubes. At each 
end of the stent-graft, an additional nitinol ring, which has a conical shape, is attached 
to provide anchorage of stent-graft inside the aorta.  
 
Upon folding, the stent-graft is first straightened in a way that some polymer partly 
climbs onto the nearest nitinol ring. Then, the stent-graft can be easily folded as a  
traditional straight stent-graft because the nitinol rings are positioned in a way that the 
peaks of a nitinol ring point the valleys of the adjacent nitinol ring. 
 
The folded stent-graft is kept in a delivery catheter and can be delivered to the 
lesion site just as the tradition stent-graft does. Once the stent-graft is correctly 
positioned, the catheter is retrieved slightly by first releasing the distal end of stent-
graft. Because the end of the stent-graft has a conical shape, it will help to anchor the 
stent-graft in position. Then, the catheter is further pulled back to gradually release the 
rest of the stent-graft. 
 
To manufacture such a curved stent needs to follow the steps described in figure 3.13. 
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Figure 3.13: Schematic diagram showing step-wise development of a curved 
stent-graft. Aortic arch dimensions from patient’s MRI used and 3D mandrel developed 
which is dip-coated with POSS-PCU polymer 
 
First, a curved plastic mandrel, the geometry of which can be carefully defined to match 
the shape of TAA, is made on a 3D printer.  
 
Second, this mandrel is placed in a box into which silicone mould compound (for 
example, SE2005 from ACC Silicone Ltd) is poured; wait the silicone compound to dry 
and take the plastic mandrel out of the silicone mould.  
 
Third, melt Alloy 117 at an elevated temperature and pour the Alloy 117 into the 
silicone mould; lower the temperature below Alloy 117’s melting point; take the Alloy 
117 mandrel, which has exactly the same shape as that of the previous plastic mandrel, 
out of the silicone mould. 
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Fourth, paint one thin layer of polymer on the Alloy 117 mandrel; wait until the 
polymer to dry. 
 
Fifth, place the nitinol rings over the polymer layer on the Alloy 117 mandrel. 
 
Sixth, paint another thin layer of polymer over the entire mandrel; wait until the 
polymer to dry so that the nitinol rings are embedded in the polymer. 
 
Finally, bring the whole assembly to an elevated temperature which is higher than the 
melting point of Alloy 117 to let the Alloy 117 mandrel melt and run out of the stent-
graft.   
The final assembled prototype in fully expanded shape is shown in figure 3.14. 
 
 
Figure 3.14: A curved stent-graft in fully expanded shape and matching curvature of 
aortic arch 
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3.5 CONCLUSION 
Combining deployable structures technology with advanced biomaterials provides 
exciting possibilities for improving stent-graft design. In this study, a prototype has 
been presented that demonstrates the feasibility of combining these technologies to 
create a sutureless device with an efficient folding system. The prototype represents the 
first step in a development process; work is underway to enhance the design by 
exploiting its capability to be moulded to fit a particular arterial anatomy. 
The next stage of this work will be development of a model for physiological 
assessment of this stent-graft, measure compliance and analyse long-term durability of 
the sutureless design. 
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Chapter 4 
 
Development of an aortic model for the physiological assessment of an advanced 
stent-graft system and in vitro compliance measurement 
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4.1 INTRODUCTION 
Polyurethanes have been extensively investigated for biomedical applications, 
because of their excellent biocompatibility, chemical versatility, and superior 
mechanical properties
136
. As described earlier, we have developed and patented a non-
biodegradable nanocomposite polymer based on polyhedral oligomeric silsesquioxanes 
(POSS) and poly (carbonate-urea) urethane (PCU), where the POSS nanocages are 
pendant groups covalently attached to the polymer backbone (POSS-PCU). This 
polymer is viscoelastic, durable, and has been shown to be biologically stable
137
. In 
addition, the POSS nanocages alter the surface morphology of the material they are 
attached to, resulting in a surface that is non-thrombogenic
138
. In the earlier chapter, we 
have described development of an innovative self-expanding, suture-less stent-graft for 
endovascular aortic aneurysm repair (EVAR) use that incorporates a Nitinol alloy 
scaffold bonded with this nanocomposite polymer. Because of novel physicochemical 
and biological properties, this new polymer has superior properties to Dacron and PTFE 
and favours spontaneous endothelialisation
139
. The next stage of our work is to 
accurately test the fatigue life of the stent-graft under physiological conditions 
simulating the nature of the pumping heart.  
 
We identified the need to develop an aortic model in which these stent-grafts 
could be deployed during their assessment under simulated physiological conditions as 
they need to be analysed for 400-million cycles of pulsatile mechanical fatigue 
(equivalent to 10 years in human body) according to Food and Drug Administration 
(FDA) guidelines. Current models of aortic aneurysms for stent-graft assessment and 
development are anatomically correct but do not match physiological properties of 
living aortic tissue. A need exists for a circulation model that behaves in a physiological 
manner for testing vascular devices in normal and pathological states. Our main goal 
was to develop a synthetic tube using a material which exhibits properties of 
compliance, anti-thrombogenicity and spontaneous endothelialisation. So we made a 
preliminary assessment of elastic properties of porcine abdominal aorta. We developed  
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an aortic model using nanocomposite polymer due to its superior properties as described 
above.  We also used latex synthetic aortic model which has been used before for in 
vitro testing in cardiovascular research
140;141
.  
 
The compliance is a function of the diameter and a vessel is defined as distensible or 
compliant when a small change in pressure translates into large volume change
142;143
. 
The mechanical properties of the arterial wall have a significant effect on blood flow 
characteristics and should therefore be mimicked in any model of the circulation. To 
perform compliance studies, we fabricated a flow circuit specifically designed 
accurately to reproduce the haemodynamic characteristics of pulsatile arterial blood 
flow. 
4.2 MATERIALS AND METHODS 
 
4.2.1 Acquisition of porcine abdominal aorta 
 
Porcine abdominal aortas were obtained from the animal research centre at Northwick 
Park Hospital, London. All abdominal aortas were excised from the same portion and 
stored in an ice box before the experiment. The vessel diameter varied from 18-mm to 
22-mm. The aortas were removed and stored with surrounding tissues. Before the study, 
bench surgery was performed to dissect and skeletonise the aortas. Six pieces were used 
from six different animals. The main branches of the aorta were controlled taking 
sutures with Silk 3-0. The tissues were stored in Ringer Lactate’s solution at 4ºC and 
studied within 24 hours of harvest. The tissues were obtained in accordance with the 
local ethics committee standing orders regarding experimental use of animal tissues and 
the care of animals was in accordance with the institution guidelines and National 
Research Council's guide. They were stored in Ringer Lactate’s solution at 4ºC and 
studied within 24 hours of harvest.  
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4.2.2 Development of an aortic model using novel nanocomposite polymer 
The nanocomposite polymer POSS-PCU developed by our group was used. A 
cylindrical rod of 25-mm diameter was immersed in the polymer and allowed to dry for 
15 min. A small portion of the polymer dripped down. It was then re-immersed for two 
more times in a similar fashion. The rod coated with triple-layered polymer was then 
placed in an oven overnight at 60°C. After 12 hours, the polymer had completely dried 
and formed a uniform layer. It was then peeled off the cylindrical tube thus forming a 
synthetic tube adjusted to a length of 20-cm.  
 
4.2.3 Latex synthetic aortic model 
For comparison, a latex tube of similar diameter (25-mm) was used. It has been used 
before in models for analysis of vascular stents and grafts. 
 
4.2.4 Compliance Methodology 
 
4.2.4.1Flow Circuit 
We have developed an ideal flow circuit for assessing the dynamic behaviour of grafts. 
The flow model comprised of a variable-speed electromagnetic centrifugal pump (Bio 
Medicus, Minnetonka, MN, USA), flexible plastic tubing and a fluid reservoir (Figure 
4.1). A previously developed governable flow waveform conditioner was sited in series 
with the circuit and used to generate arterial flow waveforms. Instantaneous flow rate 
was measured using a 6-mm tubular flow probe connected to a Transonic Medical 
flowmeter system (HT207; Transonic Medical System, Ithaca, NY, USA). Serial 
intraluminal pressure measurements were made at discrete sites along the porcine and 
synthetic aortas using a Millar Mikro-tip catheter transducer (Millar Instruments, 
Houston, Texas, USA) introduced via a Y-connection port. For aortas, no difference 
was noted at different sites like juxta renal aorta, aortic bifurcation or opposite branches. 
The solution used for perfusion of porcine aortas was anticoagulated blood from the  
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Royal Free Hospital Blood Bank, to simulate the in vivo situation. For synthetic aortas, 
the perfusion solution was made using 8% low molecular weight Dextran (molecular 
weight 77000-Da; Sigma-Aldrich, Poole, UK) added to a solution of M199 (minimum 
essential medium), 20% fetal bovine serum, 7.5% sodium bicarbonate (Sigma-Aldrich), 
200-mmol L-glutamine (Gibco BRL; Life Technologies, Paisley, UK), penicillin 
10000-units/ml and streptomycin 10-mg/ml, buffered at pH 7.20 ± 0.01. The viscosity 
of this medium has previously been determined to approach that of whole human blood 
using a cone plate viscometer (Low-Shear 30; Contraves, Zurich, Switzerland)
144
. 
Studies using blood were feasible in our prosthetic models. However, we preferred to 
use a synthetic solution as this was the solution to be used for long-term fatigue-testing 
and we felt it would be appropriate to determine the compliance of this model keeping 
the physiological parameters constant. Blood was unsuitable for fatigue-testing due to 
the need for long-term usage (more than one year), limited availability and potential for 
pump-related cell damage in the fatigue-testing experiment. This perfusion fluid has 
practically Newtonian properties with linear relationship between shear rate and shear 
stress. It differs slightly from blood, which has higher viscosity at low shear rates, but 
this discrepancy is of importance only in capillaries and for the purpose of this study 
can therefore be ignored. A gas mixture of 95% oxygen and 5% carbon dioxide was 
bubbled through the fluid reservoir and the perfusate was maintained at 37ºC via a heat 
exchanger (Portex, Hythe, UK). Pressure was varied by increasing the level of fluid 
reservoir above the graft segment and by varying the diameter of outflow resistance 
sited distally to the grafts. 
 
The porcine abdominal aorta, 25-mm triple coated polymer tube and 25-mm latex tube 
were all studied. To ensure minimal leakage transmurally and through the branches, the 
aortic segments were subjected to a pre-clotting procedure. This was carried out by 
forcing 10-ml freshly obtained whole human blood through graft interstices; once the 
blood had clotted, a further 10-ml fresh blood was perfused through the graft and the  
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process repeated, if necessary until no further leakage of blood was observed.  The 
aortas and the synthetic tubes were mounted in series with the flow circuit, exposed to 
flow and placed in a bath containing normal saline maintained at 37ºC. All outputs were 
fed into a commercial analogue-to-digital data acquisition recording system 
(ADC/MacLab; AD Instruments, Hastings, UK). 
 
 
Figure 4.1: Diagrammatic representation of the flow model used for measurement of 
compliance and elastic stiffness index. ADC, analogue-to-digital data acquisition 
recording system; FWC, flow waveform conditioner; MHFO, maxima hollow fibre 
oxygenator (Medtronic, Anaheim, CA, USA); P1 and P2, Millar Mikro-tip pressure 
transducer; TMF, Transonic Medical flowmeter system; VSECP, variable-speed 
electromagnetic centrifugal pump; WTS, wall-tracking system 
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4.2.4.2 Measurement of vessel wall movement 
The change in vessel wall diameter with respect to each cardiac cycle was measured at 
discrete sites along the graft, with measurements taken in the sagittal plane at 90º to the 
long axis of the tube. The segments of the aorta and the synthetic tubes were scanned 
with a specially adapted, duplex colour-flow ultrasonography system (Wall Track; Pie 
Medical Systems). This system allowed the measurement of vessel wall movement over 
time by automatically tracking assigned points of the induced radiofrequency signal 
deemed to be representative of the anterior and posterior arterial walls. A detailed 
description of the system has been published elsewhere
145;146
. Briefly, a 7.5-MHz linear 
array probe was immersed in the bath and positioned directly over the segment under 
investigation. The M-mode cursor was positioned at the midpoint of each test segment 
and perpendicular to the direction of flow; the change in induced radiofrequency signal 
received from the vessel walls was then sampled over time. These data were then 
transferred to a personal computer for real-time display of the displacement waveforms 
of the anterior and posterior artery walls. In this way, end-diastolic and end-systolic 
intra-luminal diameters were determined automatically over the pulsatile cycle (Figure 
4.2). Measurements were made using a near-constant pulse pressure over a range of 
mean pressures (Table 4.1). For each mean pressure and test segment, three 
measurements of wall movement were made, and the experiment was repeated six 
times. 
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 Figure 4.2: Distention-time curve generated by wall-tracking system to show change in 
vessel wall diameter with each cardiac cycle. Distention in µm on X-axis and time in 
seconds on Y-axis  
 
 
4.2.5 Data Analysis and Statistical Methods 
Diametrical compliance (C) defined as the inverse of Petersen’s elastic modulus 
Ep
147;148
, and expressed as per cent per millimetre of mercury X 10
-2
, was determined 
for each test segment at each mean pressure as follows: 
C = (Ds-Dd/Dd) X 10
4
/ (Ps-Pd) 
where Ds and Dd are systolic and diastolic diameter, and Ps and Pd are systolic and 
diastolic pressure, respectively.  
Arterial wall stiffness index, ß as formulated by Kawasaki et al
149
, was calculated using 
ß = [loge (Ps/Pd)] X Dd/ (Ds-Dd) 
For each mean pressure, the compliance and stiffness values of porcine aorta, polymer 
tube and latex tube were compared with one-way analysis of variance and Bonferroni 
test
150
. 
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4.3 RESULTS 
 
When the aortas and tubes were inserted in the model, triphasic flow was seen in all of 
them with little difference in flow waveforms. The analysis was done on six aortas and 
four polymer models. For latex, two tubes were initially used but as the model failed, it 
was not carried any further. 
 
4.3.1 Flow Circuit haemodynamic values 
 
These values are shown in Table 4.1. For each model the frequency of pulsatile cycle 
was 1-Hz.  The mean pressure range for the latex model is lower than the porcine aorta 
and polymer model; this is because the latex aorta was unable to withstand a mean 
pressure of 120 mm of Hg. The pulse pressure and flow rate were comparable for all 
three models. The perfusate temperature was constant at 37°C. The viscosity for the 
fluid used in the polymer and latex models was 0.035-poise.  
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Table 4.1 Typical Flow Circuit haemodynamic values (mean ± SD) 
 
Physical 
Parameter 
Porcine aorta Polymer aortic model Latex aortic model 
Mean 
Pressure 
(mm Hg) 
 
30-120 
 
30-120 
 
 
30-90 
Pulse 
Pressure 
(mm Hg) 
 
54 ± 8.8 
 
54 ± 8.8 
 
50 ± 4.6 
Flow rate 
ml/min 
138 ± 35 140 ± 25 132 ± 24 
Perfusate 
temperature 
(ºC) 
 
37 
 
37 
 
37 
Perfusate 
viscosity 
(poise) 
 
Blood 
 
0.035 
 
0.035 
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4.3.2 Compliance and stiffness index averaged over entire mean pressure range for 
porcine aorta, polymer and latex aortic models  
 
 
A summary of the compliance and stiffness index values for porcine aorta and polymer 
and latex aortic models is provided in Table 4.2. The compliance values and stiffness 
index decreased with progressive increase in pressure for both porcine aorta and 
polymer model, but remained nearly constant for the latex model. Figures 4.3 and 4.4 
depict the variation of compliance and stiffness index with respect to incrementally 
increased mean pressures from 30 mm Hg to 120 mm Hg. Curves of anisotropic vessels 
(aorta, polymer model) were generated using non-linear regression (single phase 
exponential decay model); however curve for isotropic latex model was generated using 
linear regression (Figure 4.3). The stiffness index-mean pressure curves were also 
generated in a similar way (Figure 4.4). 
 
Arterial compliance was observed to behave in a non-linear fashion in response to 
elevation in mean perfusion pressure. Figure V shows how latex model failed by 
significant distension when the mean pressure was increased from 90 mm Hg to 120 
mm Hg (figure 4.5). 
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Figure 4.3: Compliance-Mean Pressure curves for porcine aorta, polymer and latex 
models. Data presented as mean and error bars represent standard deviation 
 
 
 
 
Figure 4.4: Stiffness Index-Mean Pressure curves for porcine aorta, polymer and latex 
models. Data presented as mean and error bars represent standard deviation 
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Table 4.2 Compliance (C) and Stiffness index (ß ) values across a range of pressures 
Porcine Aorta 
Pressures (mm Hg) Compliance Stiffness Index 
Mean Systolic Diastolic C  (mean±s.d) ß (mean±s.d) 
30 66 12 2.97 ± 0.72 101.6 ± 28.9 
60 94 43 2.07 ± 0.47 81.7 ± 20 
90 120 75 1.98 ± 0.47 51.3 ± 10.7 
120 164 98 1.42 ± 0.37 68.2 ± 17.5 
 
Polymer aortic model 
Pressures Compliance Stiffness 
Mean Systolic Diastolic C (mean±s.d) ß (mean±s.d) 
30 66 12 3.66 ± 1.05 39.8 ± 8.5 
60 94 43 3.50 ± 0.81 39.2 ± 7.5 
90 120 75 3.28 ± 0.51 37.0 ± 5.5 
120 164 98 2.72 ± 0.28 34.2 ± 3.8  
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Latex aortic model 
 
Pressures (mm Hg) Compliance Stiffness 
Mean Systolic Diastolic C (mean±s.d) ß (mean±s.d) 
30 66 12 0.87 ± 0.22 220.1 ± 55.6 
60 94 43 0.87 ± 0.24 184.8 ± 45.7 
90 120 75 0.86 ± 0.20 146.7 ± 33.1 
Latex tube became distended at this point 
 
 
Figure 4.5: Latex model showing significant distension on increasing mean pressure 
from 90 mm Hg to 120 mm Hg 
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Compliance of aorta ranged from 2.97 ± 0.72 (mean ± s.d.) to 1.42 ± 0.37 percent per 
mm of Hg X 10
-2
. By one-way analysis of variance, the polymer aortic model was 
significantly more compliant (range 3.66 ± 1.05 to 2.72 ± 0.28; P<.05) as compared to 
porcine aorta with no significant difference in elastic stiffness but similar anisotropic 
behaviour. This was further confirmed by Bonferroni’s Multiple Comparison Test 
(Aorta vs. Polymer, Mean Diff.: -1.180, 95% CI: -2.175 to -0.184, P<.05). However the 
stiffness index, although lower than the aorta, did not reach statistical significance 
(Mean Diff.: 38.15; 95% CI: -9.967 to 86.27, P>.05) and as shown in Figure 4.4, it 
exhibited similar anisotropic behaviour on serial increment in mean pressure. 
 
Latex tubes exhibited compliance lower than the aorta. This was significantly low on 
Bonferroni’s testing (Aorta vs. Latex, Mean Diff.: 1.243, 95% CI: 0.169 to 2.318, P 
<.05) and it was significantly more stiff than the aortic tissue (Mean Diff.: -108.2, 95% 
CI: -160.1 to -56.2, P<.001).  It also exhibited an isotropic behaviour unlike aorta.  
 
4.4 DISCUSSION 
 
Arteries are not merely passive conduits, conducting blood from one part of the 
circulation to another. Their elastic structure allows the energy-efficient transmission of 
pulsatile blood flow together with simultaneous damping of excessive pressure 
fluctuations and the matching of the impedance characteristics of the proximal arterial 
tree to distal branches
151-153
. The aim of this study is to develop a new aortic model with 
physiological properties for the assessment of aortic stent-grafts under simulated 
conditions. The model should have compatible compliance and viscoelasticity for long-
term fatigue analysis of vascular stents and grafts. 
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4.4.1 Methodological considerations 
The elastic behaviour of a vessel can be determined statically by measuring incremental 
change in vessel diameter during step-wise inflation of an intraluminal balloon, but this 
approach does not allow for the contribution that vessel or graft wall viscosity (i.e. 
inertia) makes upon the in vivo elastic response
154
. The amount of radial movement 
(strain) that a vessel wall exhibits in response to a change in intra-luminal pressure 
(stress) is not only dependent upon the magnitude of the pressure change but also the 
rate at which the pressure is applied i.e. wall behaviour is viscoelastic
153
. Thus, in order 
to fully characterise likely in vivo graft or vessel viscoelastic behaviour, a dynamic 
approach was required. So, a pulsatile flow circuit, capable of supporting biological 
tissues, was designed to allow cyclical application of wall stress and the reproduction  
and manipulation of physiological flow parameters. This in vitro approach allowed 
rigorous control of the physical forces that the grafts or vessels were exposed to in order 
to allow valid comparison of different vessels and graft types. 
 
An ultrasound echo-locked wall tracking system was used to record change in graft or 
vessel diameter over each pulsatile cycle. The perfusion rig allowed uniform stretch of 
the vessels. Both the anterior and posterior walls of the aorta or the synthetic tube being 
tested must be imaged by ultrasound wall tracking to be successful. The aim to use 
porcine aorta was to establish values of compliance for natural vascular tissue.  
 
4.4.2 Anisotropy and Isotropy 
It was decided to measure the elastic behaviour of the aortas and synthetic models over 
a range of mean pressures. This is because arterial tissue is heterogeneous; non-hookean 
(i.e. does not exhibit a linear pressure-distension curve) material whose compliance 
behaviour is strongly pressure-dependent
151;155
. In patients with significant 
cardiovascular disease, central arterial stiffness becomes significantly nonlinear
156
. At 
low pressures the load is predominantly borne by highly distensible elastic fibres but at 
high pressures it is transferred to the poorly elastic collagen fibres
157;158
.  
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The stretch behaviour of arteries is anisotropic i.e. the extent of distension is dependent 
upon the degree of pre-stretch (the operating mean blood pressure) prior to the 
application of the stress (the pulse-pressure). Generally, non-biological prosthetic grafts 
do not exhibit this behaviour and there is little or no change in degree of circumferential 
stretch (compliance) as mean pressure changes, at least over the physiological range
159
.  
 
Our aim was to analyse a model that could be used for assessment of fatigue and 
pulsatile durability of an aortic stent-graft. We wanted to perform this testing using the 
ASTM standards (ASTM F2477 - 07 Standard Test Methods for in vitro Pulsatile 
Durability Testing of Vascular Stents). This test method requires that model used for 
durability testing is assessed for compliance at physiological pressures. So we decided 
to measure at this range achieving diastolic blood pressure up to 100 mm Hg. Our study 
did have a high mean pressure of 120 mm Hg and high systolic pressure of 164 mm Hg 
for accurate assessment over a wide pressure range. In this study, POSS-PCU did not 
fail at these pressures. We have not calculated burst pressures as it was not our aim but 
it has been analysed in a different series of experiments done in our department.  
 
4.4.3 Comparison of compliance of porcine abdominal aorta and the synthetic 
polymer and latex aortic models 
The new model appears “over-compliant” compared to aorta in this pressure range, 
principally because of the homogenous, uni-elastic quality of the honeycombed 
urethane.  However, it can be argued from a theoretical viewpoint that this pattern of 
compliance might be advantageous. Following implantation, all prosthetic grafts 
become invaded by connective tissue elements that can fix the graft wall thereby 
diminishing the compliance that initially existed
160
. Thus it may be necessary to 
engineer a degree of “over-compliance” into the prosthetic models in order to buffer 
subsequent tissue-induced stiffening. In addition, in humans a significant decrease in 
AAA compliance is immediately observed after endovascular stenting which reflects 
complex interactions between all components of stented aneurysms
161
. 
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Latex model was less compliant and significantly stiffer than aorta and on increase in 
pressure from mean of 90 mm Hg, it failed by significant distention. In addition, due to 
the isotropic and linear elastic response of the latex-wall and Laplace principle, it is not 
possible to simulate the non-elastic response effect, as found in vivo, in the latex 
model
162
. 
 
4.4.4 Utility of stiffness index (ß) for in vitro measurements 
Stiffness index ß was originally formulated in order to allow valid comparison of 
distensibility between vessels exposed to different mean blood pressure
163;164
 as  
comparison of compliance is only allowed when mean pressures are equivalent. Thus its 
maximum utility lies in the in vivo arena where comparison between subjects is desired. 
In this study, measurement of graft or vessel distensibility were undertaken for the same 
mean pressure over a pressure range of 30-120 mm Hg and therefore comparison of 
compliance values is valid. However the similarity in the stiffness index between the 
polymer and aortic tissue further confirms that this model exhibits similar physiological 
properties. The latex model is significantly stiffer. 
 
4.4.5 Compliance match between model and graft material 
We will be testing a stent-graft made from the same nanocomposite polymer as in the 
aortic model. It is fair to conclude that there is no compliance mismatch between this 
model and stent material. When the stent-graft is deployed in this model, it will result in 
increase in the thickness of the polymer exposed to pulsatile flow. In a previous 
study
165
, compliance was assessed for different thicknesses of POSS-PCU 
(approximately 0.35 mm for thin grafts vs. 0.50 mm for thick grafts) and it was noted 
that with the increase in thickness, the compliance becomes more constant. So we think 
that this model is appropriate. This model has now been successfully used for fatigue-
testing over a period of 12 months for 400 million cycles equivalent to 10 years in 
human body without any signs of failure or change in compliance. 
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4.4.6 Limitations 
The criticism of using the in vitro approach is the limited applicability to the in vivo 
situation. In vitro studies may overestimate in vivo arterial elasticity as the latter is 
influenced by the degree to which adjacent connective tissues tether arterial wall 
excursion
151
. Furthermore, in vivo vessels experience a variable amount of smooth 
muscle tone secondary to sympathetic and humoral influences
166
. Although artificial 
circulation testing systems cannot replace in vivo models, they can be used for 
mechanical fatigue testing and in addition, to develop experimental protocols, testing  
device feedback control algorithms, and investigating flow profiles. 
 
 
4.5 CONCLUSIONS 
 
Our wok demonstrated that the new aortic model based on a novel nanocomposite 
polymer (POSS-PCU) provides a greater degree of compliance and stiffness match than 
the current available model. It has shown great promise for use in models of the arterial 
system. It is physiologically relevant exhibiting compatible anatomy, compliance and 
viscoelasticity which could be used for long-term fatigue analysis of vascular stents and 
grafts. The use of these compliant artificial vessels will allow the construction of more 
physiologically accurate flow systems with the possibility of making comparative 
measurements between a vascular model, normal subjects and patient group with aortic 
disease. The commercially available latex mock aortas can fail at physiological 
pressures. We have utilised this model for long-term fatigue and durability assessment 
of our stent-graft as described in the next chapter. 
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Chapter 5 
 
Fatigue Analysis and Accelerated Durability Testing of AAA stent-graft based on 
Nitinol scaffold bonded to a Nanocomposite polymer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
 
 
5.1 INTRODUCTION 
As discussed in the introductory chapter, endovascular aneurysm repair (EVAR) 
has evolved but graft-related complications and reinterventions remain substantial and 
are associated with significant aneurysm-related mortality
167
. Newer devices need to be 
developed in the quest to improve long-term durability of EVAR stent-grafts. 
 
As mentioned, our stent-graft is based on polyhedral oligomeric silsesquioxanes 
(POSS) and poly (carbonate-urea) urethane (PCU) and its structure is shown in figure 
5.1).  
 
 
 
 
 
 
Figure 5.1: Three-dimensional structure of polyhedral oligomeric silsesquioxane 
molecule with hard and soft segments of polyurethane attached to POSS nanocage 
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Nanocomposite components interact at a nanoscale level conferring greater 
mechanical strength and anti-fracture properties to these polymers
168
. As already 
mentioned, the POSS-PCU polymer is viscoelastic and durable, and has been shown to 
be biologically stable
169
. In addition, it has a nonthrombogenic surface and shows 
potential for spontaneous endothelialisation
170-172
. In our design, the graft material is 
bonded to the metal skeleton rather than being sutured. The scaffold design uses 
principles of maximised folding efficiency to provide effective long-term fatigue 
resistance. A surface treatment protocol for nitinol that uses anodisation and chemical 
surface modification increases its bond strength with the polymer.  
 
  The US Food and Drug Administration (FDA) recommends durability testing to 
the equivalent of 10-15 years of pulsatile loading (400- to 600- million cycles at 72  
heartbeats per minute) for cardiovascular implant devices
173
. Implant fatigue 
performance is of prime importance as stent-grafts are subjected to complex loading 
conditions in vivo. At the end of the testing phase, devices need to be examined for 
fractures thus resulting in a “pass/fail” acceptance criterion.  
 
The main aim of this study was to assess durability of our aortic stent-graft 
under simulated physiological conditions for 10-years according to FDA guidelines 
analysing changes in surface, mechanical and thermal properties in comparison to 
control stent-graft of the same type with zero-cycles.  
 
5.2 METHODS 
5.2.1. Fabrication of the sutureless non-modular aortic stent-graft 
The fabrication of non-modular stent-graft is revisited here with emphasis on 
coating strength and durability as it is a paramount factor.  
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The stent-graft was made using a 30-mm collapsible stainless steel scaffold dip 
coated with polymer. Its synthesis has been described previously
174
. A low viscosity or 
thin polymer formulation was chosen to promote a homogenous coating. This 
formulation was developed by adding additional dimethylacetamide (DMAC) to a 20 
wt% polymer solution rested overnight to ensure that DMAC was fully dissolved. 
Nitinol wire with shape-memory properties was constrained between pins in a rig to 
make Z stents. These were wrapped around a cylinder tube, heated in an oven at 550°C 
for 15 minutes and air cooled to allow  cut to a suitable length and joined using copper 
sleeves to form a hoop. The collapsible mandrel was dipped in polymer solution and air-
dried for one hour before being placed in an oven at 60°C for two hours. A second coat 
was similarly applied. In parallel, a 250 µm thick polymer sheet was cast in a glass dish. 
The wire segments were embedded in the sheet during the casting process and 
subsequently cut allowing a 0.5 mm border to protect sharp edges. The straight 
segments were then glued in place using the polymer and a further two more thin coats 
were applied to develop a graft wall thickness of approximately 100 µm.  
 
The sutureless stent-graft design is based on the principles of our previous work 
on polymer coating of surface modified nitinol stent
175
. The results of this work confirm 
that a three-fold increase in bond strength between nitinol and POSS-PCU polymer can 
be achieved by surface modification of metal alloy and comparative in vitro degradation 
studies demonstrate the ability of the coating to remain integral with the stent upon long 
time (70 days) on exposure to biological environment in static conditions. The coating 
stability has also been confirmed by exposing to plasma fractions and hydrolysis. The 
coating maintained its integrity and strong adhesion to the strut during the entire 
degradation process without any signs of instability or delamination. 
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The final assembled prototype deployed in a similarly made 25-mm cylindrical 
tube cutting from POSS-PSU with thickness of approximately 200 µm used as a mock 
artery is shown in figure 5.2. The deployment was similar to endovascular aneurysm 
repair without any external constraints. We have previously assessed the folding 
efficiency of this stent-graft and we achieved a collapsed diameter of 6.5 mm from 
expanded diameter of 31.1 mm and this corresponded to a reduction ratio of 4.8. This 
compared favourably to currently used device. For example, the Medtronic Talent has 
delivery profiles between 7.3 mm and 8.3 mm with expanded diameters between 22 and 
46 mm
176
. However as a part of this work, we did not focus on deployment using 
packing and sheathing systems and it was achieved manually. The choice of the inside 
diameter of the artificially simulated vessels is critically important to the effectiveness 
of the durability test. We selected a model with the diameter of 25-mm to match the size 
of the normal aorta. The stent-grafts deployed were 30-mm in diameter as a degree of 
oversizing is desirable.  
 
 
 
Figure 5.2: Final assembled stent-graft prototype deployed in a compliant polymer 
model, ready to be implanted in the fatigue-testing circuit 
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5.2.2. Fatigue-testing circuit 
The designed apparatus used in this experiment is shown in figure 5.3.  
 
 
 
Figure 5.3: Schematic of the pulsatile flow circuit used in the experiment. Sample-
holder connected to the pumping system and monitor. A valve controlling pressure and 
motor connected to eccentric and linked to diaphragm by connecting rod 
 
 Chapter 5 – Fatigue Testing of AAA Stent-graft 
120 
 
 
 
The stent-grafts were subjected to an accelerated circumferential pulsatile fatigue test at 
45-Hz. The inner side of the sample-holder chamber was filled with distilled water, in 
direct contact with the pumping system, exposing the samples to pulsatile mechanical 
stress. The solution tank and samples were placed in an incubator at 37º C and 5% CO2 
over the test period. We closely considered the solution to be used for perfusion. It 
would have been ideal to use blood however we felt it was unsuitable due to the need 
for long-term usage (more than one year), limited availability and potential for pump-
related cell damage in the fatigue-testing experiment. Normal saline has been used 
predominantly in in vivo models and we did not think it would offer any advantage over 
distilled water. Phosphate-buffered saline has also been used in biological research but 
we did not use it due to concerns of bacterial growth, as it was not possible to keep the 
entire apparatus sterile for long periods of time as required in this experimental work.   
 
Pressure head of fluid provided mean pressure to the system and was connected 
to a pump, which provided oscillatory pressure about the mean (i.e. pulse).  A solenoid-
operated valve controlled application of pressure to the specimens. The motor was 
operated by speed controller allowing it to run at 2500-rpm and was connected to an 
adjustable eccentric, which was linked to the diaphragm by a connecting rod. The 
eccentric could be adjusted to pump between 0-19 mm
3 
of fluid and the diaphragm 
pump was used to create pulsatile force for dynamic testing of samples. Leading down 
from the diaphragm was a connector, which was joined to a tube that was passed into a 
cell culture incubator (Hercell 150, Heraeus, USA) and was connected to the sample 
holder device. A small outlet in the sample holder device connected it by a small tube to 
a Datex-Engstrom Light monitor (Datex-Engstrom Division, Instrumentarium Corp., 
Finland). This was used to monitor the pressure of the pulsatile stress of the inside fluid 
of sample holder chamber during the test on a weekly basis. 
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5.2.3. Surface topography  
Following completion, all stent-grafts were visually assessed for any damage to the 
polymer graft or nitinol wires. 
 
5.2.3.1 Scanning electron microscopy 
The fatigue-tested polymer and control sheets were dehydrated with ethanol/distilled 
water in increments of 10% ethanol at 41 °C and then freeze-dried for 2 days. Following 
this, sections of the nanocomposite were attached to aluminium stubs before being 
coated with gold using an SC500 (EM Scope) sputter coater. Next, a scanning electron 
microscope system (Philips SEM Model 501, Netherlands) was used to analyse 10 areas 
 of the polymer sheets chosen at random for surface degradation namely pitting, 
fissuring, cracking
177
 and crystalline segment shearing (‘balding’). 
 
5.2.3.2 Fourier transform infra-red spectroscopy (FTIR)  
The stent-graft sheets of POSS-PCU were subjected to infra-red spectrophotometric 
analysis to detect any sub-surface bond degradation. Pre and post fatigue test, using an 
ATR-FTIR analyser (FTIR-4200, Jasco, UK), the surfaces of the polymeric films were 
exposed to infra-red spectra of 4000–600 cm−1 at 4 cm−1 resolution with thirty scans per 
sample. The analysis was repeated 3 times and averaged. Both surfaces of polymer 
sheets were exposed at an incident angle of 30° and the subsequent spectrum was 
presented in relation to absorbance. The peaks present in these spectra represent the 
excitation of chemical bonds within the material as a result of applying infrared energy 
corresponding to the specific vibrational energy of that bond. Loss in intensity of the 
absorbance peaks is indicative of the degradation behavior of the material. 
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5.2.4 Compliance analysis 
As described before
178
 POSS-PCU grafts were placed in series within a flow circuit 
containing a solution with viscosity similar to blood (0.035-poise) pumped at 1-Hz and 
at mean pressures of 60 to 120-mmHg using a variable speed pump (BioMedicus, 
Minnetonka, MN, USA) in order to simulate arterial pulsation. The change in the 
diameter of the graft with respect to each cardiac cycle was measured at discrete sites 
along the stent-free graft wall at 90° to the long axis of the stent-graft. Segments of the 
graft were scanned with a specially adapted duplex colour-flow ultrasonography system 
(Pie 350; Pie Medical Systems, Maastricht, The Netherlands). A 7.5 MHz linear array 
probe was positioned directly over the segment under investigation. The change in 
induced radiofrequency signal received was then sampled over a 4 second interval. 
These data were then transferred to a personal computer for real-time display of 
displacement waveforms of the anterior and posterior graft walls. In this way, end-
diastolic and end-systolic intraluminal diameters were determined automatically over  
the pulsatile cycle. Diametrical compliance (C) defined as the inverse of Petersen’s 
elastic modulus Ep
147;148
, and expressed as %/mm Hg X 10
-2
, was determined for each 
test segment at each mean pressure as follows: 
C = (Ds-Dd/Dd) X 10
4
/ (Ps-Pd), where 
Ds and Dd are systolic and diastolic diameter, and Ps and Pd are systolic and diastolic  
pressure, respectively. 
 
5.2.5. Mechanical resistance and elasticity 
5.2.5.1 Radial stress-strain studies 
An Instron 5565 tensometer equipped with a 500 N load cell was used to measure the 
radial strength of the POSS-PCU polymer. Sample thickness was measured using a 
micrometer and specimens loaded in the test machine (figure 5.4). This study is based 
on the ASTM D413 standard, to determine the force per unit width required to separate 
a rubber layer from a flexible substrate such as fabric, fibre, wire, or sheet metal (ASTM 
D413 2007). The adhesion strength is equal to the mean force recorded during the test.  
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The lower and upper machine grips clamped the polymer film, at a starting distance of 
10-mm. The test was conducted with a crosshead displacement rate of 5-mm/min to a 
final length of 40-mm. Both stent-graft and control specimens were tested. The system 
was programmed to collect data relating static stress and static modulus as a function of 
strain (strain %). A stress–strain curve was plotted with strain/vessel wall distension on 
the x-axis and systolic pressure representing circumferential stress on the y-axis to 
understand the difference in biomechanical behaviour of fatigue-tested and control 
polymers and then to correlate this information with the classical Hookean laws. 
 
 
 
Figure 5.4: Schematic for stress-strain studies. The polymer film clamped in the 
pneumatic machine grips. 
 
 
Lower and upper machine 
grips used to clamp the 
polymer film 
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5.2.5.2 Linear elasticity 
This investigation was performed using ASTM F703 methodology using ISO 37 
dumbbell-shaped specimens (size type 3). Polymer tubes were opened to flat sheets and 
dumbbell shapes cut using a cutting machine. A 10-mm long portion was marked along  
the inner 20-mm length segment of the dumbbell and wall thickness was measured at 
three points along the 10-mm marked segment (at both ends and middle). The 
dumbbells were then attached to a tensometer. The marked segments were manually 
stretched to 200% (20mm), 400% (40mm) and 500% (50mm) lengths. The samples 
were left in the stretched position for 60 seconds, removed and allowed to relax for a 
further 60 seconds. The length of the marked segment was then measured and the 
percentage elastic deformation calculated for a total of six samples from each group 
using the following formula:  
 
     
 
 
 
 
 
5.2.6 Thermo-mechanical resistance 
 
5.2.6.1 Differential scanning calorimetry (DSC) 
The POSS-PCU grafts pre and post-fatigue were studied by differential scanning 
calorimetry to determine whether the respective samples had undergone a significant 
change in glass transition temperature (Tg) and melting temperature (Tm) using a heat-
flux differential scanning calorimeter (DSC-60 Shimadzu Ltd., Japan) in a dry nitrogen 
atmosphere equipped with a liquid nitrogen cooling unit.  
 
 
-1 
 
Length after Stretching 
10 
X 100 
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Samples 20 mg in weight and 3 mm x 3 mm in size from different parts of the polymer 
were used for Tm and Tg measurements. The DSC was calibrated using an indium 
standard. The thermal cycle ranged from -50 °C to +280 °C at a heating rate of 10 
°C/min. The glass transition Tg was calculated as inflection in the Cp change and all 
specimens were run three times. All samples were weighed pre- (W) and post-test (W′) 
to confirm that there was no change in mass after melting.  
 
 
5.2.6.2 Thermo-mechanical analysis (TMA) 
Thermo-mechanical analysis (TMA) was performed using a Shimadzu TMA-50 
analyser. Samples 4-mm  4-mm were placed in a covered aluminium crucible. 
Previously the probe displacement had been set to zero on the crucible and lid. The 
sample in the crucible was then cooled to -100 C to induce its glassy state. A static 
load (0.5-N) was applied to the sample and the initial displacement of the probe was 
measured giving the starting sample thickness. The sample was then linearly heated at 2 
C/min to 300 C and the resulting displacement or sample compression (expressed as 
% of sample thickness) was plotted against temperature. 
 
5.2.7. Acceptance criteria 
The stent-graft was classified as “failed” if it met any one of the following: 
1. At least one broken strut in the nitinol. 
2. Cracks on SEM analysis of nitinol compared to any visible cracks in the control, 
a significant change being classified as failure. 
3. Significant change in compliance. 
4. Significant loss of mechanical strength evidenced by stress-strain and linear 
elasticity studies 
5. Significant loss of thermo-mechanical resistance 
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5.2.8. Statistical Analysis 
The data from each experiment obtained was plotted and analysed using GraphPad 
Prism 4 software (GraphPad, San Diego, CA, USA). The data are presented as means 
and standard deviation. Statistical analysis of tests was carried out using the student’s t-
test. 
 
5.3 RESULTS 
All four stent-grafts successfully completed the 400-million cycles equivalent to 10 
years of cardiac cycles in an average human adult. The test parameters are outlined in 
table 5.1.  
Table 5.1: Test parameters from fatigue-testing circuit 
 
Physical parameter Variable 
Mock vessel dimensions (n=4) Diameter: 25 mm 
Length: 25.28 ± 0.51 cm (mean±s.d.) 
Test stent-grafts dimensions (n=4) Diameter: 30 mm 
Length: 7.07±0.14 cm 
Control stent-graft dimensions 
(n=1) 
Diameter: 30 mm 
Length: 7.1 cm 
Temperature 37 ± 1°C 
Pressures Systolic pressure range: 65 to 112 mm Hg 
Diastolic pressure range: -32 to 8 mm Hg 
Pulse pressure: 94±14 mm Hg 
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5.3.1. Surface topography  
 
5.3.1.1 Visual inspection and scanning electron microscopy  
 
The polymer graft appeared intact with no holes or leakage points on visual inspection 
(figure 5.5). The nitinol wire showed no breakage. SEM images confirmed these 
findings (figure 5.6). The POSS-PCU polymer showed smooth surface with flat areas 
and very few crystalline peaks, a consistent feature seen in all analysed samples. Post 
fatigue-testing, there was some wear and tear on the inner surface of POSS-PCU 
polymer (figure 5.6c) but there were no cracks, pits, fissures or balding. Similarly, the 
outer surface showed uniform covering over the nitinol stents (figure 5.6d) with no 
signs of failure.  
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Figure 5.5: Images of the stent-grafts post-fatigue testing. Visual inspection revealed 
intact polymer and nitinol with no signs of breakage. 
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(a) Inner surface of control POSS-PCU 
 
(b) Outer surface of control POSS-PCU (covering over the nitinol stent) 
 
 Chapter 5 – Fatigue Testing of AAA Stent-graft 
130 
 
 
(c) Inner surface of fatigue-tested POSS-PCU 
 
(d) Outer surface of fatigue-tested POSS-PCU with smooth covering over nitinol 
Figure 5.6: Scanning electron microscopy images of stent-grafts (160X 
magnification). (a) Inner surface of zero-cycled control POSS-PCU (b) Outer surface of 
control POSS-PCU (c) Inner surface of fatigue-tested POSS-PCU (d) Outer surface of 
fatigue-tested POSS-PCU. No significant signs of degradation seen 
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 5.3.1.2 Fourier transform infra-red spectroscopy (FTIR) 
It was found that there were only small spectral differences between the pre and post 
fatigue test observed in Si-O (1111.76 cm
-1 
in control vs. 1105.01 cm
-1
 in fatigue-tested 
sample), NHCO (1738.51 cm
-1 
in control vs. 1728.87 cm
-1
 in fatigue-tested sample) and 
N-H (3324.68 cm
-1 
in control vs. 3327.57 cm
-1
 in fatigue-tested sample) bonds (figure 
5.7 and figure 5.8). These differences were insignificant in terms of loss or gain of 
POSS-PCU chemical bonds for each bond wavelength as compared to control except 
the difference noted in the –NHCO- bonds (62% transmittance (1728.87 cm-1) for 
fatigue-tested sample as compared to 47% (1738.51 cm
-1
) for control). The increase in 
intensity of amine peak (N-H stretching) absorbance near 3300 cm
-1
 is likely to be the 
products of the biodegradation.  
 
 
 
 
Figure 5.7: Fourier transform infrared spectroscopy (FTIR) curves for POSS-PCU 
(fatigue-tested and control). Wavelength on X-axis and %Transmittance on Y-axis 
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Figure 5.8: Comparison of the intensity of main bonds of fatigue-tested and control 
POSS-PCU by FTIR (%Transmittance based on their wavelengths) 
5.3.2. Compliance analysis 
The test parameters for the flow circuit are outlined in table 5.2. Compliance values for 
both fatigue-tested, 3.46 ± 1.27 (mean ± S.D. %/mm Hg X 10
-2
 ), and control stent-
grafts, 3.26 ± 0.65 (%/mm Hg X 10
-2
) across mean pressures of 60-120 mm Hg were  
not significantly different (mean difference 0.215 ± 0.286, 95% confidence interval -
0.357 to 0.787, P=.455). (figures 5.9 and 5.10)  
Table 5.2: Test parameters for flow circuit to measure compliance 
Physical parameter Variable 
Mean pressure (mm Hg) 60-120 
Pulse pressure 60.5 ± 0.8 
Frequency of pulsatile cycle (Hz) 1 
Mean flow rate (ml/min) 132 ± 24  
Perfusate viscosity (poise) 0.035 ± 0.001 
 
Analysis of main bonds for POSS PCU
N-H O-H -NHCO- C-O-C Si-O
0
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Chemical Bonds
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T
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Figure 5.9: Compliance study results across mean pressure range 60-120 mm Hg. 
Columns represent mean values and error bars represent standard deviation. Fatigue-
tested POSS-PCU in red and control POSS-PCU in blue 
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Figure 5.10: Combined compliance results of fatigue-tested (F) and control (C) 
specimens. Data presented as mean and error bars represent standard deviation 
 
5.3.3. Mechanical strength and elasticity  
 
5.3.3.1 Radial stress-strain studies 
 
Stress–strain curves showed no significant difference in stress–strain behaviour between 
control and fatigue-tested grafts (table 5.3). This data shows that the soft segment of the 
polyurethane nanocomposite remains intact in spite of accelerated degradation as 
illustrated by the preservation of elasticity (figure 5.11).  
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Table 5.3: Radial stress-strain results 
Test Fatigue-tested 
polymer 
Control polymer P value 
Thickness (mm) 
 
0.169 ± 0.434 0.193 ± 0.0352 .360 
Max Stress (MPa) 15.563 ± 4.487 20 ± 7.241 .197 
Strain at Break (%) 477.176 ± 77.109 546.06 ± 82.759 .164 
Stress at 50% strain (MPa)  3.970 ± 0.793 4.318 ± 0.877 .484 
Stress at 100% strain 
(MPa) 
5.806 ± 1.067 5.989 ± 1.191 .784 
Stress at 200% strain 
(MPa) 
8.201 ± 1.011 8.530 ± 1.571 .655 
Stress at 300% strain 
(MPa) 
10.351 ± 1.190 11.320 ± 2.202 .335 
Stress at 500% strain 
(MPa) 
18.863 ± 1.950 50.566 ± 2.909 .447 
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Figure 5.11: Stress-strain curve of fatigue-tested (F) and control (C) POSS-PCU. Data 
presented as mean and error bars represent standard deviation 
 
 
5.3.3.2 Linear elasticity  
 
Average lengths of 10mm length sections of dumbbell-shaped samples stretched by 
200% (30mm), 300% (40mm) and 400% (50mm) are shown in table 5.4. As seen in 
figure 5.12, stretching samples up to 500% produced no significant difference with both 
polymers exhibiting similar elastic properties. 
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Table 5.4: Linear elasticity test results 
Length Stretched Tube Average Length 
after stretching 
(mm) 
Deformation  
 
300% 
(30 mm) 
F 10.9 mm 9% 
C 11.1 mm 11% 
400% 
(40 mm) 
F 11.3 mm 13% 
C 11.3 mm 13% 
500% 
(50 mm) 
F 11.8 mm 18% 
C 11.4 mm 13% 
 
F – fatigue tested specimens, C – control specimens 
 
Figure 5.12: Linear elasticity test. Data presented as mean. Length stretched in % on X-
axis and distance in mm on Y-axis 
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5.3.4. Thermo-mechanical resistance 
5.3.4.1 Differential scanning calorimetry (DSC) 
DSC scans of the fatigue-tested and control samples of POSS-PCU are illustrated in 
figure 5.13. DSC showed a systematic decrease in the glass transition exothermic peak 
temperature in the fatigue-tested sample compared with the control. The Tg value 
characteristic (long-range molecular movement within the soft segment domains)  
decreased for fatigue tested polymer from -25°C to -28°C compared to control. This 
phase transition is due to the onset of long-range coordinated molecular motion 
accompanied by a change in the free volume properties in the polymer. Because of the 
low weight average molecular weight (MW), hard and soft segments were not long 
enough to form highly ordering soft and hard regions, so these polyurethanes showed 
amorphous state, without any melting endotherm observed in the DSC curves.  
 
 
Figure 5.13: DSC thermal analysis curves of fatigue-tested and control POSS PCU 
specimens. Temperature in °C on X-axis and DSC in mW/mg on Y-axis 
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5.3.4.2 Thermo-mechanical analysis (TMA) (figure 5.14) 
The TMA curves describe the behaviour of the material under load when heated from its 
glassy state. As the temperature increases the material softens as it goes through its 
glass transition temperature (Tg) with Tg measured by TMA showing a decrease in 
dimension change with the increase in temperature similar to the DSC results. Post 
fatigue testing there was a decrease of Tg up to 4 C (decreased to -19.8°C for the 
fatigue test as compared to -24.1°C for the control). 
 
 
 
Figure 5.14: Typical TMA thermo-graph curve of POSS PCU (fatigue-tested and 
control specimens). Temperature in °C on X-axis and TMA (%) on Y-axis 
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5.4 DISCUSSION 
 
The past 15 years have seen a gradual improvement in long-term stent-graft 
performance as designs evolved through the elimination of features associated with late 
failure and the replication of features associated with durable success
179
. The Mintec 
(later called the Vanguard; Boston Scientific, Natick, MA) stent-graft suffered from 
every form of graft failure, including fabric erosion
180;181
. The stent structure was held 
in alignment by polypropylene sutures, which fractured or untied. The resulting 
distortion of the stent and impingement of stent apices on fabric caused fabric erosion, 
type III endoleak, and rupture. Stronger sutures and tighter weaves have made current 
designs more stable, but none is free from occasional instances of graft failure
182-184
. So 
our aim was to develop a sutureless stent-graft using a graft material which has superior 
properties of compliance, antithrombogenicity, biostability and spontaneous 
endothelialisation
170;171;185;186
. Accelerated durability testing validates fatigue analysis 
and evaluates failure modes such as fretting, abrasion and wear
187
. So we performed 
 this testing for the recommended duration to the equivalent of ten years of real-time use 
under pulsatile flow and physiologic loading that simulates blood pressure conditions in 
the human body.  
 
Migration and endoleak are the most important factors in failure after EVAR
188
. 
Our in vitro model was not designed to test migration of the stent-graft as we did not 
simulate the drag forces experienced by the stent-graft especially at the proximal end. 
The surface treatment and bonding with nitinol remained robust with no occurrence of 
wire breakage or obvious fractures. SEM images confirmed uniformity of polymer 
covering the nitinol surface. 
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Our FTIR results showed no difference in integrity of all major chemical bonds 
following exposure to fatigue, except for –NHCO– (indicative of the carbonyl segments 
of carbonate) bonds. The chemical changes caused by biodegradation can be from 
severe oxidation of the aliphatic soft segment, hydrolysis of the urethane bonds joining 
hard to soft segments, and significant hydrolysis of aliphatic hard segment. Hydrolysis 
and biodegradation of the aliphatic hard segment of polyurethane results in loss of 
absorbance in non-hydrogen-bonded carbonyl (1740-1718 cm-1), urethane C-N (1231-
1222 cm-1), and urethane C-O-C (1080cm-1) but amine absorbance (near 33OOcm-1). 
Hydrolysis of the hard segment also gives significant loss of hydrogen-bonded carbonyl 
absorbance (1702 cm-1). Enhanced phase separation resulting from hydrolysis can also 
cause significant increase in hydrogen bonding (urea hydrogen-bonded absorbance at 
1630 cm
-1
). The absence of these changes in this study shows that no significant 
hydrolysis occurred in our sample.  
 
The commonly used polymers ePTFE and Dacron are highly crystalline and 
stiff
189
. After EVAR, the graft lying within the sac generates most of the wall movement 
by transmission of its own movement through the sac contents
190
. To improve device 
longevity and reduce the risk of late rupture, it is important for the graft material to be 
 resistant to structural failure and aneurysmal change. Compliance is a measure of the 
biomechanical properties of the graft with significant positive correlation between AAA 
compliance and risk of rupture
191
. So we measured compliance and our results 
confirmed that POSS-PCU shows resistance to failure from significant distension. 
 
Mechanical strength of a polymer is a critical parameter for use in biomedical 
devices. Polyurethanes are the most compliant polymers and are natural choices; 
however they characteristically have poor resistance to degradation. To overcome this 
problem, our group have synthesized polyhedral oligomeric silsesquioxane integrated 
poly (carbonate-urea) urethane (POSS-PCU) nanocomposite to be biostable and 
biocompatible. In a recent study, it showed no signs of degradation after three years of  
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implantation in a sheep model
192
. We have used solid POSS PCU to develop a stent-
graft system as we wanted it to be mechanically robust enough to withstand the forces it 
will be exposed to in an in vivo environment, whilst maintaining its compliance enough, 
which is a key parameter. An open walled, porous structure allows the mass transport of 
signalling molecules, nutrients and metabolic waste removal, all of which lead to 
improved adhesion and growth of endothelial cells and angiogenesis. However, this 
factor is more relevant in small diameter grafts. Following accelerated durability testing, 
mechanical strength is not lost as shown by the unchanged radial stress-strain curves. 
This data implies that the soft segment of the polyurethane nanocomposite remains 
intact in spite of the increased transmittance observed in carbonyl segment of carbonate 
(-NHCO-) on FTIR. This also correlates well with the observations on SEM. It has been 
noted in previous studies that a reduction in intensities of -NHCO- groups is due to 
degradation of polyurethane in coatings
193
. 
 
Previous studies of segmented polyurethane elastomers have demonstrated that 
their thermo-mechanical properties are markedly influenced by composition and 
morphological details
194
. Morphological changes in polyurethanes are generally 
associated with changes in phase separation and subsequent crystallinity of hard and 
 soft segment domains
195
 which results in interchange between non-hydrogen bonded 
and hydrogen-bonded carbonyl and amide absorbance. Thermal analysis can be used to 
characterize the thermal behavior of the polyurethanes. DSC and TMA on fatigue-tested 
and control POSS-PCU determined the glass transition temperature (Tg) over which an 
amorphous polymer softens and loses its glass-like properties and assumes properties 
more commonly associated with rubber. The thermo-analysis of fatigue tested POSS-
PCU showed essentially one characteristic thermo-tropic transition which was 
comparable to control samples. This result confirms that incorporation of the POSS 
nanomolecule in our polyurethane has conferred biostability and the probability of long 
term durability. The nano-engineering of POSS on the polymer surface means that the 
bulk of the polymer consists of PU molecules cross-linked by POSS nanocages, which  
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preserve radial elasticity
196
 and enhances its resistance to degradation
197
. Due to the 
protective layer of silica on the surface, POSS-PCU is even more resistant to 
degradation compared to PCU polyurethane.  
 
Our study has limitations. This study showed no significant hydrolysis of the 
polymer however we used distilled water and obviously this analysis needs repetition in 
an in vivo model to confirm the resistance of POSS-PCU to hydrolysis and oxidation. 
We used straight configuration for the stent-graft instead of a bifurcated system and 
consequently, it was not possible to reproduce the axial or cyclic drag forces acting on 
the stent-graft to assess migration. Furthermore, hooks or barbs were not used for 
fixation. We aim to analysis this in the next stage of our work, which will involve 
implantation of the stent-graft in a large animal model. The exact nature of relationship 
of porous structure of POSS-PCU in large vessels like the aorta, with graft compliance 
and long-term durability needs to be further evaluated and this will be addressed in our 
future work.  
 
5.5 CONCLUSION 
Our study confirms that simulated physiological in vivo hydrodynamic loading has no 
significant degradative effect on an innovative sutureless stent-graft made from POSS-
PCU nanocomposite polymer bonded to nitinol. The fundamental soft and hard segment 
domain chemistry of the poly (carbonate-urea) urethane polymer material did not 
change on exposure to fatigue. This study validates the use of POSS-PCU 
nanocomposite polymer as a durable graft material for endovascular stents. Sutureless 
technology incorporating nitinol stents proved to be robust with no separation over 
simulated 10 year cycle. This may allow development of durable stent-grafts with better 
compliance and antithrombogenicity, potentially at a lower cost. In the next two 
chapters, we have analysed the properties of the curved stent-graft. 
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A Nanocomposite Polymer Based Thoracic Endoprosthesis to Improve Aortic 
Compliance Mismatch Following Endovascular Repair 
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6.1 INTRODUCTION 
Further to confirmation of durability and robustness of the sutureless stent-graft 
for AAA, we now wanted to evaluate the properties of the curved stent-graft. Our aim 
was to develop a stent-graft with superior compliance to presently used graft materials 
as compliance mismatch is a critical factor for thoracic aorta as discussed below. 
 
Thoracic endovascular aortic aneurysm repair (TEVAR) has several advantages 
over open surgery which include decreased all-cause mortality at 30 days, reduced risk 
of paraplegia/paraparesis, reduction of renal dysfunction, transfusions, reoperation for 
bleeding, cardiac complications, neurologic complications, pneumonia, respiratory 
complications, reduced incidence of any complication, and shorter procedure time, and 
length of stay in intensive care unit or hospital
198;199
. Thoracic endograft placement has 
been found to be efficacious and safe for use in the treatment of other pathologies such 
as type B aortic dissection, penetrating atherosclerotic ulcer, intramural haematoma, 
pseudoaneurysms, acute traumatic aortic disruption, and left subclavian artery 
aneurysms
200-203
 as well as ruptured thoracic aortic aneurysms
204
. 
 
The proximal aorta is a highly compliant vessel, which reduces left ventricular 
workload and damps the propagated pressure wave
205
. It is the major contributor to total 
arterial compliance and an important determinant of cardiac afterload
206
. Ejection of the 
blood from the left ventricle is possible because the volume of the large arteries is able 
to increase in order to accommodate the ejected blood. This function is described as the 
``Windkessel property'' of the aorta and the major conduit arteries and results in a 
considerable damping of the pressure wave and a significant reduction of cardiac 
afterload, enabling the heart to work efficiently near the optimum point on the Starling 
curve. Aortic reconstruction with a prosthetic non-compliant graft reduces this 
compliance and may have an adverse effect on cardiovascular haemodynamics, which 
in turn may lead to hypertension, cardiac hypertrophy and ischaemia, the development 
of vessel wall disease and thrombosis formation
207-209
.  
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Most currently available graft materials are stiff and poorly compliant. It has 
been estimated that woven Dacron graft is approximately 170 times stiffer than natural 
aorta
210
. Compliance mismatch caused by surgical replacement of thoracic aorta with  
prosthetic grafts is well documented. The outcome of thoracic endografting is largely 
dependent upon the interaction of the endovascular device and the aortic wall at the 
zones of fixation. A tight, durable seal to isolate the aortic pathology from pressure and 
flow is the ultimate goal of these techniques. Failure to achieve this initial technical 
success or subsequent dilatation of the aorta at the landing zones leads to endoleak that 
compromises the integrity of the endovascular reconstruction. The extent to which the 
compliance mismatch
211
 induced by the insertion of the stent-graft might contribute to 
subsequent dilation is not known. The effect of using endografts of different design on 
thoracic aortic stiffness and compliance has been poorly studied. However, the 
development of more compliant prostheses, which match the host artery compliance, is 
expected to reduce the haemodynamic changes induced after their implantation.  
 
We have presented an innovative design for a self-expanding thoracic stent-graft 
that incorporates a Nitinol alloy scaffold with a polyhedral oligomeric silsesquioxane 
(POSS) - poly (carbonate-urea) urethane (PCU) nanocomposite polymer (NP), chosen 
for its excellent biocompatibility and superior vascular properties. The polymer is 
hydrophobic and non-thrombogenic, and favours spontaneous endothelialisation
212
. It 
displays impressive anti-thrombogenic properties in vitro compared with expanded 
polytetrafluoroethylene (ePTFE), making it a promising biomaterial for cardiovascular 
applications
213
. POSS-PCU is currently undergoing a range of clinical studies from 
small conduits for lacrimal duct treatment to nasal reconstruction in cancer patients to 
development of heart valve leaflets and small diameter bypass graft
214
.  
 
The main aim of this study was to develop “compliant” POSS-PCU Nitinol 
stent-graft for repair of thoracic aorta and the aortic arch that may result in better long-
term durability and more effective endovascular repair. 
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6.2 METHODS 
6.2.1 Material Properties for the Curved Stent-graft 
The polymer development has been described in detail previously
215
. We adopted 
similar method. In brief, polycarbonate polyol and trans-cyclohexanediolisobutyl 
silsesquioxane were placed in a reaction flask equipped with a stirrer under nitrogen. 
Next, the mixture was heated to dissolve the nanocage. To this was added methylene di-
isocyanate (MDI), and the reaction allowed to proceed at 70° C for 90 min to form a 
pre-polymer. Then N, N-dimethylacetamide (DMAC) was added. Chain extension of 
the pre-polymer was carried out by the addition of ethylenediamine and diethylamine in 
DMAC. 1-Butanol in DMAC was added to the mixture to form a 2% polyhedral 
oligomeric silsesqioxane–poly (carbonate urea) urethane (POSS–PCU) solution. All 
chemicals and reagents were purchased from Aldrich (Gillingham, UK). The typical 
mechanical properties of POSS-PCU used are outlined in table 6.1 
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Test Method Typical Value 
Maximum Tensile Strength (Mpa) ISO 37 71 
Elongation at Break (%) ISO 37 691 
Tensile Stress at 50% Strain (Mpa) ISO 37 4.62 
Tensile Stress at 100% Strain (Mpa) ISO 37 6.95 
Tensile Stress at 200% Strain (Mpa) ISO 37 13.24 
Tensile Stress at 300% Strain (Mpa) ISO 37 23.00 
Young's Tensile Modulus 10-25mm (Mpa) ISO 37 5.45 
Tear Strength (N/mm) ISO 34 96 
Tensile Set ASTM F 703  
 
Table 6.1: Typical Mechanical Properties of POSS-PCU 
Tensile tests carried out to ISO 37, Specimen size type 3, Crosshead speed 100 mm/min 
on an Instron 5565 
Tear Strength carried out to ISO 34, Angle test piece with nick, Crosshead speed 
500mm/min on an Instron 5565 
Elongation measured at the grips 
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6.2.2 Design of a Curved Stent-graft for Thoracic Aorta and Aortic Arch 
 
As discussed earlier, a curved mould was developed from a three-dimensional printer 
using dimensions from patient magnetic resonance imaging data. The curved mould was 
used to develop a silicone mandrel in four components. A thin layer of polymer, 
approximately 50 µg in thickness was applied over the mandrel with all four 
components joined together by a long screw. The polymer was allowed to dry and 
placed in an oven at 60°C for 2 hours. Now previously laser-cut nitinol rings were 
placed over the polymer layer at equal distance. A second polymer layer of similar 
thickness was applied and heat-treated as above. A further third layer of polymer was 
applied, aiming to achieve a thickness of 150 µg. Finally, the stent-graft with the 
mandrel was placed in an oven overnight at 60°C for 12 hours. It was removed and 
allowed to cool down for 4 hours. The polymer was carefully peeled off the mandrel 
and the components were separated by unscrewing.  
 
6.2.3 Stent-graft Control 
 
We used the Gore Tag stent-graft (W. L. Gore & Associates, Flagstaff, AZ), which was 
the first FDA-approved stent-graft, as control. It is comprised of an expanded 
polytetrafluoroethylene (ePTFE) graft with an outer self-expanding nitinol support 
structure.  
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6.2.4 Flow Phantom  
As used earlier, we have utilised the flow circuit for assessing the dynamic behaviour of 
stent-grafts
216
. The flow model comprised of a variable-speed electromagnetic 
centrifugal pump (Bio Medicus, Minnetonka, MN, USA), flexible plastic tubing and a 
fluid reservoir (figure 6.1). A previously developed governable flow waveform 
conditioner was cited in series with the circuit and used to generate arterial flow 
waveforms. Instantaneous flow rate was measured using a 6-mm tubular flow probe 
connected to a Transonic Medical flowmeter system (HT207; Transonic Medical 
System, Ithaca, NY, USA). Serial intraluminal pressure measurements were made at  
 
discrete sites along the stent-grafts using a Millar Mikro-tip catheter transducer (Millar 
Instruments, Houston, Texas, USA) introduced via a Y-connection port. A gas mixture 
of 95% oxygen and 5% carbon dioxide was bubbled through the fluid reservoir and the 
perfusate was maintained at 37ºC via a heat exchanger (Portex, Hythe, UK). Pressure 
was varied by increasing the level of fluid reservoir above the graft segment and by 
varying the diameter of outflow resistance sited distally to the grafts. All outputs were 
fed into a commercial analogue-to-digital data acquisition recording system 
(ADC/MacLab; AD Instruments, Hastings, UK). 
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Figure 6.1: Diagrammatic representation of the flow model used for measurement of 
compliance and elastic stiffness index. ADC, analogue-to-digital data acquisition 
recording system; FWC, flow waveform conditioner; MHFO, maxima hollow fibre 
oxygenator (Medtronic, Anaheim, CA, USA); P1 and P2, Millar Mikro-tip pressure 
transducer; TMF, Transonic Medical flowmeter system; VSECP, variable-speed 
electromagnetic centrifugal pump; WTS, wall-tracking system 
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6.2.5 Measurement of Vessel Wall Movement 
The change in vessel wall diameter with respect to each cardiac cycle was measured at 
discrete sites along the graft, with measurements taken in the sagittal plane at 90º to the 
long axis of the graft. The stent-grafts were scanned with a specially adapted, duplex  
colour-flow ultrasonography system (Wall Track; Pie Medical Systems). This system 
allowed the measurement of vessel wall movement over time by automatically tracking 
assigned points of the induced radiofrequency signal deemed to be representative of the 
anterior and posterior arterial walls. A detailed description of the system has been 
published elsewhere
145;217
. Briefly, a 7.5-MHz linear array probe was immersed in the 
bath and positioned directly over the segment under investigation. The M-mode cursor 
was positioned at the midpoint of each test segment and perpendicular to the direction 
of flow; the change in induced radiofrequency signal received from the vessel walls was 
then sampled over time. These data were then transferred to a personal computer for 
real-time display of the displacement waveforms of the anterior and posterior artery 
walls. In this way, end-diastolic and end-systolic intra-luminal diameters were 
determined automatically over the pulsatile cycle (figure 6.2).  
 
 
Figure 6.2: Distension-time curve generated by wall-tracking system. The Y-axis is 
represented by Distention in µm on the graph above and Pressure in mm of Hg in the 
graph below. The time in seconds is on X-axis for both the graphs 
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6.2.6 Haemodynamic and Arterial Parameters 
 
 
The solution used for perfusion was made using 8% low molecular weight Dextran 
(molecular weight 77000-Da; Sigma-Aldrich, Poole, UK) added to a solution of M199 
(minimum essential medium), 20% fetal bovine serum, 7.5% sodium bicarbonate 
(Sigma-Aldrich), 200-mmol L-glutamine (Gibco BRL; Life Technologies, Paisley, 
UK), penicillin 10000-units/ml and streptomycin 10-mg/ml, buffered at pH 7.20 ± 0.01. 
The viscosity of this medium has previously been determined to approach that of whole 
human blood (Low-Shear 30; Contraves, Zurich, Switzerland)
218
. Viscosity of the 
perfusion solution was determined and was calibrated with a cone-plate viscometer at 
0.035 poise. This was facilitated by using 8% low molecular weight Dextran in the 
nutrient solution. Measurements were made using a near-constant pulse pressure over a 
range of mean pressures (table 6.1). For each mean pressure and test segment, three 
measurements of wall movement were made, and the experiment was repeated six 
times. 
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Physical Parameter ePTFE stent-graft NP stent-graft 
Mean Pressure 
(mm Hg) 
 
30-100 
 
 
30-100 
Pulse Pressure 
(mm Hg) 
 
49±6 
 
49±6 
Flow rate ml/min 140 ± 25 132 ± 24 
Perfusate temperature 
(ºC) 
 
37 
 
37 
Perfusate viscosity 
(poise) 
 
0.035 
 
0.035 
 
Table 6.1: Typical Flow Circuit haemodynamic values (mean ± SD) 
 
6.2.7 Statistical Analysis 
The data from each experiment obtained were plotted and analysed using GraphPad 
Prism 4 software (GraphPad, San Diego, CA, USA). Grouped data are presented as 
mean ± SD (standard deviation). The unpaired Student’s t-test was used for statistical 
comparison of the two stent-grafts. Only p values < 0.05 were considered significant.  
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6.3 RESULTS 
6.3.1 Stent-graft Design 
The NP stent-graft had uniform thickness of 150.7±6.6 µg and in its fully expanded 
shape, with diameter of 30 mm, matched curvature of aortic arch and descending 
thoracic aorta (figure 6.3).  The inner side of the stent-graft was covered with a smooth 
layer of polymer (figure 6.4). Upon folding, the stent-graft was first straightened in a 
way that some polymer partly covered onto the nearest nitinol ring. Then, the stent-graft 
was easily folded as a traditional straight stent-graft because the nitinol rings are 
positioned in a way that the peaks of a nitinol ring point to the valleys of the adjacent 
nitinol ring. The folded stent-graft can be delivered to the aorta just as the traditional 
stent-graft does. 
 
 
Figure 6.3: A fully expanded curved stent-graft from POSS-PCU NP bonded to nitinol 
and having curvature similar to aortic arch 
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Figure 6.4: The smooth inner surface of the stent-graft with uniform thickness and 
curved design 
6.3.2 Compliance Measurement 
Compliance is a tool used to measure distensibility of the artery. Diametrical 
compliance (C) defined as the inverse of Petersen’s elastic modulus Ep147;148, and 
expressed as %/mm Hg X 10
-2
, was determined for each test segment at each mean 
pressure as follows: 
 
C = (Ds-Dd/Dd) X 10
4
/ (Ps-Pd) 
 
Here C is the compliance value of the stent-graft at a particular cross-section. Ds and Dd 
are systolic and diastolic diameter, and Ps and Pd are systolic and diastolic pressure, 
respectively. The compliance of the stent-grafts was measured at four locations. When  
 
!
Uniform thickness 150.7± 6.6 μg 
30 mm
Smooth inner surface
Curved design
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the stent-grafts were inserted in the model, triphasic flow was seen in all of the 
measurements with no difference in flow waveforms. The haemodynamic and arterial 
parameters were nearly consistent for both the stent-grafts.  
 
The compliance results are shown in figure 6.5. The mean compliance of the 
ePTFE stent-graft was 2.3 ± 0.95 (95% CI 1.7-2.9) %/mm Hg X 10
-2
. The mean 
compliance of the NP stent-graft was significantly better at 3.3 ± 0.61 (95% CI 3.0-3.5) 
%/mm Hg X 10
-2
 (P=0.0003). 
 
 
 
 
Figure 6.5: Compliance results. Data presented as mean values. Pressures in mm Hg on 
X-axis and Compliance in %/mm Hg x 10
-2 
on Y-axis 
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6.3.3 Stiffness Index 
 
Arterial stiffness is one of the primary attributes of vasculopathy, involving several 
mechanisms and results in damaged arterial compliance
219
. Arterial wall stiffness index, 
ß as formulated by Kawasaki et al
220
, and utilised as a cardiovascular risk factor, was 
calculated using the following equation. 
 
ß = [loge (Ps/Pd)] X Dd/ (Ds-Dd) 
 
The results of stiffness index measurement are shown in figure 6.6. The ePTFE stent-
graft was significantly more stiff as compared to the NP stent-graft [ß 92.7 ± 46.1 (95% 
CI 64.9-121) vs. ß 39.1 ± 5.91 (95% CI 36.9-41.3); P<0.0001]. The stiffness index-
mean pressure curves were generated using non-linear regression (single phase 
exponential decay model). For both the stent-grafts, stiffness index was observed to 
behave in a non-linear fashion in response to elevation in mean perfusion pressure. It 
was observed that for NP stent-graft the stiffness remained nearly constant; however, 
the ePTFE stent-graft was significantly stiffer at physiological pressures.  
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Figure 6.6: Elastic Stiffness Index Results. Data presented as mean values. Pressures in 
mm Hg on X-axis and Elastic stiffness index β on Y-axis 
 
 
6.4 DISCUSSION 
Our results confirm superior compliance profile of an innovative stent-graft 
based on POSS-PCU nanocomposite polymer, as compared to an ePTFE-based FDA-
approved stent-graft in current clinical use. Using an in vitro flow phantom in a 
simulated physiological environment, we were also able to demonstrate that POSS-PCU 
stent-graft is significantly less stiff.  
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There have been studies on aortic compliance assessment after abdominal aortic 
aneurysm repair and it has been shown that stent-graft design alters aortic stiffness and 
elastic modulus at several sites after endograft implantation, which may have serious 
consequences for endograft efficacy and durability
221
. The implantation of endovascular 
devices in the proximal descending aorta has been shown to increase left ventricular 
afterload
222
. These changes may have long-term consequences especially in younger 
patients undergoing stenting for traumatic disruption of the aorta, patients with coronary 
artery disease and in patients with reduced left ventricular systolic reserve. Although, 
careful quantification of the interaction in vivo is required to characterise this response, 
information regarding endograft-aortic wall interaction from imaging following 
endografting has suggested that ‘compliance-matched’ stent-grafts may result in better 
long-term durability and more effective endovascular repair
223
. Haemodynamic studies 
have shown changes after endografting were similar in magnitude to open interposition 
grafts. The insertion of Dacron prosthesis in the descending aorta during the repair of 
traumatic disruption has been shown to increase characteristic impedance (stiffness) of 
the ascending aorta and this can potentially reduce cardiac efficiency and may 
predispose to the development of left ventricular hypertrophy
224;225
. Simulated reduced 
aortic compliance by banding has been shown to significantly increase characteristic 
and input impedance, a significant decrease in systemic arterial compliance and a 
subsequent increase in systolic and pulse pressures leading to left ventricular  
hypertrophy
206
. Reduced compliance caused by endografting may have similar effects 
and so, having a better compliance-matched stent-graft can help improve the long-term 
durability of this procedure.  
 
Arterial stiffness is one of the primary attributes of vasculopathy, involving 
several mechanisms and has been suggested as a strong independent predictor of 
cardiovascular disease
226
. The stent-grafts in current clinical use are based on either 
ePTFE (Tag), woven polyester (Zenith TX2) or monofilament polyester (Talent). As 
shown in our results, ePTFE is stiffer than POSS-PCU and this may have clinical  
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implications by having adverse structural and functional changes, however this 
statement is purely hypothetical and further research is necessary to support this.  
 
6.5 LIMITATIONS 
 
There are some limitations. We have studied the effect of graft material but the effects 
of other factors on stent-graft compliance such as intraluminal thrombus in the 
aneurysm sac are not factored. The non-Newtonian behaviour of blood has not been 
considered. The pressure range that we used included a maximum mean pressure of 100 
mm Hg and confirmation of findings at higher pressure range possible in clinical 
situations is essential. At present, our study cannot model any long-term effects that a 
rigid stent-graft might have on vascular haemodynamics. 
 
6.6 CONCLUSIONS 
 
We present an innovative curved stent-graft, based on a new biomaterial for 
endovascular repair of thoracic aorta, which matches the curvature of aortic arch and 
can be used to develop fenestrated or branched devices in the future.  In an in vitro 
model over a range of pressures, it shows superior compliance profile and is less stiff in 
comparison to graft material in current clinical use in thoracic endografts. Although, 
this research is still in infancy, we believe that with improvement in physiological and 
haemodynamic properties of stent-grafts, clinical management of patients with thoracic 
aortic pathologies and stent-graft design can by vastly improved in the future. 
 
Our future work will be aimed at analysing the imaging properties of the stent-
graft on exposure to flow, especially with magnetic resonance imaging to confirm its 
compatibility. 
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Chapter 7 
Magnetic Resonance Signal Attenuation and Image Artefact Testing of a 
Nanocomposite Polymer Nitinol Thoracic Stent-graft 
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7.1 INTRODUCTION 
The curved stent-graft developed from POSS-PCU bonded to Nitinol and 
matching the conformability of aortic arch has shown superior compliance profile with 
better elastic stiffness as compared to ePTFE used in some of the current devices. For 
thoracic stent-grafts, it is important to assess compatibility with imaging modalities, 
particularly magnetic resonance imaging (MRI) and this has been highlighted in this 
chapter. 
 
As already described in the earlier chapters, the curved design combines 
deployable structure technology to improve the folding efficiency and performance of 
the device in vivo. The scaffold geometry is designed similar to the aortic vessel. The 
new technology allows pre-forming of the angulation of the host aortic arch into the 
device and due to the bonding of the graft around the metal skeleton, we hypothesize 
that it reduces the risk of mechanical stress-related disruption, which can help in 
reducing the incidence of kinking, migration, and endoleak. Because of the folding 
technology, a more flexible and potentially narrower gauge delivery system can be 
employed but most importantly device can be constructed so that once deployed it will 
be inherently stronger, more stable and have the degree of angulation tailored to the 
individual patient. There is also scope to include branch grafts in the folded metal 
structure to incorporate the major vessels. Such a device has the potential to treat many 
more patients with this increasingly common condition in our ageing population. It will 
reduce the need to occlude or reconstruct the great vessels thus significantly reducing 
complications and risk of operative death associated with hybrid procedures. 
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Magnetic Resonance Imaging (MRI) is increasingly being used for assessment 
and follow-up of patients with aortic disease. It has the advantage over other imaging 
modalities such as computed tomography, of being able to give anatomical and 
functional information in a single scan. MRI has superior soft tissue contrast and can be 
used to assess the quality of endovascular repair, by assessment of device positioning 
and device to wall apposition. Gadolinium contrast agents (used in MRI) are less 
nephrotoxic compared with iodinated agents and this may improve survival in patients 
with poor renal function following endovascular aneurysm repair (EVAR).
227
 
Application of MRI can be compromised by poor visibility of the device, susceptibility 
artefacts introduced by the stent or severe signal reduction by radio-frequency shielding. 
The safety and compatibility of devices within the magnetic field is one of the key 
parameters in aortic stent-graft development. The Food and Drug Administration (FDA) 
therefore recommends that stent-grafts undergo MRI assessment prior to clinical use.  
 
The objectives of this study were to assess MRI characteristics of POSS-PCU 
and Nitinol thoracic stent-graft including image artefacts and flow velocity 
measurement in a dedicated in vitro aortic phantom. 
 
7.2 METHODS 
7.2.1. Magnetic Resonance Imaging (MRI) assessment 
All images were acquired on a 3T MR scanner (Achieva, Philips Healthcare, Best, The 
Netherlands) with a 32-element coil. Initial survey and reference scans obtained 
localisation images and coil sensitivity maps respectively. Comparison was made with a 
commercially available Valiant stent-graft (Medtronic, Minneapolis, MN) which is 
based on polyester graft fabric sutured to a self-expanding nitinol wire stent.  
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7.2.1.1 Static Fluid MRI Signal Assessment 
Medtronic and NP stent-grafts were scanned separately in a glass cylindrical container 
filled with water dosed with 10mL gadopentetate dimeglumine (Magnevist, Bayer 
Healthcare, Germany) to observe stationary signal attenuation (figure 7.1). 
 
 
 
Figure 7.1: Phantom setup for NP stent-graft. Stent-grafts were scanned separately in a 
glass cylindrical container filled with water dosed with 10mL gadopentetate 
dimeglumine 
Isotropic three-dimensional (3D) T1-weighted Fast Field Echo (FFE) images were 
acquired using the following scan parameters: FOV: 200x200 mm
2
, acquired voxel size:  
1.0x1.0x1.0 mm
3
, flip angle 9º, TR/TE: 4.2/1.9 ms.  
 
Image data were analysed using commercially available software (Philips ViewForum, 
Best, The Netherlands).  The amount of artefact generated by the devices was assessed 
and graded by RC using a three-point grading scale:  
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Grade 1: Severe artefacts with poor visualisation of the device;  
Grade 2: Minor artefacts;  
Grade 3: Excellent visualisation and delineation of device details
228
.  
 
Potential signal shielding from inside the device was assessed by placement of a region 
of interest inside and outside the centre of each stent-graft and calculation of percentage 
signal loss within each stent-graft lumen.  
 
7.2.1.2 Flow Encoded MRI Signal Assessment 
 
A steady flow phantom was set up using a large elevated fluid reservoir to a large empty 
tank at floor level.  Water was transmitted from the elevated reservoir to the lower tank 
via a (½ØID X ⅝ " ØOD) Tygon (Cole-Parmer Instrument Co. Ltd., London, UK) tube 
conduit passing into the scanner and out again. The stent-grafts were positioned around 
the tubing with the tubing orientation such that both stent-grafts had an uncovered  
section of Tygon tube running beside it at the same position to the static magnetic field 
(B0) for comparison (baseline) (figure 7.2).Before commencing each flow encoded scan, 
the tube was unclamped and the flow allowed to develop for at least five seconds.   
Image slices were positioned perpendicular to the stent and tubing. 2D through-plane 
phase contrast images were acquired using the following scan parameters: FOV: 
250x250 mm
2
, slice thickness: 10mm, acquired voxel size: 1.0 x 1.0 mm
2
, flip angle 
10º, venc 150cm/s, TR/TE: 5.2/2.9 ms, retrospective ECG-gating, temporal resolution 
45ms, NSA: 1. Prior to analysis the data were corrected for eddy currents and Maxwell 
phase offsets.  
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Figure 7.2: Schematic diagram illustrating the MRI flow phantom setup. Large elevated 
fluid reservoir connected to fluid tank on the floor using Tygon tubing. Stent-grafts 
positioned as shown with corresponding uncovered tubing for baseline comparison 
 
Image data were analysed using commercially available software (Philips 
ViewForum, Best, The Netherlands). A region of interest was created using semi-
automatic segmentation within the lumen of each stent and the corresponding uncovered 
tubing in each image set. All voxels within the contour were evaluated and by 
integration over all time phases the amount of water passing through each contour per 
second was calculated (flow).  
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7.2.3. Statistical analysis 
All statistical tests were performed using Graphpad for Prism 5 (La Jolla, CA, USA). 
Normalisation of data was used for baseline correction. The comparison was done using 
unpaired t-test and p-value <0.05 was considered significant. 
 
7.3 RESULTS 
 
7.3.1 Stent-graft Design 
The NP stent-graft had uniform thickness of 150.7±6.6 µg and in its fully expanded 
shape, with diameter of 30 mm, matched curvature of aortic arch and descending 
thoracic aorta. Upon folding, the stent-graft was first straightened in a way that some 
polymer partly covered onto the nearest nitinol ring. Then, the stent-graft was easily 
folded as a traditional straight stent-graft because the nitinol rings are positioned in a 
way that the peaks of a nitinol ring point to the valleys of the adjacent nitinol ring. The 
folded stent-graft can be delivered to the aorta just as the traditional stent-graft does.   
 
7.3.2 Subjective data analysis for image artefact testing 
Imaging results of the endograft and its lumen on the 3D T1-weighted MR images 
showed that both Medtronic and NP stent-grafts had no significant susceptibility 
artefacts affecting the image quality. There was no image distortion and the nitinol 
struts could be easily distinguished. There was minimal signal attenuation within the 
lumen of Medtronic stent-graft but none on NP stent-graft (figures 7.3 and 7.4). No 
significant susceptibility artefacts affecting the image quality were seen and the nitinol 
struts could be easily distinguished. The artefacts were graded as 3 on most occasions 
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Figure 7.3: MR static images for Medtronic Valiant
TM
 stent-graft. Minimal 
susceptibility artefacts were seen, however the image quality was good 
 
 
 
 
Figure 7.4: MR static images for NP stent-graft. No significant susceptibility artefacts 
affecting imaging quality were seen 
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7.3.3 Objective data analysis for signal magnitude on image artefact testing 
 
The signal inside and outside the Medtronic stent-graft was 644.2 (SD 36.2) and 
659.6(SD 85.8) respectively. The percentage signal attenuation for this device was 
2.39%. The signal inside and outside the NP stent-graft was 1561.7 (SD 31.2) and 
1595.5 (SD 40.8) respectively. The percentage signal attenuation for this device was 
2.16%. Selected slices of the high-resolution datasets demonstrated the individual 
amount of RF signal shielding of the stent-grafts (figures 7.5 and 7.6). There was no 
relevant signal attenuation within the lumen of Medtronic and NP stent-grafts. There 
was no regional signal enhancement. Quantitative assessment of RF signal caging 
showed that the percentage attenuation was around 2-10%, for the Medtronic stent-graft 
and only 0-2% for NP stent-graft. Small variations in the attenuation score might be due 
to a different location of the measurement regions of interest (ROIs) relative to the 
position of the surface coils (inherent spatial signal variations).  
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Figure 7.5: Axial slice from Medtronic Valiant
TM
 stent-graft showing signal magnitude 
inside and outside used to calculate % signal attenuation 
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Figure 7.6: Axial slice from NP stent-graft showing signal magnitude inside and 
outside used to calculate % signal attenuation 
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7.3.4 Analysis of flow measurement 
In MRI velocity attenuation study, steady flow phantom was set at mean flow rate of 
105.3 ml/sec and mean velocity of 79.5 cm/sec. Following normalisation of the data, the 
flow in the Medtronic stent-graft was 102±2.27 ml/sec with no significant difference to 
baseline (104±1.98 ml/sec; P=0.892). Flow through the NP stent-graft was 99.8±2.4 
which was not different to baseline (104±0.96 ml/sec; P=0.176). There was no 
significant difference in flow between Medtronic and NP stent-grafts (102±2.27 vs. 
99.8±2.4 ml/sec; P=0.328). As shown above, the velocity attenuation in the NP stent-
graft was 4.6% as compared to 1.9% in Medtronic stent-graft (figure 7.7).  
 
 
 
Figure 7.7: Velocity flux comparison for Medtronic and NP stent-grafts. Columns 
represent mean values and error bars represent standard deviation 
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7.4 DISCUSSION 
We have designed an innovative sutureless stent-graft for endovascular repair of 
thoracic aorta and our results confirm the feasibility and compatibility of its assessment 
using MRI. This stent-graft has a unique curved shape with a potential to have branches 
and promise of use in the repair of aortic arch. Endovascular prostheses currently in use 
are not designed for the treatment of arch pathologies
229
, where blood flow generates 
high forces, the aorta moves through a wide excursion with every pulse, and temporary 
flow interruption can lead to stroke or cardiac arrest
230
. Therefore, incomplete 
alignment, type 1 endoleaks and retrograde type A dissections may occur.  
 
These can be potentially avoided by our curved design simulating accurate aortic 
dimensions and a hybrid approach can be replaced by complete endovascular 
intervention. Furthermore, this stent-graft is based on a nanocomposite polymer having 
properties of compliance, antithrombogenicity and spontaneous endothelialisation, 
superior to presently used Dacron and Polytetrafluoroethylene (PTFE). 
 
MRI has been incorporated into diagnostic routine for the assessment of aortic 
abnormalities and several studies have suggested that MRI may be superior to standard 
techniques for detecting endoleaks during follow-up, as well as for evaluation of 
aneurysm sac exclusion and graft patency. The application of MRI in patients with 
endovascular stent-grafts has limitations. The image quality may be compromised by 
susceptibility artefacts introduced by the stent material
231
 or severe signal reduction in 
the stent-graft due to radio-frequency (RF) shielding of the mesh
232
. The Food and Drug 
Administration (FDA) therefore recommends that stent-grafts undergo MRI assessment 
prior to clinical use because safety issues such as RF heating and dislocation must be 
carefully considered
233
. In direct comparison to CT, MRI has proven to provide all 
relevant information required for follow-up of endoluminally treated abdominal aortic 
aneurysm with superior performance in the assessment of thrombus reorganisation
234
 
and inferior performance in the identification of stent fracture
235
.  
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Our study has shown that the novel NP stent-graft is not associated with any 
relevant susceptibility artefacts or relevant RF signal loss within the stent-graft lumen. 
RF shielding effects depend on stent material and wall geometry. Our results of no 
significant RF shielding for nitinol based stent-grafts are comparable to previous 
studies
236
. The shielding effects vary substantially with the orientation of a stent. 
Consequently, the shielding effects need to be confirmed following implantation in 
humans. However, this should not pose a problem considering the negligible 
susceptibility and shielding effects exhibited by Nitinol stents. 
 
Our results did show difference in velocity attenuation between two stent-grafts 
to some extent, however it did not significantly affect appreciation of graft’s exterior or  
interior. The detectability of instent stenosis can be affected by overall attenuation 
inside the stent but this is more relevant in smaller stents. In these stents, flow patency 
has to be assessed proximally and beyond the stent where arterial flow signal could be 
seen. However, in thoracic stents, with high systolic velocities and flow volumes with 
larger stent diameter, in stent flow measurements are unlikely to be significantly 
affected. The findings of our investigation and previous studies suggest that nitinol 
stent-grafts do not cause any major artefact that could significantly influence flow 
measurements
237
.  
 
MR-safe is defined by ASTM as a device which when used in an MRI 
environment under specified conditions, has demonstrated to present no additional risk 
to the patient or other individual but may affect the quality of the diagnostic 
information. No additional risk to the patient due to stent movement, dislodgement or 
migration using an MRI system with a static magnetic field of 3.0T or less is 
expected
238
. Another potential safety hazard associated with MRI examinations is the 
possibility of localised increases in the radiofrequency Specific Absorption Rate (SAR) 
near metallic implants. The local electric field can be amplified, especially if the 
implants are composed of long conducting structures that potentially can couple  
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significantly with RF energy of the body coil
239
. This might lead to excessive tissue 
heating. These resonance effects, however, occur only when the length of implants 
exceeds one half of the RF wavelength
240
. For endografts, that are small as compared to 
RF wavelength (<20 cm in length, as used in this study), RF resonance is considered 
unlikely
241
, so no significant heating of these devices is expected. Accordingly, this 
testing is not essential. Furthermore, for Valiant stent-graft, the whole-body averaged 
SAR of 3.0 W/kg for 15 minutes exposure to MRI will produce a maximum temperature 
increase of only 0.7 °C, which is considered physiologically inconsequential and does 
not pose additional risk to the patient
242
. 
 
This study has limitations. Although, the image artefacts have been addressed, the 
safety and compatibility concerning magnetically induced displacement force and 
torque and RF heating remains to be proven, before the device can be classified as MR-
safe.  The flow rate probably wasn’t consistently at exactly 100 ml/s; we didn’t assess 
the amount of signal loss and artefacts with different device orientations and we have 
assessed at 3T magnetic strength only. Another limitation might be that we did not 
perform an in vivo analysis. However, the purpose of this study was to assess the 
accuracy in relation to our gold standard, i.e. a stent-graft in current clinical use. 
Because in addition to graft material, stent diameter and pulsatility of flow, other 
haemodynamic parameters including viscosity and compliance of arteries affect the 
distortion of magnetic field, our results will need to be confirmed in an in vivo model. 
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7.5 CONCLUSION 
MRI is likely to be an integral part of follow-up after implantation of thoracic 
endografts. Since flow in arch and descending thoracic aorta exhibits very high systolic 
velocities and flow volumes it is an especially challenging environment. The knowledge 
gain on blood flow alterations within aortic stent-grafts could be used to identify risk 
factors for later stent-graft failure as well as to improve stent- graft design. We have 
designed a stent-graft from NP that does not display any relevant material-induced 
artefacts on MRI. On flow assessment, signal attenuation is comparable with 
commercial device. The small difference noted was statistically insignificant and is 
unlikely to be of any clinical implication. These properties are important in developing 
this stent-graft, sutureless, compliant, durable and made from biocompatible and 
antithrombogenic polymer, for future clinical use. In future, we aim to perform 
haemodynamic testing to further improve the stent-graft design and confirm its 
properties in an in vivo model  Our work will also involve making a branched device for 
branches of the aortic arch in addition to assessment of folding profile and deployment. 
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8.1 DISCUSSION 
 
The key findings of this work are: 
 
a) We have developed aortic stent-grafts using surface-modified nitinol bonded to 
a nanocomposite polymer based on polyhedral oligomeric silsesquioxane 
(POSS) – poly carbonate-urea urethane (PCU). Using several modifications, the 
prototype for infra-renal abdominal aortic aneurysm (AAA) repair has been 
optimised. 
b) The stent-graft utilises deployable structures technology and has shown folding 
efficiency similar to current devices with a potential to develop delivery systems 
for future percutaneous insertion. 
c) Using similar principles, we have also developed an innovative design for a 
thoracic stent-graft which is conformable to the aortic arch anatomy. This device 
can be further modified to have fenestrations and branches. 
d) We have developed an aortic model for physiological analysis of endografts and 
shown superiority to presently used models. 
e) Through extensive in vitro analysis, our results show that the sutureless 
technology proved to be durable and robust on exposure to fatigue equivalent to 
10 years of use in human body in an accelerated simulated physiological 
environment. This test was carried out based on FDA recommendations. 
f) On in vitro testing, the POSS PCU stent-graft showed superior compliance and 
elastic stiffness profile in comparison to ePTFE-based stent-graft in current 
clinical use. 
g) Finally, the curved stent-graft showed comparable properties to current device in 
magnetic resonance signal attenuation analysis in a dedicated in vitro flow 
phantom. There were no significant artefacts affecting the visibility or image 
quality. 
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8.1.1 Endovascular stent-grafts 
 
The long-term durability of EVAR remains a concern and the potential for 
adverse events related to endograft migration, endoleak or endograft failure requires 
lifelong surveillance. The data on longer-term benefits are less clear, with no obvious 
survival advantage and an expense of increased reintervention rates, and additional 
costs
243
. 
 
The endograft technology needs to advance further with next-generation devices 
and novel properties to address these shortcomings and subsequently lead to further 
widespread adaptation of this treatment modality. 
 
The use of TEVAR in thoracic aortic pathology is a rapidly developing field that 
carries many promises for the future on multiple fronts. Current devices will definitely 
become more developed and new devices will be introduced. It is important to develop 
devices which are more flexible and can conform better to the aorta, specifically in the 
hostile aortic arch environment as well as other tortuous areas. Also, the development of 
branched devices will expand the utility of the technology in covering more pathologies 
and treating them in a more effective manner. 
 
8.1.2 Contemporary graft materials 
 
The endografts in current clinical use are mainly made from either thin woven 
polyester (Dacron) or ePTFE. Sac enlargement after endovascular aneurysm repair 
(EVAR), without evidence of endoleak, has been attributed largely to endotension or 
material porosity. The first-generation Gore Excluder
TM
 graft allowed serous transudate 
contributing to continued sac pressurisation.  AneuRx
TM
 grafts had a higher incidence of 
microleaks, or persistent transgraft blood flow, occurring through the thin graft material. 
The Excluder
TM
 and AneuRx
TM
 devices modified their graft material in 2004 with 
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reduced permeability
244
. Stent and graft materials have different mechanical properties 
and any repetitive movement between them may damage the fabric. Stronger sutures 
and tighter weaves have made current designs more stable, but none is yet free from 
fabric graft failure
245
.  
 
With the availability of new materials, reducing mismatch in aortic stiffness and 
compliance may become important in future EVAR grafts. Indeed, some differences in 
presently used materials have already been observed by van Herwaarden and colleagues 
finding differences in compliance between Gore Excluder
TM
 and Medtronic Talent
TM
 
stent-grafts at the level of aneurysm neck
246
. In the next decade, we can expect 
continuing improvements in device design. Plasmid-loaded cationised gelatin (CG) 
hydrogel-coated stent-grafts have been proposed offering transduction of therapeutic 
genes into the vascular wall facilitating the biologic healing between the aorta and 
graft
247
. Novel graft materials need to be developed and tested, which have the potential 
to deliver compliance, antithrombogenicity, and biocompatibility to provide better 
configurations and reduce the risk of complications.  
 
 
8.1.3 POSS-PCU nanocomposite polymer as graft material 
 
Our group has developed a family of nanocomposite polymers for biomedical 
applications. Polyhedral oligomeric silsesquioxane–poly(carbonate urea)urethane 
(POSS–PCU) is a biostable, durable and has displayed impressive anti-thrombogenic 
properties in vitro compared with ePTFE, making it a promising biomaterial for 
cardiovascular applications
248-251
. Polyurethanes are composed of hard and soft 
segments, incompatibility between which, results in microphase separation. This 
behaviour infers tough, viscoelastic response, that is ideal for vascular applications. 
Biostability is achieved by incorporation of a biologically stable soft segment group 
made up of polycarbonate molecules to form a PCU. The material’s surface properties  
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are defined by POSS groups that are covalently bonded to the polymer backbone. These 
nanoparticle pendant groups modify the material’s surface morphology making it 
resistant to thrombus formation and they are also suitable for chemically modification to 
promote endothelialisation. 
 
8.1.4 Metallic stent designs in modern endografts and folding efficiency 
 
The Zenith Flex
TM
 and Zenith TX2
TM
 devices are constructed with a frame of 
self-expanding stainless steel Z-stents. The Powerlink
TM
 is created with self-expanding 
cobalt-chromium stents that form the inner structure of the device. All the other stent-
grafts involve a metal skeleton made from Nickel-Titanium commonly referred as 
Nitinol. This material is chosen for its ability to elastically recover large strains and 
thereby, expand from the delivery catheter and conform to geometry of the host artery. 
The material’s high elasticity also infers good flexibility, critical for navigation and 
deployment in tortuous vessels. Several different nitinol stent designs have been used. 
The AneuRx
TM
 uses diamond shaped nitinol rings for high radial strength required to 
achieve fixation without active anchoring barbs. The Excluder
TM
 is composed of nitinol  
wire construct in helical configuration. The Talent
TM
 uses nitinol springs and the 
Endurant
TM
 has M-shaped stents. 
 
Our design is based on principle of compact packaging of a tubular structure, by 
carefully designed creases that behave as line hinges. We have used a folding pattern 
composed of a number of rows of rectangular elements. Each repeated element 
comprised of hill and valley fold lines that allow it to collapse efficiently to a minimal 
volume. The advantage of this configuration includes forming a scaffold structure 
arranged so that each support hoop is opposing the next, so that when this structure is 
collapsed, an efficient folding can be achieved. Our stent design is similar to the 
Excluder
TM
, the Endurant
TM
, and the Talent
TM
 devices but different to the AneuRx
TM
. 
We analysed the folding efficiency by feeding it through a reducing funnel and into  
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sheath that was heat shrunk to constrain the device in its folded condition. A collapsed 
diameter of 6.5 mm was achieved from an expanded diameter of 31.1 mm. This 
corresponded to a reduction ratio of 4.8. The prototype’s folding ratio compared 
favourably with Talent
TM
 stent-graft
 135
. Moreover, improvements to the packing and 
sheathing systems used should make it possible to reduce the packaged diameter to less 
than 4mm, thereby making it suitable for percutaneous insertion.  
 
8.1.5 Bonding versus suturing of graft material to metal skeleton 
 
The Excluder
TM
 and Powerlink
TM
 have sutureless designs. All the other stent-grafts 
involve suturing of the graft material to metal exoskeleton. Similarly, for thoracic 
endografts, the Tag
TM
 design does not involve any sutures.  
 
We have used a sutureless design for endografts using nitinol, which has been surface-
modified. Chemical treatment induces a chemical bond between the POSS-PCU 
polymer and the substrate. This approach requires a metal substrate which has an oxide 
layer that can enhance the polymer coating bond strength
252
. This oxide layer was  
achieved using a variety of chemical, thermal and electrochemical pre-treatment 
methods
253;254
. The results have shown three-fold increase in the bond-strength between 
the graft material and nitinol
255
.  
 
8.1.6 Physiological model for in vitro testing 
 
Many investigators have undertaken in vivo studies into specific aspects of 
preoperative and post operative AAA’s using silicone rubber or latex AAA models256-
259
. The most important component in any in vitro study should be the AAA model 
itself. These models should be reproducible, have consistent material properties, 
consistent thickness and be physiological in behaviour.  
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There are a number of important considerations when attempting to develop 
models with physiological properties. Creating materials with a similar stress-strain 
response to aortic tissue may not lead to models that behave similar to the vessel itself. 
Because of this, the compliance (or stiffness) of arteries has become the attribute which 
researchers attempt to mimic
258;260
. The manufacturing methods for creating both 
idealised and realistic AAA models have been previously reported
258;260;261
. The 
abdominal aorta is surrounded by visceral organs, abdominal muscle and the spine 
which undoubtedly influence its deformation under pressure
262
. So it is important that in 
vitro models engineer a degree of “over-compliance” to buffer subsequent tissue-
induced stiffening effect. 
 
Our aim was to develop a new model which has superior compliance to the 
presently used models. In order to assess the compliance of aorta, we used porcine 
aortas and measured their compliance. We know from previous pulsatile flow studies 
that there are several regions with oscillating shear stress on the posterior aortic wall 
opposite the superior mesenteric artery and downstream the right renal artery.  
Although, it was not possible to factor this in our model, we measured compliance at 
several areas including the juxta-renal aorta, close to the bifurcation and at the level of 
main branches. Our results confirmed that the new model had superior compliance and 
elastic stiffness profile and presently available latex model can fail at physiological 
pressures. Previous similar reports from other groups have analysed compliance of 
AAA models, however they analysed the effect of intra-luminal thrombus on 
compliance
263;264
. This was not essential in our study as we used non-aneurysmal aorta. 
Furthermore, our main aim was to develop a model for long-term in vitro fatigue 
analysis of endovascular stent-grafts. Our model was developed with physiological 
properties and this can be further utilised for careful design of realistic AAA geometries 
in the future.  
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8.1.7 Long-term fatigue and durability analysis 
 
In the next stage of our work, the long-term durability of the stent-graft using the 
new physiological model was analysed. The first commercially available stent-grafts 
were unable to withstand the haemodynamic forces of the vascular environment. The 
past 15 years have seen a gradual improvement in long-term stent-graft performance as 
designs evolved through the elimination of features associated with late failure and the 
replication of features associated with durable success.  Any new stent-graft should be 
tested to failure in a realistic model of the endovascular environment. Computational 
techniques, such as finite element analysis, enable to map the distribution of strain and 
strain as a basis for estimates of stent life. Accelerated fatigue testing subjects 
prototypes of the stent-graft, or its components, to cyclical deformation at rates far 
higher than the human pulse, the goal being to compress the effects of years in the 
human circulation into a few months of testing
265
. Clinical manifestations of stent-graft 
instability often present long after the stent-graft is inserted, and the lessons of clinical 
experience take a long time to become evident. As a result, the interactive cycle of 
device evolution, from design to failure and redesign was quick to correct the causes of 
early failure, but slow to correct sources of late failure. By the time a late-occurring  
problem was identified, acknowledged, and corrected, many patients had already been 
treated using  stent-grafts that were destined to fail
45;49;266
. 
 
Due to these factors, the FDA, which has the regulatory authority, recommends 
testing new stent-grafts for duration equivalent to 10 years in human body. The aorta 
and all its contents are in constant motion. Cyclical loading, unloading, and deformation 
causes work hardening and fracture of stents at sites of localised stress, strain, surface 
irregularities, and asymmetric loading. As discussed earlier, nitinol is the material of 
choice for many stents because it is versatile, easy to form, and magnetic resonance 
imaging compatible. Unfortunately, nitinol stents are fracture-prone. So it was 
important to confirm the durability of nitinol after surface  
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modification. Our results show that the bonding of POSS-PCU with nitinol remained 
robust with no occurrence of device failure on completion of accelerated fatigue testing.  
 
Long-term graft performance is of vital importance as now more and more 
patients are being offered endovascular aortic repair even in a younger age group. In 
previously reported work, suture-generated holes in the graft fabric were seen in 
virtually all explanted AneuRx
TM
 stent-grafts
61
. These holes were not generally large 
enough to cause a type III endoleak, but they did cause worrisome pressurisation and 
dilatation of the aneurysm
51
, leading to the substitution of a tighter weave graft fabric 
for the loose woven fabric of the original design. Our results confirmed the durability of 
POSS-PCU on exposure to long-term cyclic loading. There was no significant change in 
its essential properties. The radial strength, elasticity and thermo-mechanical strength 
were preserved. More importantly, there was no significant change in its compliance. 
Loss of compliance after implantation has been a known factor associated with 
polyurethane grafts. So with POSS backbone in our nanocomposite polymer, more 
biostability is achieved.  
 
 
8.1.8 The curved design: the first step towards a new branched endograft 
 
Despite expanding indications for stent-grafting to more proximal lesions in the 
aortic arch, technical and anatomic difficulties persist, caused by the inflexible structure 
of most tubular stent-grafts and their inability to conform to the curved aortic arch
267
. 
Several articles have reported inadequate stent-graft apposition along the inner curve of 
the arch resulting in type I endoleaks and stent-graft collapse
268-271
. Current thoracic 
stent-grafts are straight and semi-rigid due to their segmentation. Several techniques 
have been tried to improve conformability including in situ bending
272
 or in situ 
fenestrations
273
.  
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We utilised the aortic arch dimensions from real patient magnetic resonance 
imaging data to develop a curved design. The graft thickness for POSS-PCU used was 
approximately 150 µg and because of its elastic properties, it can be easily conformed 
into the desired shape. A better proximal apposition of the device at the inner curve of 
the aortic arch can be potentially achieved that may prevent early and late stent-graft 
related complications. Although, still in infancy, this design is promising as there is a 
potential to add fenestrations and branches which will make complete endovascular 
repair of aortic arch pathologies feasible, obviating the need for extra-anatomic bypass.  
 
8.1.9 Improving compliance mismatch: POSS-PCU versus ePTFE 
 
Studies show that TAA compliance is closely associated with many factors among 
which the implantation of the stent-graft is the most important
274
. Before stent-graft 
implantation, the elastic TAA wall receives direct impact from the pulsatile blood. 
Hence, it has strong motion behaviour before TEVAR, and the compliance value is 
high. After TEVAR, part of the pulse energy is absorbed by the stent-graft directly, and 
the stagnant blood as well as the soft intra-luminal thrombus serve as excellent buffer. 
Therefore, the compliance value after TEVAR is much smaller than the one before  
TEVAR
275
. Compliance mismatch in the proximal aorta can potentially reduce cardiac 
efficiency and may predispose to the development of left ventricular hypertrophy. 
“Compliance-matched” stent-grafts can help avoid this problem, although there is lack 
of significant evidence for this hypothesis due to limited published work. Dacron and 
ePTFE in presently used stent-grafts are inherently stiff with poor compliance. Our 
results confirm superior profile of POSS-PCU stent-graft as compared to commercial 
device based on ePTFE in current clinical use. We hope to be able confirm translation 
of this superior property in a suitable in vivo model. If successful, this can address 
limitation of current graft materials and help in making TEVAR a more effective and 
durable procedure.  
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8.1.10 Magnetic Resonance Imaging conditioning: mandatory in new designs 
 
For adequate evaluation of treatment success after EVAR, several specific items 
should be monitored: the effectiveness of aneurysm sac exclusion, graft patency, graft 
migration, and graft integrity. Several recent studies have shown magnetic resonance 
imaging (MRI) and magnetic resonance angiography (MRA) techniques are more 
sensitive for endoleak detection than standard computed tomographic angiography 
(CTA).  
 
One possible disadvantage of MRI techniques is that the endografts have to be 
MRI compatible, so a major potential problem is the presence of metallic components in 
the endografts. Metallic structures can produce artefacts that may considerably degrade 
image quality. Following stent-graft implantation, MRI image artefacts can extend 
throughout the anatomical region containing the device. This can obscure the view of 
immediately adjacent anatomical structures. The MRI compatibility of the POSS-PCU 
nitinol stent-graft was confirmed by absence of significant artefacts that could 
potentially degrade the diagnostic value of the images. The findings of our investigation 
and previous studies suggest that nitinol stent-grafts do not cause any major artefact that  
could significantly influence flow measurements
276;277
. The surface-modification 
protocol applied in our stent-graft did not affect its MRI properties. In a dedicated in 
vitro aortic flow phantom, the results were comparable to a commercially available 
stent-graft.  
 
8.2  CONCLUSIONS AND FUTURE WORK 
 
This work describes a basic science/engineering project with clear implications for 
clinical application of aortic endografts. Combining deployable structures technology 
with advanced biomaterial provides exciting possibilities for improving stent-graft 
design. A sutureless device with an efficient folding pattern has been developed for  
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repair of abdominal aortic aneurysms. Similarly, a conformable anatomically accurate 
stent-graft is developed which matches the curvature of human aortic arch. We have 
developed a physiologically relevant aortic model for long-term fatigue analysis and 
confirmed the durability of the sutureless design. The POSS-PCU graft bonding with 
nitinol skeleton remains robust with no signs of failure after 10 years of equivalent 
usage in an accelerated in vitro environment with simulated physiological conditions. 
Several essential properties of POSS-PCU nanocomposite polymer remain unaltered. 
The developed stent-grafts are MRI-compatible and show superior compliance and 
elastic stiffness profile as compared to presently used devices.  
 
Based on positive results from this work, the following recommendations are made for 
future 
a) POSS-PCU needs further characterisation for use in stent-grafts. Future work 
should be directed at determining the optimum thickness of the graft material to 
ensure folding efficiency, mechanical strength and compliance. In addition, the 
ends of the polymer tube are vital as type I endoleak can occur if the material is 
thin and forms an internal flap allowing the blood to flow through the aneurysm 
sac. 
b) The stent-grafts proposed in this project are based on solid POSS-PCU. Several 
current devices use material with pores, which would allow tissue cellular 
infiltration. Porous POSS-PCU has been utilised to develop small diameter 
bypass grafts in addition to several other cardiovascular devices. The implication 
of using porous as opposed to solid POSS-PCU on its biomechanical properties 
in the stent-graft design needs further evaluation. 
c) The addition of fenestrations and branches to the curved device is essential to 
make it suitable for clinical use. 
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d) Several variants to which the stent-graft is exposed in vivo cannot be factored in 
bench testing. The biostability of the sutureless design and its properties, 
especially the effects of oxidation and hydrolysis need confirmation in a suitable 
animal model. 
 
 
The modern design of aortic stent-grafts is very complex. In addition to the properties of 
stent and graft materials, which are evaluated in this experimental work, axial migration 
force at the proximal attachment which changes with variations in pressure, angulation, 
and tortuousity, is a critical parameter in stent-graft development. Deployment using 
packing and sheathing systems needs to be considered. Due to the complexity involved, 
further evaluation and design development may be more appropriate by partnership with 
a current device-manufacturing company. 
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